Therapeutic agent comprising isolated recombinant oncolytic adenovirus and immune cells and its application

By designing recombinant oncolytic adenoviruses that lack E1B19K, E1B55K and E3 genes and integrating shRNAs that inhibit PDL1 expression, combining immune cells modified by T cell receptors, tumor escape and oncolytic adenoviruses are solved. The problem has achieved efficient synergistic effects of tumor killing and immune stimulation, and improved the safety and effectiveness of treatment.

CN111743923BActive Publication Date: 2024-11-08BEIJING CONVERD CO LTD
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN201910237560.1
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2019-03-27
Publication Date
2024-11-08
Estimated Expiration
2039-03-27

AI Technical Summary

Technical Problem

In the existing tumor immunotherapy, the tumor escape mechanism leads to poor treatment effect, especially T cells lose their killing function in the later stage, and the lack of costimulation signals leads to immune tolerance. The existing oncolytic adenovirus has a high replication ability in normal cells. , affects security.

Method used

A recombinant oncolytic adenovirus was designed to delete E1B19K, E1B55K and E3 region genes, and integrate exogenous shRNA coding sequences that can inhibit PDL1 expression, and bind immune cells modified by T cell receptors for synergistic combined therapy.

Benefits of technology

It improves the replication ability and killing effect in tumor cells, reduces the toxicity to normal cells, enhances the anti-tumor effect of immune cells, achieves a synergistic effect of 1+1>2, and enriches the tumor treatment model.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure FT_1
    Figure FT_1
  • Figure FT_2
    Figure FT_2
  • Figure FT_3
    Figure FT_3
Patent Text Reader

Abstract

The present invention provides a therapeutic agent comprising a separated recombinant oncolytic adenovirus and immune cells and its application. The therapeutic agent comprises: a first composition, wherein the first composition comprises a first active ingredient located in a first pharmaceutically acceptable carrier, the first active ingredient comprising a separated recombinant oncolytic adenovirus, wherein the recombinant oncolytic adenovirus is a selective replication-type oncolytic adenovirus, and the genome of the recombinant oncolytic adenovirus is integrated with a coding sequence of an exogenous shRNA capable of inhibiting PDL1 expression in tumor cells; and a second composition, wherein the second composition comprises a second active ingredient located in a second pharmaceutically acceptable carrier, the second active ingredient comprising a T cell receptor-modified immune cell or a chimeric antigen receptor-modified immune cell. The present invention combines the oncolytic adenovirus and immune cells to achieve a synergistic therapeutic effect, and this mode of administration enriches the treatment mode and treatment means for tumor treatment.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biotechnology, and in particular, relates to a therapeutic agent comprising separated recombinant oncolytic adenovirus and immune cells, and applications thereof, a drug kit, and a method for treating tumors and / or cancers. Background Art

[0002] According to the latest report on causes of death published on the World Health Organization website in January 2013, about 7.6 million people died of cancer in 2008, accounting for 13% of the world's total deaths. This number is still growing rapidly every year, and it is expected that by 2030, this number will exceed 13.1 million. In my country, the incidence of malignant tumors is increasing at an average annual rate of 3% to 5%. In 2002, the number of new cases of malignant tumors in the country reached 2.19 million per year. By 2020, the number of new patients will exceed 3 million per year. Cancer has become one of the world's leading causes of death. Moreover, the treatment of tumors has become the focus and difficulty of today's medical field, and it has also attracted more and more attention.

[0003] Tumorigenesis is a multi-factor and multi-step process, mainly due to the stimulation of cells by external carcinogenic factors (including physical radiation, chemicals and viruses, etc.), which causes the damage of cells, resulting in changes in genetic materials such as DNA inside the cells, which in turn causes abnormalities and disorders in the signal transduction pathways inside the cells. The cells show crazy proliferation, resistance to apoptosis, cessation of differentiation, and the ability to invade tissues and migrate, which ultimately affects the functions of important organs of the human body and endangers life. At present, the main treatments for tumors include surgery, radiotherapy, chemotherapy, biological therapy and immunotherapy. Although these treatments help control tumors to a certain extent, they still cannot fundamentally solve the problem.

[0004] Oncolytic virus therapy also belongs to the category of biological therapy. The research on oncolytic viruses can be traced back to the 1950s. At that time, it was found that a patient with cervical cancer had a tumor that subsided after being infected with rabies virus. Inspired by the phenomenon that some tumor patients experienced spontaneous tumor remission after being infected with the virus, the first wave of oncolytic virus research began. Oncolytic viruses refer to a type of virus that can selectively replicate in target cells after infecting tumor cells, ultimately leading to tumor cell lysis and death. This type of virus relies on its own specificity to replicate in tumor cells to lyse tumor cells. The viruses released after cell lysis can further infect surrounding tumor cells, while having no destructive effect on normal cells and tissues, or having little effect. Oncolytic viruses are generally divided into two categories: one is wild-type viruses and naturally mutated attenuated virus strains. These viruses naturally have affinity for certain tumor cells, such as reovirus, Newcastle disease virus, and autonomously replicating parvoviruses. These viruses can reproduce and lyse cells in certain tumor cells and have natural specific oncolytic activity; the other is a virus that can only replicate in tumor cells after the viral genome is modified. At present, people have modified adenovirus, herpes simplex virus, influenza virus and human vaccinia virus through genetic engineering methods. Among them, adenovirus is an oncolytic virus that has been studied relatively early and has a relatively clear oncolytic mechanism. Among adenoviruses, adenovirus type 5 has been studied more clearly. Shortly after the discovery of adenovirus, it was used to treat head and neck malignant tumors. After injection of adenovirus, the tumor shrank to varying degrees, but the tumor was prone to recurrence after treatment, and the effect was difficult to last. It was not until 1996 that Bischoff et al. first reported that the recombinant adenovirus Onyx-015 with partial E1B removed could selectively replicate in tumor cells with abnormal p53 and cause tumor killing. Oncolytic adenovirus research has once again attracted widespread attention and developed rapidly, resulting in the emergence of many new types of oncolytic adenoviruses. In 2006, my country approved the marketing of a recombinant human adenovirus type 5 H101 (an oncolytic adenovirus with E1B55K and E3 genes deleted) developed by Shanghai Sanwei Biotechnology Co., Ltd. (NDA No.: National Medicine Standard S20060027), which can replicate specifically in p53 mutant tumor cells and dissolve tumor cells. Oncolytic adenovirus is increasingly becoming a new means of treating malignant tumors.

[0005] In addition, tumor immunotherapy is also a very important means in the fight against tumors. It mainly includes antibody therapy, T cell therapy and tumor vaccines. Antibodies are called new target molecules "drugs" for cancer. They can help activate effector cells by targeting immune cells around tumors, promote more effective anti-tumor immunity, or kill tumor cells through complement-dependent cytotoxicity, or induce tumor cell apoptosis. T cell therapy is a therapy that injects in vitro expanded tumor-specific autologous T cells (for example: CAR-T) into the body through intravenous administration. Tumor vaccine therapy is a method of mobilizing the body's immune system to produce specific antibodies and effector T cells, which is called active specific immunotherapy. A large number of clinical experiments have shown that tumor immunotherapy plays a very positive role in the treatment of tumors, but the biggest problem in the process of tumor immunotherapy is tumor escape. There is an extremely complex relationship between the immune escape mechanism of tumors and the body's immune response to tumors. In the process of tumor immunotherapy, early tumor-specific CD8 + T cells are activated, but they lose their killing function as the tumor grows to the later stage. In addition to providing the first signal to antigen-specific T cells through APC presenting MHC-antigen peptides, T cell activation usually requires a series of co-stimulatory molecules to provide the second signal, so that T cells can reach the physiological activation threshold and produce a normal immune response. If the second signal provided by the co-stimulatory molecules is lacking, T cells will become unresponsive or have specific immune tolerance or even enter apoptosis. Therefore, the regulation of positive and negative co-stimulatory signals and the balance between the two play an important regulatory role in the entire process of the body's immune response.

[0006] With the significant anti-tumor efficacy of immune checkpoint inhibitors such as CTLA-4 and PD-1 / PD-L1 in clinical trials (see the reference "Cancer Cell 27, 450-461 (2015)"), and the long-term effective therapeutic effect of adoptive T cell therapy represented by CAR-T (chimeric antigen receptor-T cells) on B-cell blood tumors (see the reference "N Engl J Med 2017; 377: 2545-2554"), tumor immunotherapy has become one of the most promising fields, which is expected to transform malignant tumors into controllable chronic diseases and even cure some advanced cancers. At present, an effective tumor immunotherapy strategy is to adoptively transfer T cells obtained in vitro that can effectively recognize tumor antigens. These T cells are derived from infiltrating T lymphocytes (TILs) of tumor tissues, or they can be peripheral blood T cells (TCR-T) that can effectively recognize tumor antigens after being modified with antigen-specific T cell receptor (TCR) genes. In vitro culture avoids the inhibitory microenvironment of tumor tissue and provides optimized culture conditions, so that a sufficient number of anti-tumor T cells can be obtained for adoptive transfer therapy (see the document "Adv Immunol. 2016; 130: 279-94"). Adoptive T cell therapy includes chimeric antigen receptor-based CAR-T therapy and TCR-T therapy based on T cell receptor. CAR-T mainly targets tumor antigens expressed on the cell surface. Although the number of tumor antigens recognized is limited, CAR-T targeting CD19 has shown significant clinical efficacy against blood tumors including B-cell leukemia and lymphoma, and some products have been approved by the FDA for marketing (see the document "N Engl J Med. 2017 Oct 05; 377 (14): 1313-1315"). For the treatment of solid tumors, CAR-T has not yet seen clear clinical efficacy. TCR-T mainly targets peptide antigens presented by human major histocompatibility antigen HLA molecules. Epitope peptides can be derived from intracellular proteins and cell membrane surface proteins. The types and number of target antigens are much greater than the tumor antigens recognized by CAR-T (see the document "Int Immunol. 2016 07; 28(7): 349-53"). However, immunotherapy based on TCR-T and CAR-T has various shortcomings that affect the treatment effect of tumors.

[0007] Currently, in the immunotherapy of tumors and / or cancers, there is still a need for more effective treatment options and drugs developed thereby. Summary of the invention

[0008] In order to solve the problems existing in the above-mentioned prior art, the present invention provides a therapeutic agent and application, a drug kit, and a method for treating tumors and / or cancers comprising separated recombinant oncolytic adenovirus and immune cells.

[0009] Specifically, the present invention provides:

[0010] (1) A therapeutic agent for treating tumors and / or cancers, comprising:

[0011] (a) a first composition, wherein the first composition comprises a first active ingredient in a first pharmaceutically acceptable carrier, the first active ingredient comprising an isolated recombinant oncolytic adenovirus, wherein the recombinant oncolytic adenovirus is a selective replication-type oncolytic adenovirus, and the genome of the recombinant oncolytic adenovirus is integrated with a coding sequence of an exogenous shRNA capable of inhibiting PDL1 expression in tumor cells; and

[0012] (b) a second composition, wherein the second composition comprises a second active ingredient in a second pharmaceutically acceptable carrier, the second active ingredient comprising a T cell receptor modified immune cell or a chimeric antigen receptor modified immune cell.

[0013] (2) The therapeutic agent according to (1), wherein the coding sequence of the exogenous shRNA is shown in any one of SEQ ID NOs. 45, 48 and 51.

[0014] (3) The therapeutic agent according to (1), wherein the genome of the recombinant oncolytic adenovirus is deleted from the E1B19K gene, the E1B55K gene and all E3 region genes.

[0015] (4) The therapeutic agent according to (1) or (3), wherein the genome of the recombinant oncolytic adenovirus contains an E1A gene coding sequence; preferably, the E1A gene coding sequence is under the control of a CMV promoter.

[0016] (5) The therapeutic agent according to (1), wherein the recombinant oncolytic adenovirus is obtained by genetically modifying adenovirus type 5.

[0017] (6) The therapeutic agent according to (1), wherein the T cell receptor-modified immune cells include primitive T cells or their precursor cells, NKT cells, or T cell strains; and the chimeric antigen receptor-modified immune cells include primitive T cells or their precursor cells, NKT cells, T cell strains or NK cells.

[0018] (7) The therapeutic agent according to (1), wherein the first composition and the second composition are each independently present in the therapeutic agent without being mixed with each other.

[0019] (8) The therapeutic agent according to (1), wherein the first composition comprises a therapeutically effective amount of the recombinant oncolytic adenovirus.

[0020] (9) The therapeutic agent according to (1), wherein the second composition comprises a therapeutically effective amount of the immune cells.

[0021] (10) The therapeutic agent according to (1), wherein the recombinant oncolytic adenovirus is formulated for administration by intratumoral injection, intraperitoneal administration, subarachnoid administration, or intravenous administration.

[0022] (11) The therapeutic agent according to (1), wherein the immune cells are formulated for administration via an artery, vein, subcutaneous, intradermal, intratumoral, intralymphatic, intralymphatic, subarachnoid, intramedullary, intramuscular or intraperitoneal route.

[0023] (12) The therapeutic agent according to (1), wherein the therapeutic agent consists of the first composition and the second composition.

[0024] (13) Use of the therapeutic agent according to any one of (1) to (12) in the preparation of a medicament for treating tumors and / or cancer.

[0025] (14) The use according to (13), wherein the tumor and / or cancer includes: breast cancer, head and neck tumors, synovial cancer, renal cancer, connective tissue cancer, melanoma, lung cancer, esophageal cancer, colon cancer, rectal cancer, brain cancer, liver cancer, bone cancer, choriocarcinoma, gastrinoma, pheochromocytoma, prolactinoma, von Hippel-Lindau disease, Zollinger-Ellison syndrome, anal cancer, bile duct cancer, bladder cancer, ureter cancer, glioma, neuroblastoma, meningioma, spinal cord tumors, osteochondroma, chondrosarcoma, Ewing's sarcoma, carcinoma of unknown primary site, carcinoid, fibrosarcoma, Paget's disease, cervical cancer, gallbladder cancer, eye cancer, Kaposi's sarcoma, prostate cancer, testicular cancer, squamous cell carcinoma of the skin, mesothelioma, multiapical myeloma, ovarian cancer, pancreatic endocrine tumor, glucagonoma, pancreatic cancer, penile cancer, pituitary cancer, soft tissue sarcoma, retinoblastoma, small intestine cancer, stomach cancer, thymic cancer, trophoblastic carcinoma, hydatidiform mole, endometrial cancer, vaginal cancer, vulvar cancer, mycosis fungoides, insulinoma, heart cancer, meningeal cancer, blood cancer, peritoneal cancer, and pleural cancer.

[0026] (15) A kit of combined drugs with synergistic effects for treating tumors and / or cancers, comprising:

[0027] A first container containing a first composition of the therapeutic agent according to any one of (1) to (12);

[0028] a second container containing a second composition of the therapeutic agent according to any one of (1) to (12), wherein the first container and the second container are separate; and

[0029] Instructions for use that specify when and how to administer the drug.

[0030] (16) Use of the drug kit according to (15) in the preparation of a drug for treating or preventing tumors and / or cancer.

[0031] (17) The use according to (16), wherein the tumor and / or cancer includes: breast cancer, head and neck tumors, synovial cancer, renal cancer, connective tissue cancer, melanoma, lung cancer, esophageal cancer, colon cancer, rectal cancer, brain cancer, liver cancer, bone cancer, choriocarcinoma, gastrinoma, pheochromocytoma, prolactinoma, von Hippel-Lindau disease, Zollinger-Ellison syndrome, anal cancer, bile duct cancer, bladder cancer, ureter cancer, glioma, neuroblastoma, meningioma, spinal cord tumors, osteochondroma, chondrosarcoma, Ewing's sarcoma, carcinoma of unknown primary site, carcinoid, fibrosarcoma, Paget's disease, cervical cancer, gallbladder cancer, eye cancer, Kaposi's sarcoma, prostate cancer, testicular cancer, squamous cell carcinoma of the skin, mesothelioma, multiapical myeloma, ovarian cancer, pancreatic endocrine tumor, glucagonoma, pancreatic cancer, penile cancer, pituitary cancer, soft tissue sarcoma, retinoblastoma, small intestine cancer, stomach cancer, thymic cancer, trophoblastic carcinoma, hydatidiform mole, endometrial cancer, vaginal cancer, vulvar cancer, mycosis fungoides, insulinoma, heart cancer, meningeal cancer, blood cancer, peritoneal cancer, and pleural cancer.

[0032] (18) A method for treating tumors and / or cancers, comprising:

[0033] administering the first composition of the therapeutic agent according to any one of (1) to (12) to a tumor and / or cancer patient; and

[0034] The second composition of the therapeutic agent according to any one of (1) to (12) is administered to the tumor and / or cancer patient.

[0035] (19) The method according to (18) comprises the following steps performed in sequence:

[0036] 1) administering the first composition to the tumor and / or cancer patient; and

[0037] 2) After administering the first composition, administering the second composition of the therapeutic agent to the tumor and / or cancer patient.

[0038] (20) The method according to (19), wherein the tumor and / or cancer includes: breast cancer, head and neck tumor, synovial cancer, kidney cancer, connective tissue cancer, melanoma, lung cancer, esophageal cancer, colon cancer, rectal cancer, brain cancer, liver cancer, bone cancer, choriocarcinoma, gastrinoma, pheochromocytoma, prolactinoma, von Hippel-Lindau disease, Zollinger-Ellison syndrome, anal cancer, bile duct cancer, bladder cancer, ureter cancer, glioma, neuroblastoma, meningioma, spinal cord tumors, osteochondroma, chondrosarcoma, Ewing's sarcoma, carcinoma of unknown primary site, carcinoid, fibrosarcoma, Paget's disease, cervical cancer, gallbladder cancer, eye cancer, Kaposi's sarcoma, prostate cancer, testicular cancer, squamous cell carcinoma of the skin, mesothelioma, multiapical myeloma, ovarian cancer, pancreatic endocrine tumor, glucagonoma, pancreatic cancer, penile cancer, pituitary cancer, soft tissue sarcoma, retinoblastoma, small intestine cancer, stomach cancer, thymic cancer, trophoblastic carcinoma, hydatidiform mole, endometrial cancer, vaginal cancer, vulvar cancer, mycosis fungoides, insulinoma, heart cancer, meningeal cancer, blood cancer, peritoneal cancer, and pleural cancer.

[0039] Compared with the prior art, the present invention has the following advantages and positive effects:

[0040] The present invention proposes to make the oncolytic adenovirus lack the coding regions of the E1B19K gene, the E1B55K gene, and all the E3 genes, and at the same time make it carry the coding sequence of exogenous shRNA, so that the resulting recombinant oncolytic adenovirus can selectively replicate in tumor cells, and express shRNA that can inhibit the expression of PDL1 in tumor cells. The oncolytic adenovirus provided based on this concept has a strong tumor killing ability, and its replication ability in normal cells is much lower than its replication ability in tumor cells, so it has low toxicity to normal cells and improves safety; and the shRNA expressed by the virus can significantly reduce the expression level of PDL1 protein in tumor cells, thereby reducing the immunosuppression of tumor cells to immune cells (including T lymphocytes and NK cells), thereby enhancing the anti-tumor immune killing effect of immune cells. The present invention finds that the integration of the shRNA coding sequence in the oncolytic adenovirus can produce a synergistic effect between the oncolytic killing effect of the oncolytic virus and the anti-tumor immune stimulation of immune cells.

[0041] In addition, the inventors of the present invention unexpectedly found that the above-mentioned oncolytic adenovirus, in addition to its own oncolytic ability against tumor cells, can also enhance the killing effect of immune cells (such as TCR-T, CAR-T or CAR-NK) affected by the PDL1 / PD1 immune checkpoint on tumors (especially solid tumors), thereby playing a synergistic role of 1+1>2. Furthermore, the present invention, in view of the problems and difficulties faced by adoptive immune cell therapy and oncolytic virus treatment of tumors, proposes the concept of combined treatment using the above-mentioned oncolytic adenovirus and immune cells (such as TCR-T, CAR-T or CAR-NK) affected by the PDL1 / PD1 immune checkpoint through theoretical research and experimental verification. The therapeutic agent and method provided based on this concept can give full play to the recombinant oncolytic adenovirus of the present invention to selectively replicate and kill tumor cells in tumor cells, and further cause the subsequent immune response of the body, while also giving full play to the function of immune cells modified by T cell receptors and immune cells modified by chimeric antigen receptors to kill tumor cells. This ultimately produces a further enhanced synergistic killing effect of tumors. This drug delivery mode of combining oncolytic viruses and immune killer cells to kill tumors has enriched the treatment modes and methods of tumor treatment, and is very likely to become one of the breakthroughs in tumor treatment (especially solid tumors).

[0042] definition

[0043] In the present invention, the terms "tumor", "cancer", "tumor cell", "cancer cell", "T cell", "T cell receptor", "T cell receptor modification", "TCR variable region", "TCR constant region", "antigen", "antigen epitope polypeptide", "homologous sequence", "encoding", "antigen presentation", "recombinant DNA expression vector", "promoter", "complementary sequence", "transfection", "autologous", "allogeneic", "specific recognition", and "TCR-T therapy" cover the meanings generally recognized in the art.

[0044] As used herein, the term "oncolytic virus" refers to a virus that is able to selectively replicate in tumor cells and lyse tumor cells.

[0045] The term "therapeutically effective amount" as used herein refers to the amount of a functional pharmaceutical agent or pharmaceutical composition that can exhibit a detectable therapeutic effect or inhibitory effect, or an amount that exerts an anti-tumor effect. The effect can be detected by any test method known in the art.

[0046] As used herein, the term "administration" or "administering" refers to providing a compound, complex or composition (including viruses and cells) to a subject.

[0047] The term "patient" as used herein refers to a human or non-human organism. Therefore, the methods and compositions described herein are applicable to both human and veterinary diseases. In some embodiments, the patient suffers from a tumor. In some instances, the patient suffers from one or more types of cancer at the same time.

[0048] As used herein, the term "synergistic effect" refers to the effect of two or more agents working together, which is greater than the sum of the individual effects of each agent.

[0049] The term "pfu" or "plague forming unit" used herein means: the amount of virus that produces one plaque is called one plaque forming unit (pfu).

[0050] The term "VP" as used herein refers to the number of viral particles.

[0051] The term "VP / kg" as used herein refers to the number of viral particles per kilogram of patient body weight.

[0052] The term "TCID50" as used herein refers to the median tissue culture infectious dose, which refers to the viral dose that infects half of the tissue cultures and causes cytopathic effects.

[0053] The term "MOI" or "multiplicity of infection" as used herein, i.e., the ratio of virus to cell number, refers to the number of virus particles that are used to initiate virus infection per cell. MOI = pfu / cell, i.e., number of cells x MOI = total PFU. BRIEF DESCRIPTION OF THE DRAWINGS

[0054] Figure 1 The gel electrophoresis diagram of PCR amplification of the E1A gene of adenovirus type 5 is shown; wherein

[0055] Lane M is a DNA molecular weight marker, and lane 1 is the PCR product using H101 genomic DNA as a template.

[0056] Figure 2 The PCR screening results of pShuttle-E1A plasmid positive clones are shown; wherein lane M is a DNA molecular weight marker, and lanes 1-3 are candidate clones.

[0057] Figure 3 The diagram shows the construction process of the pShuttle-E1A plasmid and a map of the constructed plasmid.

[0058] Figure 4The diagram (left) and gel electrophoresis (right) show the PCR amplification of the E1A expression cassette from the pShuttle-E1A plasmid; wherein lane M is a DNA molecular weight marker, and lanes 1-2 are PCR products.

[0059] Figure 5 The PCR screening results of the pShuttle-MCS-E1A candidate plasmid are shown; wherein lane M is a DNA molecular weight marker, lanes 1-13 are candidate plasmids, lane NC is a negative control of the PCR system (i.e., a PCR product whose template is water), and lane PC is a positive control of the PCR system (i.e., the template is pShuttle-E1A plasmid DNA containing the target fragment).

[0060] Figure 6 The results of BglII digestion identification of the pShuttle-MCS-E1A candidate plasmid are shown; wherein lane M is a DNA molecular weight marker, samples 1-3 are candidate plasmids, and each sample has two lanes, namely: lane N is the candidate plasmid without digestion, and lane B is the candidate plasmid after BglII digestion.

[0061] Figure 7 The diagram shows the construction process of the pShuttle-MCS-E1A plasmid and a map of the constructed plasmid.

[0062] Figure 8 The inhibition of human PDL1 mRNA in U251 and H460 cells by three shPDL1s according to one embodiment of the present invention is shown. The abscissa axis represents four groups of cell samples collected at 24h and 48h after U251 and H460 cells were treated with four shRNAs, and the ordinate axis represents the ratio of the expression level of PDL1 mRNA in cells after each shRNA treatment to the expression level of PDL1 mRNA in cells after the control shRNA treatment.

[0063] Fig. 9The inhibition of exogenous hPDL1 expression in 293T cells by three shPDL1s according to one embodiment of the present invention is shown. The left figure is the result of Western Blot, which shows the expression changes of hPDL1 (containing FLAG tag) in cell samples after cells are treated with different shPDL1s and the expression of the protein internal reference β-actin (β-actin) in the cells; the right figure is the grayscale scanning value of the hPDL1 band obtained according to the Western Blot results, using the protein internal reference β-actin as the standardized control, the horizontal axis represents the 293 cell sample group after different shPDL1 treatments, and the "control" refers to the control group that only transfected pcDNA3.3-hPDL1-FLAG to express hPDL1 (containing FLAG tag), and the vertical axis is the grayscale scanning value of the target protein after standardized with β-actin.

[0064] Fig.10 The diagram shows the construction process of the pShuttle-U6-shPDL1-CMV-E1A plasmid and a map of the constructed plasmid.

[0065] Fig.11 The result of enzyme digestion identification of pShuttle-U6-shPDL1-CMV-E1A plasmid is shown; wherein lane M is a DNA molecular weight marker, lane C is a control plasmid (pShuttle-MCS-E1A) after KpnI / HindIII digestion, and lanes 1-7 are candidate plasmids after KpnI / HindIII digestion.

[0066] Fig.12 Schematic diagram showing the process of homologous recombination between pShuttle-U6-shPDL1-CMV-E1A plasmid and pAdEasy-1 in BJ5183 bacteria.

[0067] Fig.13 Schematic diagram showing homologous recombination between pShuttle-related plasmids and pAdEasy-1 during the construction of pAdEasy-U6-shPDL1-CMV-E1A plasmid.

[0068] Fig.14The PacI digestion identification results of the constructed positive pAdEasy-U6-shPDL1-CMV-E1A plasmid are shown; wherein lane M is a DNA molecular weight marker, and lanes 1-8 are PacI digestion products of different plasmids, specifically, lane 1 is a PacI digestion product of C-4.5K, lane 2 is a PacI digestion product of 1-4.5K, lane 3 is a PacI digestion product of C-3K, lane 4 is a PacI digestion product of 1-3K, lane 5 is a PacI digestion product of 2-4.5K, lane 6 is a PacI digestion product of 3-4.5K, lane 7 is a PacI digestion product of 2-3K, and lane 8 is a PacI digestion product of 3-3K.

[0069] Fig.15 Schematic diagram showing the process of completing virus packaging in AD293 cells using pAdEasy-U6-shPDL1-CMV-E1A plasmid and pAdEasy-CMV-E1A control plasmid.

[0070] Fig.16 A schematic diagram of the sample layout of a 12-well plate in one embodiment of the present invention is shown. As shown in the figure, OAd-shPDL1#1-4.5K (1-4.5K), OAd-shPDL1#2-4.5K (2-4.5K), OAd-shPDL1#3-4.5K (3-4.5K) and the control oncolytic virus OAd-C-4.5K (C-4.5K) were selected to treat cells at the indicated MOI values. Wherein "NC" refers to a blank control group without any virus treatment.

[0071] Fig.17 The comparison results of the replication ability of the oncolytic virus OAd-shPDL1 (OAd-shPDL1#1-4.5K (1-4.5K), OAd-shPDL1#2-4.5K (2-4.5K) and OAd-shPDL1#3-4.5K (3-4.5K)) constructed by the present invention in Example 1 in different cells are shown, wherein OAd-C-4.5K (C-4.5K) is used as a system control virus. The horizontal axis represents different oncolytic virus groups, and the vertical axis is the multiple of the copy number of the specific gene E1A of the oncolytic adenovirus after the GAPDH gene in the cell is used as a standardized control.

[0072] Fig.18The killing effects of the oncolytic virus OAd-shPDL1 (OAd-shPDL1#1-4.5K (1-4.5K), OAd-shPDL1#2-4.5K (2-4.5K) and OAd-shPDL1#3-4.5K (3-4.5K)) constructed by the present invention in Example 2 and the system control virus OAd-C-4.5K (C-4.5K) as well as the control group H101 and the control group paclitaxel (Paclitaxel) on U251 cells are shown. The horizontal axis represents the different viral infection doses (in MOI) used to treat the cells, and the vertical axis is the inhibition rate (%) of cell growth after the cells are treated with the virus. The left figure shows the results of the 48-hour experiment, and the right figure shows the results of the 72-hour experiment. "***" means p<0.001.

[0073] Fig.19 The killing effect of the oncolytic virus OAd-shPDL1 (OAd-shPDL1#1-4.5K (1-4.5K), OAd-shPDL1#2-4.5K (2-4.5K) and OAd-shPDL1#3-4.5K (3-4.5K)) constructed by the present invention in Example 2 and the system control virus OAd-C-4.5K (C-4.5K) and the control group H101 and the control group paclitaxel on A549 cells is shown. The horizontal axis represents the different virus infection doses (in MOI) used to treat the cells, and the vertical axis is the inhibition rate (%) of cell growth after the virus treats the cells. The left figure shows the results of the 48-hour experiment, and the right figure shows the results of the 72-hour experiment.

[0074] Fig. 20 The killing effect of the oncolytic virus OAd-shPDL1 (OAd-shPDL1#1-4.5K (1-4.5K), OAd-shPDL1#2-4.5K (2-4.5K) and OAd-shPDL1#3-4.5K (3-4.5K)) constructed by the present invention in Example 2 and the system control virus OAd-C-4.5K (C-4.5K) as well as the control group H101 and the control group paclitaxel on Hela cells is shown. The horizontal axis represents the different virus infection doses (in MOI) used to treat the cells, and the vertical axis is the inhibition rate (%) of cell growth after the virus treats the cells. The left figure shows the results of the 48-hour experiment, and the right figure shows the results of the 72-hour experiment.

[0075] Fig.21The IC values ​​of the oncolytic virus OAd-shPDL1 (OAd-shPDL1#1-4.5K (1-4.5K), OAd-shPDL1#2-4.5K (2-4.5K) and OAd-shPDL1#3-4.5K (3-4.5K)) constructed in the present invention and the system control virus OAd-C-4.5K (C-4.5K) and the control group H101 on different cells are shown in Example 2 50 (72h) Comparison results of dosage. The horizontal axis represents different types of tumor cell groups, and the vertical axis represents the amount of virus used to kill 50% of the corresponding tumor cells when the cells are incubated with the virus for 72h (in MOI).

[0076] Fig. 22 The inhibition of hPD-L1 overexpressed in A549 / hPD-L1-FLAG cell line by oncolytic adenovirus OAd-shPDL1 (OAd-shPDL1#1-4.5K(1-4.5K), OAd-shPDL1#2-4.5K(2-4.5K) and OAd-shPDL1#3-4.5K(3-4.5K)) constructed by the present invention in Example 3 and system control virus OAd-C-4.5K(C-4.5K) and control group H101 is shown. The upper figure is the Western blot result, which shows the expression changes of hPDL1 (containing FLAG tag) in cell samples after cells are treated with different viruses and the expression of protein internal reference β-actin in cells. "Control" refers to the blank control group without any virus treatment; the lower figure is the grayscale scan value of the hPDL1 band obtained according to the Western blot results, using protein internal reference β-actin as a standardized control. The horizontal axis represents different groups, and the vertical axis represents the grayscale scan value.

[0077] Fig.23 The inhibition of hPD-L1 overexpressed in Hela / hPD-L1-FLAG cell line by oncolytic adenovirus OAd-shPDL1 (OAd-shPDL1#1-4.5K (1-4.5K), OAd-shPDL1#2-4.5K (2-4.5K) and OAd-shPDL1#3-4.5K (3-4.5K)) constructed by the present invention in Example 3 and control group H101 is shown. The upper figure is the Western blot result, which shows the expression changes of hPDL1 (containing FLAG tag) in cell samples after cells are treated with different viruses and the expression of protein internal reference β-actin in cells. "Control" refers to the blank control group without any virus treatment; the lower figure is the grayscale scan value of the hPDL1 band obtained according to the Western blot results, using protein internal reference β-actin as a standardized control.

[0078] Fig.24 A schematic diagram showing the p53 and Rb signaling pathways in cells.

[0079] Fig.25 The killing effect of the oncolytic virus OAd-shPDL1 (OAd-shPDL1#1-4.5K (1-4.5K), OAd-shPDL1#2-4.5K (2-4.5K) and OAd-shPDL1#3-4.5K (3-4.5K)) constructed by the present invention in Example 4, the system control virus OAd-C-4.5K (C-4.5K), the control group H101 and the control group paclitaxel on HCT116 cells is shown. The horizontal axis represents the different viral infection doses (in MOI) used to treat the cells, and the vertical axis is the inhibition rate (%) of cell growth after the virus treats the cells. Figure A is the result of the 48-hour experiment, and Figure B is the result of the 72-hour experiment.

[0080] Fig.26 The killing effect of the oncolytic virus OAd-shPDL1 (OAd-shPDL1#1-4.5K (1-4.5K), OAd-shPDL1#2-4.5K (2-4.5K) and OAd-shPDL1#3-4.5K (3-4.5K)) constructed by the present invention in Example 4, the system control virus OAd-C-4.5K (C-4.5K), the control group H101 and the control group paclitaxel on PANC1 cells is shown. The horizontal axis represents the different virus infection doses (in MOI) used to treat the cells, and the vertical axis is the inhibition rate (%) of cell growth after the virus treats the cells. Figure A is the result of the 48-hour experiment, and Figure B is the result of the 72-hour experiment.

[0081] Fig. 27 The killing effect of the oncolytic virus OAd-shPDL1 (OAd-shPDL1#1-4.5K (1-4.5K), OAd-shPDL1#2-4.5K (2-4.5K) and OAd-shPDL1#3-4.5K (3-4.5K)) constructed by the present invention in Example 4, the system control virus OAd-C-4.5K (C-4.5K), the control group H101 and the control group paclitaxel on HT29 cells is shown. The horizontal axis represents the different virus infection doses (in MOI) used to treat the cells, and the vertical axis is the inhibition rate (%) of cell growth after the virus treats the cells. Figure A is the result of the 48-hour experiment, and Figure B is the result of the 72-hour experiment.

[0082] Fig.28The killing effect of the oncolytic virus OAd-shPDL1 (OAd-shPDL1#1-4.5K (1-4.5K), OAd-shPDL1#2-4.5K (2-4.5K) and OAd-shPDL1#3-4.5K (3-4.5K)) constructed by the present invention in Example 4, the system control virus OAd-C-4.5K (C-4.5K), the control group H101 and the control group paclitaxel on H460 cells is shown. The horizontal axis represents the different virus infection doses (in MOI) used to treat the cells, and the vertical axis is the inhibition rate (%) of cell growth after the virus treats the cells. Figure A is the result of the 48-hour experiment, and Figure B is the result of the 72-hour experiment.

[0083] Fig.29 The IC values ​​of the oncolytic viruses OAd-shPDL1 (OAd-shPDL1#1-4.5K (1-4.5K), OAd-shPDL1#2-4.5K (2-4.5K) and OAd-shPDL1#3-4.5K (3-4.5K)) constructed in the present invention and the system control virus OAd-C-4.5K (C-4.5K) and the control group H101 on different cells are shown in Example 4. 50 (72h) Comparison results of dosage. The horizontal axis represents different types of tumor cell groups, and the vertical axis represents the amount of virus used to kill 50% of the corresponding tumor cells when the cells are incubated with the virus for 72h (in MOI).

[0084] Fig.30 The inhibition of hPDL1 expressed in human breast cancer cells MDA-MB-231 by the oncolytic adenovirus OAd-shPDL1#1-4.5K (1-4.5K) and the system control virus OAd-C-4.5K (C-4.5K) constructed by the present invention in Example 5 is shown. Figure A is a Western blot result, showing the expression changes of hPDL1 in cell samples after cells were treated with different viruses and the expression of the protein internal reference β-actin in the cells. "Control" refers to a blank control group without any virus treatment; Figure B is the grayscale scan value of the hPDL1 band obtained based on the Western blot results, using the protein internal reference β-actin as a standardized control. The horizontal axis represents different groups, and the vertical axis is the grayscale scan value.

[0085] Fig.31The figure shows the change in the percentage of cells expressing hPDL1 on the tumor cell membrane detected by FACS after treating MDA-MB-231 cells with the oncolytic adenovirus OAd-shPDL1#1-4.5K (1-4.5K) constructed by the present invention and the system control virus OAd-C-4.5K (C-4.5K) in Example 5; wherein "control" refers to a blank control group without any virus treatment. The horizontal axis represents different groups, and the vertical axis represents the percentage (%) of cells expressing hPDL1.

[0086] Fig.32 The figure shows the change in the percentage of cells expressing hPDL1 on the cell membrane detected by FACS after treating HCT116 cells with the oncolytic adenovirus OAd-shPDL1#1-4.5K (1-4.5K) constructed by the present invention and the system control virus OAd-C-4.5K (C-4.5K) in Example 5; wherein "control" refers to a blank control group without any virus treatment. The horizontal axis represents different groups, and the vertical axis represents the percentage (%) of cells expressing hPDL1.

[0087] Fig.33 The inhibition of hPDL1 expression in HCT116 cells inoculated subcutaneously on the back of BALB / C nude mice by oncolytic adenovirus OAd-shPDL1#1-4.5K (1-4.5K) constructed by the present invention and system control virus OAd-C-4.5K (C-4.5K) in Example 5 is shown by Western blot; the figure shows the Western blot results, indicating the expression changes of hPDL1 in cell samples after cells were treated with different viruses and the expression of protein internal reference β-actin in cells. "Control" refers to a blank control group without any virus treatment. There are three loading wells in each group in the figure, and the samples in each loading well are from three different nude mice in the same group.

[0088] Fig.34 Show according to Fig.33 Western blot results, grayscale scan values ​​of hPDL1 bands obtained by using protein internal reference β-actin as a standard control. The horizontal axis represents different groups, and the vertical axis represents the grayscale scan value.

[0089] Fig.35 The results of Example 8 of the present invention show that + Phenotypic and functional test results of Her2 / neu 369-377 polypeptide (Her2-E75)-specific cytotoxic T cells induced from normal donor PBMC (specifically #1 PBMC). Fig.35A is the result of flow cytometric analysis of PBMC cells after two rounds of in vitro stimulation with Her2-E75 antigen peptide, stained with CD8-APC antibody and Her2-E75 pentamer-PE. The right picture shows cells stimulated with peptide, and the results of flow cytometric analysis of PBMC cells after two rounds of in vitro stimulation with Her2-E75 antigen peptide, stained with CD8-APC antibody and Her2-E75 pentamer-PE. + Pentamer + The killer T cell population was sorted by FACS to obtain T cell clones. The left picture shows the control group cells without peptide stimulation. The horizontal axis represents the fluorescence intensity of CD8 molecule expression, and the vertical axis represents the fluorescence intensity of the bound Her2-E75 pentamer. Fig.35 B is CD8 + E75-tetramer + Phenotypic analysis of killer T cell clones by flow cytometry after staining with CD8-APC and Her2-E75 tetramer-PE. The right figure shows CD8 + Her2 tetramer + T cell clone Her2 CTL 6A5 is a purified Her2-E75 peptide-specific CTL cell clone. The left picture shows the control group CTL cells without peptide stimulation. The horizontal axis represents the fluorescence intensity of CD8 molecule expression, and the vertical axis represents the fluorescence intensity of the bound Her2-E75 tetramer. Fig.35 C shows the main functional fragments of the constructed lentiviral vector carrying the Her2 TCR-6A5-mC gene (i.e., "pCDH-EF1α-Her2 TCR vector"). The fragments shown express the TCR gene driven by the EF-1α promoter, and the constant region fragments of the β chain and α chain of each TCR are mouse constant region fragments, and the β chain and α chain of the TCR are linked by the coding sequence of the cleavable connecting polypeptide (furin-F2A).

[0090] Fig.36 Shown are the phenotypic and functional test results of peripheral blood mononuclear cells (PBMCs) transfected with the Her2 TCR-6A5-mC TCR gene. Fig.36 A shows the results of flow cytometric analysis of PBMCs from two different donors transfected with a lentiviral vector encoding Her2TCR-6A5-mC and stained with Her2-E75 tetramer-PE and anti-CD8-APC antibodies. First, lymphocyte populations were separated according to cell morphology and size. + The cell population is a cell expressing Her2 TCR-6A5-mC TCR. The horizontal axis represents the fluorescence intensity of CD8 molecule expression, and the vertical axis represents the fluorescence intensity of the bound Her2-E75 tetramer. The percentages shown are the ratios of each positive cell population to the number of lymphocytes separated. The left figure relates to peripheral blood mononuclear cells provided by one donor (#1PBMC), and the right figure relates to PBMC provided by another different donor (#2PBMC). CD8 +Her2-E75 tetramer + The cells are cytotoxic T cells expressing Her2 TCR-6A5-mC. CD8 - Her2-E75 tetramer + The cells may be CD4 expressing Her2TCR-6A5-mC + Helper T cells. Fig.36 B shows that T cells expressing Her2 TCR-6A5-mC can recognize the Her2-E75 peptide presented by T2 cells. PBMCs from two different donors transfected with the lentiviral vector encoding Her2 TCR-6A5-mC were mixed and cultured with T2 cells presenting different concentration gradients of Her2-E75 peptide for 16 hours, and the cell supernatant was taken for IFN-γ ELISA analysis. The target cells in the control group were T2 cells presenting the EBV virus antigen peptide LMP2426-434 that can bind to the HLA-A2 molecule (not shown in the figure). In the figure, "0.1 μg / ml" indicates a T2 cell group presenting 0.1 μg / ml of Her2-E75 polypeptide, "0.01 μg / ml" indicates a T2 cell group presenting 0.01 μg / ml of Her2-E75 polypeptide, "0.001 μg / ml" indicates a T2 cell group presenting 0.001 μg / ml of Her2-E75 polypeptide, and "0.0001 μg / ml" indicates a T2 cell group presenting 0.0001 μg / ml of Her2-E75 polypeptide. The ordinate indicates the concentration of IFN-γ secreted by T cells. Fig.36 C shows the results of the CD8 antibody blocking test of T cell function. Among them, anti-human CD8 antibodies were added when #2PBMCs transfected with the lentiviral vector encoding Her2 TCR-6A5-mC were co-cultured with the Her2-E75 antigen polypeptide presented by T2 cells to detect whether the function of T cells to secrete IFN-γ was inhibited. In the figure, "T2+Her2-E75" represents the T2 cell group that presented 0.1μg / ml of Her2-E75 polypeptide without the addition of anti-human CD8 antibodies, and "T2+Her2-E75+anti-CD8" represents the T2 cell group that presented 0.1μg / ml of Her2-E75 polypeptide with the addition of anti-human CD8 antibodies. The horizontal axis represents different experimental groups, and the vertical axis represents the concentration of IFN-γ secreted by T cells. "ns" means that there is no significant difference between the two experimental groups. Fig.36 Each experimental group and control group in B and 36C were duplicate wells, and the results are shown as mean ± SEM.

[0091] Fig.37 The results of functional detection of tumor cell lines by peripheral blood mononuclear cells (PBMCs) transfected with Her2 TCR-6A5-mC TCR gene are shown. Fig.37A shows the expression of HLA-A2 and Her2 / neu in different tumor cell lines. The horizontal axis represents different human tumor cell lines. "Colo205" and "HCT116" are colon cancer cells; "MDA-MB-231" and "MCF-7" are breast cancer cells; "PANC-1" is a pancreatic cancer cell; "U87MG" is a glioma cell; "NCI-H446" is a lung cancer cell. The vertical axis "MFI" represents the mean fluorescence intensity of the cells after staining with anti-HLA-A2 fluorescent antibody or anti-Her2 / neu fluorescent antibody. The white bars are the expression of Her2 / neu on the cell surface, and the black bars are the expression of HLA-A2 on the cell surface. Fig.37 B shows the results of ELISA analysis of IFN-γ in #2PBMC transfected with a lentiviral vector encoding the Her2 TCR-6A5-mC TCR gene and mixed with cells of different tumor cell lines for 24 hours, and the cell supernatant was taken. Each experimental group and control group had three wells, and the results were shown as mean ± SME. The horizontal axis shows different target cells, and the vertical axis shows the concentration of IFN-γ secreted by T cells. The effector-target ratio E:T is 5:1. The white bars show that the effector cells are control peripheral blood mononuclear cells that are not transfected with the Her2 TCR-6A5-mC TCR gene, and the black bars show that the effector cells are peripheral blood mononuclear cells transfected with the Her2 TCR-6A5-mC TCR gene. Fig.37 C, D, E, F, G, H, I, J, and K show the cytotoxic activity of #2 PBMCs against different tumor cell lines after being transfected with a lentiviral vector encoding the Her2 TCR-6A5-mCTCR gene. Fig.37 The killing activity of C-37G was obtained by counting the viable cells. Fig.37 The killing activity of H-37K was determined by the MTT method, and the reaction time was 24 hours. Fig.37 C and 37H show the results for the tumor cell line MCF-7. Fig.37 D shows the results for the tumor cell line HCT116. Fig.37 E shows the results for the tumor cell line U87MG. Fig.37 F shows the results for the tumor cell line NCI-H446, Fig.37 G shows the results for the tumor cell line SKOV3. Fig.37 I shows the results for the tumor cell line PANC-1, Fig.37 J shows the results for tumor cell line HEPG2, Fig.37K shows the results for the tumor cell line HT-29. Each test group and control group consisted of three wells, and the results are shown as mean ± SME. The horizontal axis shows different effector-target ratios E:T. The vertical axis shows the percentage of T cell killing of target cells. The dot graph shows that the effector cells are control peripheral blood mononuclear cells that are not transfected with the Her2 TCR-6A5-mC TCR gene, and the upper triangle graph shows that the effector cells are peripheral blood mononuclear cells transfected with the Her2TCR-6A5-mC TCR gene. In the MTT killing experiment, another group was added with 10 μM paclitaxel as a positive control ( Fig.37 Shown as a separate lower triangular point in H-37K).

[0092] Fig.38 The figure shows the changes in tumor volume after treating HCT116 tumor-bearing NOD-SCID immunodeficient mice with the oncolytic adenovirus OAd-shPDL1#1-4.5K (1-4.5K) constructed by the present invention and the system control virus OAd-C-4.5K (C-4.5K) in Example 6; the gray triangles marked on the abscissa in the figure indicate the time point of drug administration, the abscissa indicates the time after drug administration (days), and the ordinate indicates the tumor volume (mm 3 ).

[0093] Fig.39 The figure shows the change of T / C after treating HCT116 tumor-bearing NOD-SCID immunodeficient mice with the oncolytic adenovirus OAd-shPDL1#1-4.5K (1-4.5K) constructed by the present invention and the system control virus OAd-C-4.5K (C-4.5K) in Example 6; the gray triangle marked on the abscissa in the figure indicates the time point of the drug treatment, the abscissa represents the time after the drug treatment (days), and the ordinate represents T / C (%).

[0094] Fig.40 The figure shows the changes in mouse body weight after treating HCT116 tumor-bearing NOD-SCID immunodeficient mice with the oncolytic adenovirus OAd-shPDL1#1-4.5K (1-4.5K) constructed by the present invention and the system control virus OAd-C-4.5K (C-4.5K) in Example 6; the gray triangle marked on the abscissa in the figure indicates the time point of the drug treatment, the abscissa represents the time after the drug treatment (days), and the ordinate represents the body weight (g).

[0095] Fig.41 Photos of tumors removed from mice sacrificed after HCT116 tumor-bearing NOD-SCID immunodeficient mice were treated with the oncolytic adenovirus OAd-shPDL1#1-4.5K (1-4.5K) constructed in the present invention and the system control virus OAd-C-4.5K (C-4.5K) in Example 6.

[0096] Fig.42 The figure shows the changes in tumor volume after treating HCT116 tumor-bearing BALB / C nude mice with the oncolytic adenovirus OAd-shPDL1#1-4.5K (1-4.5K) constructed by the present invention and the system control virus OAd-C-4.5K (C-4.5K) in Example 6; the gray triangles marked on the abscissa in the figure indicate the time point of drug administration, the abscissa indicates the time after drug administration (days), and the ordinate indicates the tumor volume (mm 3 ).

[0097] Fig.43 The figure shows the change in the relative tumor proliferation rate (T / C) after treating HCT116 tumor-bearing BALB / C nude mice with the oncolytic adenovirus OAd-shPDL1#1-4.5K (1-4.5K) constructed by the present invention and the system control virus OAd-C-4.5K (C-4.5K) in Example 6; the gray triangle marked on the abscissa in the figure indicates the time point of the drug treatment, the abscissa represents the time after the drug treatment (days), and the ordinate represents T / C (%).

[0098] Fig.44 The figure shows the changes in mouse body weight after treating HCT116 tumor-bearing BALB / C nude mice with the oncolytic adenovirus OAd-shPDL1#1-4.5K (1-4.5K) constructed by the present invention and the system control virus OAd-C-4.5K (C-4.5K) in Example 6; the gray triangle marked on the abscissa in the figure indicates the time point of the drug treatment, the abscissa represents the time after the drug treatment (days), and the ordinate represents the body weight (g).

[0099] Fig.45 The figure shows the tumors removed from the mice sacrificed after treating HCT116 tumor-bearing BALB / C nude mice with the oncolytic adenovirus OAd-shPDL1#1-4.5K (1-4.5K) constructed by the present invention and the system control virus OAd-C-4.5K (C-4.5K) in Example 6.

[0100] Fig.46 The figure shows the changes in tumor volume after treating HCT116 tumor-bearing BALB / C nude mice with the oncolytic adenovirus OAd-shPDL1#1-4.5K (1-4.5K) constructed by the present invention and the system control virus OAd-C-4.5K (C-4.5K) in Example 7; the gray triangles marked on the abscissa in the figure indicate the time point of drug administration, the abscissa indicates the time after drug administration (days), and the ordinate indicates the tumor volume (mm 3 ).

[0101] Fig.47The figure shows the change in the relative tumor proliferation rate (T / C) after treating HCT116 tumor-bearing BALB / C nude mice with the oncolytic adenovirus OAd-shPDL1#1-4.5K (1-4.5K) constructed by the present invention and the system control virus OAd-C-4.5K (C-4.5K) in Example 7; the gray triangle marked on the abscissa in the figure indicates the time point of the drug treatment, the abscissa represents the time after the drug treatment (days), and the ordinate represents T / C (%).

[0102] Fig.48 The figure shows the changes in mouse body weight after treating HCT116 tumor-bearing BALB / C nude mice with the oncolytic adenovirus OAd-shPDL1#1-4.5K (1-4.5K) constructed by the present invention and the system control virus OAd-C-4.5K (C-4.5K) in Example 7; the gray triangle marked on the abscissa in the figure indicates the time point of the drug treatment, the abscissa represents the time after the drug treatment (days), and the ordinate represents the body weight (g).

[0103] Fig.49 The photographs of tumors removed from the mice after HCT116 tumor-bearing BALB / C nude mice were treated with the oncolytic adenovirus OAd-shPDL1#1-4.5K (1-4.5K) constructed by the present invention and the system control virus OAd-C-4.5K (C-4.5K) in Example 7 (Figure A) and the statistical results of weighing the tumors in each group (Figure B) are shown. In Figure B, the horizontal axis represents different groups, and the vertical axis represents tumor weight (g).

[0104] Fig.50 The statistical results of the changes in the number of NK cells after standardized treatment in the tumor, blood and spleen of each group of mice are shown by FACS detection after treating HCT116 tumor-bearing BALB / C nude mice with the oncolytic adenovirus OAd-shPDL1#1-4.5K (1-4.5K) constructed by the present invention and the system control virus OAd-C-4.5K (C-4.5K) in Example 7. Figure A shows the results in the tumor, Figure B shows the results in the blood, and Figure C shows the results in the spleen. The horizontal axis in each figure represents the different groups set in the experiment, and the vertical axis represents the number of NK cells after standardized treatment.

[0105] Fig.51The statistical results of the changes in the number of T cells after standardized treatment in the tumor, blood and spleen of each group of mice are shown by FACS detection after treating HCT116 tumor-bearing BALB / C nude mice with the oncolytic adenovirus OAd-shPDL1#1-4.5K (1-4.5K) constructed by the present invention and the system control virus OAd-C-4.5K (C-4.5K) in Example 7. Figure A shows the results in the tumor, Figure B shows the results in the blood, and Figure C shows the results in the spleen. The horizontal axis in each figure represents the different groups set in the experiment, and the vertical axis represents the number of T cells after standardized treatment.

[0106] Fig.52 is a schematic diagram showing an example of the chimeric antigen receptor of the present invention.

[0107] Fig.53 The experimental scheme of Example 12 is shown, and the dosing scheme of this example is specifically shown.

[0108] Fig.54 The curves showing the average tumor volume changes of the animals in each group in Example 12 are shown.

[0109] Fig.55 The tumor volume change curve of each animal in each group of animals in Example 12 is shown.

[0110] Fig.56 The curves showing the relative tumor growth inhibition rates of the animals in each group in Example 12 are shown.

[0111] Fig.57 The average body weight change curve of each group of animals in Example 12 is shown.

[0112] Fig.58 The comparison of tumors and weights between the groups of animals in Example 12 is shown. Figure A is a photo of tumor tissues peeled from the subcutaneous tissues of the four groups of animals at the end of the experiment, and Figure B is a bar chart obtained by weighing the subcutaneous tumor tissues peeled from the animals of each group. The horizontal axis in Figure B represents different groups, and the vertical axis represents tumor weight (g).

[0113] Fig.59 The results of flow cytometry analysis of the number of T cells in the tumor tissues of the animals in each group in Example 12 are shown. Figure A shows the number of human CD3 T cells per 100,000 cells in the tumor tissues of the four groups of animals. + Figure B shows the number of human CD8 T cells per 100,000 cells in the tumor tissues of the four groups of animals. + Figure C shows the number of human CD4 T cells per 100,000 cells in the tumor tissues of the four groups of animals. + The number of T cells. The horizontal axis in each figure represents the different groups set in the experiment, and the vertical axis represents the number of T cells after standardization.

[0114] Fig.60 The results of flow cytometry analysis of the number of T cells in the blood of each group of animals in Example 12 are shown. Figure A shows the number of human CD3 T cells per 100,000 cells (excluding red blood cells) in the blood of the four groups of animals. + Figure B shows the number of human CD8 T cells per 100,000 cells (excluding red blood cells) in the blood of the four groups of animals. + Figure C shows the number of human CD4 T cells per 100,000 cells (excluding red blood cells) in the blood of the four groups of animals. + The number of T cells. The horizontal axis in each figure represents the different groups set in the experiment, and the vertical axis represents the number of T cells after standardization.

[0115] Fig.61 The results of flow cytometry analysis of the number of T cells in the spleen of each group of animals in Example 12 are shown. Figure A shows the number of human CD3 T cells per 100,000 cells in the spleen tissue of the four groups of animals. + Figure B shows the number of human CD8 T cells per 100,000 cells in the spleen tissue of the four groups of animals. + Figure C shows the number of human CD4 T cells per 100,000 cells in the spleen tissue of the four groups of animals. + The number of T cells. The horizontal axis in each figure represents the different groups set in the experiment, and the vertical axis represents the number of T cells after standardization.

[0116] Fig.62 The Her2 + / PDL1 + The horizontal axis in the figure represents the different groups set up in the experiment, and the vertical axis represents the percentage of Her2 in tumor tissue + / PDL1 + The percentage of positive cells (%).

[0117] In the above figures, the symbol “*” represents P<0.05, the symbol “**” represents P<0.01, and the symbol “***” represents P<0.001. DETAILED DESCRIPTION

[0118] The present invention will be further illustrated below through the description of specific implementation methods and with reference to the accompanying drawings, but this is not a limitation of the present invention. Those skilled in the art can make various modifications or improvements based on the basic idea of ​​the present invention, but as long as they do not deviate from the basic idea of ​​the present invention, they are all within the scope of the present invention.

[0119] The human body is a complex system, which is composed of ten major systems such as respiration, circulation, and digestion. These systems coordinate and cooperate to enable various complex life activities in the human body to proceed normally. When a tumor occurs, the body can exert anti-tumor effects through a variety of immune effector mechanisms, and the body's anti-tumor mechanisms include two aspects: cellular immunity and humoral immunity. They are closely related and influence each other, involving a variety of immune effector molecules and effector cells. It is generally believed that cellular immunity plays a leading role in the anti-tumor process, and humoral immunity plays a synergistic role in some cases. The present invention proposes to utilize the characteristics of oncolytic adenoviruses to selectively replicate and kill tumor cells in tumor cells, while carrying the coding sequence of exogenous shRNA that can inhibit the expression of PDL1 in tumor cells, so that the recombinant oncolytic adenoviruses can synergistically play the role of selective oncolysis and enhancing the anti-tumor immune effect of the body. Based on this concept, the inventors of the present invention have found through experimental research and theoretical exploration that the coding regions of the E1B19K gene, the E1B55K gene, and all the E3 genes of the oncolytic adenovirus are deleted at the same time, and the coding sequence of the exogenous shRNA is integrated into the genome, which can well achieve the above-mentioned synergistic effect.

[0120] In addition, many types of DNA viruses, such as adenovirus, can change the host cell cycle. The main reason is that the virus produces some proteins that act on the host cell cell cycle regulatory proteins, causing quiescent cells to enter the cell cycle to facilitate the replication of viral DNA. Different viruses have different mechanisms for affecting the cell cycle. Adenovirus mainly interferes with the host cell cell cycle through the Rb and p53 cell signaling pathways ( Fig.24 ) (See the literature: "Chen Jianfa et al., Research progress of oncolytic adenovirus, Cancer Prevention and Treatment Research, 2004, 31 (4): 243-245."). The oncolytic function of oncolytic adenovirus is achieved based on this principle by changing the expression of host cell cycle proteins regulated by adenovirus. The genome of adenovirus includes 4 early transcription units (i.e., E1, E2, E3 and E4) with regulatory functions and 1 late transcription unit. E1 is divided into two parts, E1A and E1B, such as Fig.24As shown, E1A binds to Rb to release free E2F, and the cell enters the S phase from the G1 phase; the adenovirus simultaneously encodes and produces two proteins, E1B55k and E1B19k, which inhibit p53 and Bax respectively, so that the division and proliferation of host cells are not inhibited by the p53 cell signaling pathway, and a large number of host cells enter the division phase from the stationary phase, allowing the adenovirus to replicate and multiply in large quantities. However, when adenoviruses with the E1A gene removed infect host cells, they cannot encode and produce E1A protein to release free E2F, and cells in the G1 phase cannot enter the S phase. Similarly, even if adenoviruses with the E1B gene removed can produce E1A protein to make host cells enter the S phase from the G1 phase, cells entering the division cycle will also undergo apoptosis or division will be blocked through the p53 signaling pathway. Therefore, adenoviruses with the E1A or E1B gene removed cannot replicate and proliferate in host cells with normal Rb and p53 cell signaling pathways, and can only proliferate in tumor cells with abnormal Rb or p53 signaling pathways. Early oncolytic adenoviruses Onyx-015 and H101 both deleted the expression of E1B55K in adenovirus (partial or complete deletion of the E3 region sequence) to achieve selective replication in p53 mutant tumor cells. When this type of virus infects normal host cells, even if it can encode and produce E1A protein to separate the Rb-E2F complex and release free E2F, and the infected cells enter the S phase from the G1 phase, it cannot encode and produce the p53 inhibitory protein E1B55K. Infected cells entering the division phase undergo division blockage or cell apoptosis through the p53 signaling pathway, and the adenovirus in the cells cannot be effectively replicated. In cells with abnormal p53 signaling pathway function, infected cells entering the division phase will not undergo division blockage or cell apoptosis through the p53 signaling pathway, and the cells will proliferate in large quantities, and the adenovirus in the cells will replicate in large quantities, causing cell lysis. However, subsequent experiments also proved that the selective replication of the above two types of viruses in normal cells was not as ideal as expected. The reason may be that they only deleted E1B55K but still retained the normal expression of E1B19K. Fig.24 , E1B55K and E1B19K play similar roles in the p53 signaling pathway. Although the deletion of E1B55K expression cannot inhibit the function of wild-type p53, the normal expression of E1B19K protein can still inhibit the function of Bax downstream of p53, so that the oncolytic adenovirus can also complete replication in normal cells. In the oncolytic adenovirus described in the present invention, in addition to deleting the E3 region, the two genes E1B55K and E1B19K are also deleted at the same time. Therefore, this type of virus has better selective replication in tumor cells than the oncolytic adenovirus in the prior art, lower replication ability in normal cells, and better safety for normal cells.

[0121] On the other hand, PD-L1 (also known as PDL1 or B7-H1) belongs to the B7 family and has IgV and IgC-like regions, transmembrane regions and cytoplasmic regions. This molecule has a wide tissue expression spectrum and is highly expressed in some tumor cell lines. Many studies have shown that it is associated with the immune escape mechanism of tumors. The microenvironment of the tumor site can induce the expression of PD-L1 on tumor cells, and the expression is widespread. The expressed PD-L1 is conducive to the occurrence and growth of tumors. PD-L1 expressed by tumor cells and APCs in the tumor microenvironment interacts with the receptor PD1 on T cells through the PD-1 / PD-L1 signaling pathway to inhibit the activation of tumor antigen-specific T cells and downregulate T cell-mediated tumor immune responses. In addition, studies have shown that blocking the PD-L1 / PD-1 signaling pathway can promote the proliferation of tumor antigen-specific T cells and upregulate infiltrating CD8 + The secretion of IFN-γ by T cells and the effective inhibition of tumor growth indicate that the blocking of the PD-1 / PD-L1 signaling pathway plays an important role in the tumor immune response aimed at inducing immune response. In addition, experiments have shown that the selection of anti-PD-L1 monoclonal antibodies in combination with tumor vaccines for tumor immunotherapy can effectively enhance the immune activation effect of tumor vaccines and weaken the impact of the tumor microenvironment on the efficacy.

[0122] Based on the above theoretical research and exploration, the oncolytic adenovirus of the present invention, in addition to reconstructing the oncolytic virus genome composition to make it have a higher oncolytic killing ability, also adds a coding frame that can express shPDL1 (shRNA that inhibits PDL1 expression), and it is expected that shPDL1 can be used to efficiently degrade the mRNA of PDL1 in the cell to achieve its gene silencing, thereby reducing the expression of PDL1 in tumor cells, weakening the transmission of PD1 / PDL1 signaling pathway to immune cell inhibitory signals, and strengthening the killing effect of immune cells on tumors. Therefore, the oncolytic virus of the present invention can be used as an oncolytic agent alone, and can also be used as an effective carrier of the coding frame of shPDL1, so that shPDL1 is expressed in large quantities along with viral replication, while playing the dual functions of viral therapy and gene therapy.

[0123] On the basis of the above-mentioned oncolytic adenovirus, the inventors of the present invention unexpectedly discovered that the oncolytic adenovirus, in addition to its own oncolytic ability against tumor cells, can also enhance the killing effect of immune cells (such as TCR-T, CAR-T or CAR-NK) affected by the PDL1 / PD1 immune checkpoint on tumors (especially solid tumors), thereby achieving a synergistic effect of 1+1>2. Furthermore, the present invention, in view of the problems and difficulties faced by adoptive immune cell therapy and oncolytic virus treatment of tumors, proposes the concept of combined treatment using the above-mentioned oncolytic adenovirus and immune cells (such as TCR-T, CAR-T or CAR-NK) affected by the PDL1 / PD1 immune checkpoint through theoretical research and experimental verification. This mode of administration of combined use of oncolytic viruses and immune killer cells to kill tumors enriches the treatment mode and treatment methods for tumor treatment, and is very likely to become one of the breakthroughs in the treatment of tumors (especially solid tumors).

[0124] Specifically, the present invention provides a therapeutic agent for treating tumors and / or cancers, comprising:

[0125] (a) a first composition, wherein the first composition comprises a first active ingredient in a first pharmaceutically acceptable carrier, the first active ingredient comprising an isolated recombinant oncolytic adenovirus, wherein the recombinant oncolytic adenovirus is a selective replication-type oncolytic adenovirus, and the genome of the recombinant oncolytic adenovirus is integrated with a coding sequence of an exogenous shRNA capable of inhibiting PDL1 expression in tumor cells; and

[0126] (b) a second composition, wherein the second composition comprises a second active ingredient in a second pharmaceutically acceptable carrier, the second active ingredient comprising a T cell receptor modified immune cell or a chimeric antigen receptor modified immune cell.

[0127] The active ingredients in the therapeutic agent are described in detail below one by one.

[0128] Recombinant oncolytic adenovirus

[0129] The present invention adopts an isolated recombinant oncolytic adenovirus, wherein the recombinant oncolytic adenovirus is a selective replication oncolytic adenovirus, and the genome of the recombinant oncolytic adenovirus is integrated with a coding sequence of an exogenous shRNA capable of inhibiting the expression of PDL1 in tumor cells.

[0130] Preferably, the coding sequence of the exogenous shRNA is shown in any one of SEQ ID NOs. 45, 48 and 51.

[0131] Preferably, the genome of the recombinant oncolytic adenovirus is deleted from the E1B19K gene, the E1B55K gene, and all E3 region genes.

[0132] The possible mechanisms of oncolytic viruses that cause tumor cell lysis after entering tumor cells include: (1) direct cytotoxic effects of viral proteins: for example, the death protein and late protein produced by adenovirus can effectively mediate tumor cell lysis. (2) Producing anti-tumor immune responses: On the one hand, viruses can kill tumors by enhancing the sensitivity of tumor cells to various cytokines. For example, adenoviruses can enhance the tumor killing effect mediated by tumor necrosis factor by replicating and expressing E1A protein in infected tumor cells. On the other hand, when tumor cells are infected by viruses, the viral antigens on the surface of tumor cells form complexes with major histocompatibility complex class I antigens, which are easily recognized by cytotoxic T lymphocytes, thereby mediating specific attacks on virus-infected tumor cells. (3) Enhancing the sensitivity of tumor cells to chemotherapy and radiotherapy: The product of adenovirus E1A gene expression is a powerful chemosensitizer. In tumor cells, the expression product of E1A gene can induce high levels of p53 protein expression, thereby enhancing the damage of chemotherapy and radiotherapy to DNA.

[0133] Therefore, preferably, the genome of the recombinant oncolytic adenovirus contains an E1A gene coding sequence. Also preferably, the E1A gene coding sequence is under the control of a CMV promoter, thereby increasing the expression of E1A to enhance its oncolytic killing effect on tumor cells.

[0134] Preferably, the recombinant oncolytic adenovirus is obtained by genetically modifying adenovirus type 5. An example of adenovirus type 5 is H101.

[0135] In a preferred embodiment, the oncolytic adenovirus genome integrates a coding frame including a U6 promoter and human PDL1 shRNA (shPDL1) after the ES sequence, and an E1A expression frame including a CMV promoter, an E1A coding region and part of its 3' UTR region and SV40 polyA.

[0136] The recombinant oncolytic adenovirus of the present invention has a strong killing ability against a variety of human tumor cells (such as human glioma cells U251, human lung cancer cells A549, human cervical cancer cells Hela, human large cell lung cancer H460, human colorectal cancer cells HCT116, human pancreatic cancer cells PANC1, human colon cancer cells HT29, etc.). The replication ability of the virus in normal human primary cells is much lower than its replication ability in human tumor cells (difference of about 2 orders of magnitude). The human shPDL1 expressed by the virus can significantly reduce the level of PDL1 protein highly expressed in human tumor cells.

[0137] The present invention also relates to a vector for preparing the recombinant oncolytic adenovirus of the present invention, wherein the vector comprises an exogenous shRNA coding sequence under the control of a promoter, and the shRNA coding sequence is shown in any one of SEQ ID NOs. 45, 48 and 51.

[0138] In a specific embodiment, the vector uses pShuttle as a basic skeleton, and the basic skeleton sequentially comprises an operably linked promoter that controls the expression of the exogenous shRNA coding sequence, the exogenous shRNA coding sequence, a promoter that controls the expression of the E1A gene coding sequence, and the E1A gene coding sequence.

[0139] The present invention also relates to a host cell containing the vector of the present invention. Preferably, the host cell stably expresses the vector.

[0140] The present invention also relates to an isolated shRNA, wherein the coding sequence of the shRNA is shown in any one of SEQ ID NOs. 45, 48 and 51, and the shRNA can inhibit the expression of PDL1 in tumor cells.

[0141] The present invention also relates to an isolated recombinant oncolytic adenovirus, wherein the recombinant oncolytic adenovirus is a selective replication-type oncolytic adenovirus, and the genome of the recombinant oncolytic adenovirus is deleted from the E1B19K gene, the E1B55K gene, and all E3 region genes; preferably, the genome of the recombinant oncolytic adenovirus contains an E1A gene coding sequence; further preferably, the E1A gene coding sequence is under the control of a CMV promoter.

[0142] The oncolytic adenovirus has a strong tumor-killing ability, and its replication ability in normal cells is far lower than its replication ability in tumor cells. Therefore, it has low toxicity to normal cells and improves safety.

[0143] T cell receptor modified immune cells

[0144] In the therapeutic agent of the present invention, the immune cells modified by T cell receptors include primitive T cells or their precursor cells, NKT cells, or T cell strains.

[0145] The T cell receptor comprises at least one of an α chain and a β chain, wherein the α chain and the β chain both comprise a variable region and a constant region, and the T cell receptor can specifically recognize the antigen epitope polypeptide on the surface of tumor cells and / or cancer cells.

[0146] Preferably, the T cell receptor can specifically recognize the antigen Her2 / neu expressed by tumor cells, and the amino acid sequence of the variable region of the α chain has at least 98%, preferably at least 98.5%, and more preferably at least 99% identity with the amino acid sequence shown in SEQ ID NO: 1, and the amino acid sequence of the variable region of the β chain has at least 98%, preferably at least 98.5%, and more preferably at least 99% identity with the amino acid sequence shown in SEQ ID NO: 2, as long as it does not significantly affect the effect of the present invention. It is also preferred that the amino acid sequence of the variable region of the α chain is as shown in SEQ ID NO: 1, and the amino acid sequence of the variable region of the β chain is as shown in SEQ ID NO: 2.

[0147] The variable regions of the TCR α chain and β chain are used to bind to antigenic peptides / major histocompatibility complex (MHC I), and each includes three hypervariable regions or complementarity determining regions (CDRs), namely, CDR1, CDR2, and CDR3. Among them, the CDR3 region is crucial for the specific recognition of antigenic peptides presented by MHC molecules. The TCR α chain is formed by the recombination of different V and J gene segments, while the β chain is formed by the recombination of different V, D, and J gene segments. The corresponding CDR3 region formed by the recombination of specific gene segments, as well as the palindromic and random nucleotide additions in the binding region, form the specificity of TCR for antigenic peptide recognition (see the literature "Immunobiology: The immune system in health and disease.5 th edition, Chapter 4, The generation of Lymphocyte antigen receptors”). The MHC class I molecule includes human HLA. The HLA includes: HLA-A, B, and C.

[0148] More specifically, the T cell receptor can specifically recognize the antigen epitope polypeptide of the antigen Her2 / neu presented by the HLA-A2 molecule. The amino acid sequence of the antigen Her2 / neu is shown in SEQ ID NO:21. Preferably, the antigen epitope polypeptide includes Her2 / neu 369-377 as shown in SEQ ID NO:3. The HLA-A2 alleles expressed by HLA-A2 positive cells include HLA-A*0201, 0202, 0203, 0204, 0205, 0206 and 0207. Preferably, the HLA-A2 molecule is preferably HLA-A*0201.

[0149] In one embodiment, the antigenic epitope polypeptide of the antigen Her2 / neu is the Her2 / neu 369-377 polypeptide (SEQ ID NO: 3). In other embodiments, the antigenic epitope polypeptide of the antigen Her2 / neu is an antigenic epitope polypeptide having 4-9 consecutive identical amino acids (e.g., 4, 5, 6, 7, 8 or 9 consecutive identical amino acids) with the Her2 / neu369-377 polypeptide, and the length of these polypeptides is 8-11 amino acids. For example, in one embodiment, the antigenic epitope polypeptide of the antigen Her2 / neu is the Her2 / neu373-382 polypeptide (SEQ ID NO: 22).

[0150] Preferably, the maximum half-reaction polypeptide concentration of the T cell receptor recognizing the Her2 / neu 369-377 polypeptide is between 1.0-10 ng / ml. In one embodiment of the present invention, the maximum half-reaction polypeptide concentration is about 1.6 ng / ml-2.9 ng / ml. The term "maximum half-reaction polypeptide concentration" refers to the concentration of the polypeptide required to induce a T cell response to reach 50% of the maximum value. It is reported that the maximum half-reaction polypeptide concentration of T cells specific for the cytomegalovirus (CMV) antigen CMV pp65 (495-503) polypeptide is between 0.1-1 ng / ml, and this TCR is considered to have a high affinity for the CMV antigen polypeptide (see the document "Journal of Immunogical Methds 2007; 320: 119-131"). In the present invention, the T cell receptor has a moderate to high affinity for the Her2 / neu antigen, thereby avoiding the off-target toxicity that may be caused by high affinity (maximum half-reaction polypeptide concentration is less than 0.1 ng / ml). In addition, the recognition of the Her2 / neu 369-377 polypeptide by the T cell receptor is independent of the auxiliary effect of the CD8 molecule, and CD8-negative CD4-positive T cells expressing the T cell receptor can also specifically recognize the Her2 / neu 369-377 polypeptide presented by HLA-A2 and secrete cytokines, thereby enhancing the function of the cytotoxic T cells expressing the T cell receptor.

[0151] The exogenous TCR α chain and β chain expressed by T cells may mismatch with the α chain and β chain of the T cell's own TCR, which will not only dilute the expression level of the correctly paired exogenous TCR, but also make the antigen specificity of the mismatched TCR unclear, thus posing a potential risk of recognizing self-antigens. Therefore, it is preferred to modify the constant regions of the TCR α chain and β chain to reduce or avoid mismatching.

[0152] In one embodiment, the constant region of the α chain and / or the constant region of the β chain are derived from humans; preferably, the present invention finds that the constant region of the α chain can be replaced in whole or in part by homologous sequences derived from other species, and / or the constant region of the β chain can be replaced in whole or in part by homologous sequences derived from other species. More preferably, the other species is a mouse. The replacement can increase the expression of TCR in cells, and can further improve the specificity of cells modified by the TCR to Her2 / neu antigen.

[0153] The constant region of the α chain may be modified with one or more disulfide bonds, and / or the constant region of the β chain may be modified with one or more disulfide bonds, such as 1 or 2.

[0154] In a specific embodiment, two different modified TCRs were prepared, one of which was to add a disulfide bond to the TCR constant region by point mutation, the method described in the document "Cancer Res. 2007Apr 15; 67(8): 3898-903.", which is incorporated herein by reference in its entirety. Her2 TCR-1B5-mC is to replace the corresponding human TCR constant region sequence with the mouse TCR constant region sequence, the method described in the document "Eur. J. Immunol. 2006 36: 3052-3059", which is incorporated herein by reference in its entirety.

[0155] In a specific embodiment, the amino acid sequence of the α chain is shown in SEQ ID NOs: 4, 5 or 6, and the amino acid sequence of the β chain is shown in SEQ ID NOs: 7, 8 or 9.

[0156] Among them, for the α chain with an amino acid sequence as shown in SEQ ID NO:4, its sequence is the original human sequence; for the α chain with an amino acid sequence as shown in SEQ ID NO:5, it is modified with one disulfide bond in the constant region; for the α chain with an amino acid sequence as shown in SEQ ID NO:6, its constant region is replaced with a mouse constant region.

[0157] Among them, for the β chain with an amino acid sequence as shown in SEQ ID NO:7, its sequence is the original human sequence; for the β chain with an amino acid sequence as shown in SEQ ID NO:8, it is modified with one disulfide bond in the constant region; for the β chain with an amino acid sequence as shown in SEQ ID NO:9, its constant region is replaced with a mouse constant region.

[0158] In a specific embodiment, the amino acid sequence of the α chain of the TCR is shown in SEQ ID NO: 4, and the amino acid sequence of the β chain is shown in SEQ ID NO: 7. In another specific embodiment, the amino acid sequence of the α chain of the TCR is shown in SEQ ID NO: 5, and the amino acid sequence of the β chain is shown in SEQ ID NO: 8. In yet another specific embodiment, the amino acid sequence of the α chain of the TCR is shown in SEQ ID NO: 6, and the amino acid sequence of the β chain is shown in SEQ ID NO: 9.

[0159] In other specific embodiments of the present invention, the α chain of the TCR has an amino acid sequence obtained by replacing, deleting, and / or adding one or more amino acids in the amino acid sequence shown in SEQ ID NOs:4, 5 or 6; for example, the α chain has at least 90%, preferably at least 95%, and more preferably at least 99% identity with the amino acid sequence shown in SEQ ID NOs:4, 5 or 6.

[0160] In other specific embodiments of the present invention, the β chain of the TCR has an amino acid sequence obtained by replacing, deleting, and / or adding one or more amino acids in the amino acid sequence shown in SEQ ID NOs:7, 8 or 9; for example, the β chain has at least 90%, preferably at least 95%, and more preferably at least 99% identity with the amino acid sequence shown in SEQ ID NOs:7, 8 or 9.

[0161] The α chain and / or β chain of the TCR of the present invention can also bind to other functional sequences at the end (e.g., C-terminus), such as functional region sequences of co-stimulatory signals CD28, 4-1BB and / or CD3zeta.

[0162] The present invention also relates to an isolated nucleic acid encoding a T cell receptor, comprising a coding sequence for at least one of the α chain and the β chain of the T cell receptor, wherein the α chain coding sequence and the β chain coding sequence both comprise a variable region coding sequence and a constant region coding sequence, and the T cell receptor is capable of specifically recognizing the antigen epitope polypeptide on the surface of tumor cells and / or cancer cells.

[0163] Preferably, the T cell receptor can specifically recognize the antigen Her2 / neu expressed by tumor cells, and the amino acid sequence encoded by the α chain variable region encoding sequence has at least 98%, preferably at least 98.5%, and more preferably at least 99% identity with the amino acid sequence shown in SEQ ID NO: 1, and the amino acid sequence encoded by the β chain variable region encoding sequence has at least 98%, preferably at least 98.5%, and more preferably at least 99% identity with the amino acid sequence shown in SEQ ID NO: 2, as long as it does not significantly affect the effect of the present invention. It is also preferred that the α chain variable region encoding sequence encodes the amino acid sequence shown in SEQ ID NO: 1, and the β chain variable region encoding sequence encodes the amino acid sequence shown in SEQ ID NO: 2.

[0164] The nucleic acid may be DNA or RNA.

[0165] Preferably, the α chain variable region encoding sequence is shown as SEQ ID NO:10, and the β chain variable region encoding sequence is shown as SEQ ID NO:11.

[0166] More specifically, the T cell receptor encoded by the nucleic acid can specifically recognize the antigen epitope polypeptide of the antigen Her2 / neu presented by the HLA-A2 molecule.

[0167] In one embodiment, the antigenic epitope polypeptide of the antigen Her2 / neu is the Her2 / neu 369-377 polypeptide (SEQ ID NO: 3). In other embodiments, the antigenic epitope polypeptide of the antigen Her2 / neu is an antigenic epitope polypeptide having 4-9 consecutive identical amino acids (e.g., 4, 5, 6, 7, 8 or 9 consecutive identical amino acids) with the Her2 / neu369-377 polypeptide, and the length of these polypeptides is 8-10 amino acids. For example, in one embodiment, the antigenic epitope polypeptide of the antigen Her2 / neu is the Her2 / neu373-382 polypeptide (SEQ ID NO: 22).

[0168] Preferably, the maximum half-reaction polypeptide concentration of the T cell receptor encoded by the nucleic acid to recognize the Her2 / neu369-377 polypeptide is between 1.0-10 ng / ml (for example, between 3.0-8.0 ng / ml, 5.0-7.0 ng / ml). In one embodiment of the present invention, the maximum half-reaction polypeptide concentration is about 1.6-2.9 ng / ml. In this case, the T cell receptor has a medium-high affinity for the Her2 / neu antigen, which can avoid the off-target toxicity that may be caused by high affinity (maximum half-reaction polypeptide concentration is less than 0.1 ng / ml).

[0169] In one embodiment, the constant region of the α chain and / or the constant region of the β chain are derived from humans; preferably, the α chain constant region encoding sequence is replaced in whole or in part by a homologous sequence derived from another species, and / or the β chain constant region encoding sequence is replaced in whole or in part by a homologous sequence derived from another species. More preferably, the other species is a mouse. The replacement can increase the expression of TCR in cells, and can further improve the specificity of cells modified by the TCR to Her2 / neu antigen.

[0170] The α chain constant region encoding sequence may comprise one or more disulfide bond encoding sequences, and / or the β chain constant region encoding sequence may comprise one or more disulfide bond encoding sequences.

[0171] In a specific embodiment, the α chain encoding sequence is shown as SEQ ID NOs: 12, 13 or 14, and the β chain encoding sequence is shown as SEQ ID NOs: 15, 16 or 17.

[0172] Among them, for the α chain with a coding sequence as shown in SEQ ID NO:12, its sequence is the original human sequence; for the α chain with a coding sequence as shown in SEQ ID NO:13, its constant region is modified with one disulfide bond; for the α chain with a coding sequence as shown in SEQID NO:14, its constant region is replaced with a mouse constant region.

[0173] Among them, for the β chain with a coding sequence as shown in SEQ ID NO:15, its sequence is the original human sequence; for the β chain with a coding sequence as shown in SEQ ID NO:16, its constant region is modified with one disulfide bond; for the β chain with a coding sequence as shown in SEQID NO:17, its constant region is replaced with a mouse constant region.

[0174] In a specific embodiment, the coding sequence of the α chain of the TCR is shown in SEQ ID NO: 12, and the coding sequence of the β chain is shown in SEQ ID NO: 15. In another specific embodiment, the coding sequence of the α chain of the TCR is shown in SEQ ID NO: 13, and the coding sequence of the β chain is shown in SEQ ID NO: 16. In another specific embodiment, the coding sequence of the α chain of the TCR is shown in SEQ ID NO: 14, and the coding sequence of the β chain is shown in SEQ ID NO: 17.

[0175] In another embodiment, the α chain coding sequence and the β chain coding sequence are connected by a coding sequence of a cleavable linking polypeptide, which can increase the expression of TCR in cells. The term "cleavable linking polypeptide" means that the polypeptide plays a connecting role and can be cleaved by a specific enzyme, or the nucleic acid sequence encoding this polypeptide is translated by ribosome skipping, so that the polypeptides connected by it are separated from each other. Examples of cleavable linking polypeptides are known in the art, such as F2A polypeptides, and F2A polypeptide sequences include but are not limited to F2A polypeptides from picornaviruses, and similar 2A sequences from other viruses. In addition, the cleavable linking polypeptide also includes a standard four amino acid motif (canonical four amino acid motif) that can be cleaved by the Furin enzyme, that is, the RX-[KR]-R amino acid sequence. The TCR encoded by this embodiment is a single-chain chimeric T cell receptor. After the single-chain chimeric T cell receptor is expressed, the cleavable linking polypeptide connecting the α chain and the β chain will be cleaved by a specific enzyme in the cell, thereby forming equal amounts of free α chain and β chain.

[0176] The α chain and β chain constituting the single-chain chimeric TCR may also be replaced in whole or in part by homologous sequences from other species in the constant region (and their corresponding coding sequences) as described above, and / or modified with (encoding) one or more disulfide bonds.

[0177] In a specific embodiment, the sequence of the nucleic acid is shown in SEQ ID NOs:18, 19, or 20.

[0178] Preferably, the nucleotide sequence of the nucleic acid is codon optimized to increase gene expression, protein translation efficiency and protein expression, thereby enhancing the ability of TCR to recognize antigens. Codon optimization includes but is not limited to modification of the translation initiation region, changing the mRNA structural fragment, and using different codons encoding the same amino acid.

[0179] In other embodiments, the sequence of the TCR encoding nucleic acid can be mutated, including removing, inserting and / or replacing one or more amino acid codons, so that the function of the expressed TCR to recognize the Her2 / neu antigen remains unchanged or enhanced. For example, in one embodiment, conservative amino acid substitutions are performed, including replacing an amino acid in the variable region of the above-mentioned TCR α chain and / or β chain with another amino acid with similar structure and / or chemical properties. The term "similar amino acids" refers to amino acid residues with similar polarity, electrical load, solubility, hydrophobicity, hydrophilicity and other properties. The mutated TCR still has the biological activity of recognizing the Her2 / neu antigen polypeptide presented by the target cell. In another embodiment, TCR maturation modification is performed, that is, including removing, inserting and / or replacing the amino acids in the complementary determining region 2 (CDR2) and / or CDR3 regions in the variable region of the above-mentioned TCR α chain and / or β chain, thereby changing the affinity of the TCR binding to the Her2 / neu antigen.

[0180] The invention also relates to an isolated mRNA transcribed from the DNA according to the invention.

[0181] The present invention also relates to a recombinant expression vector, which contains the nucleic acid (eg DNA) according to the present invention operably linked to a promoter, and / or its complementary sequence.

[0182] Preferably, in the recombinant expression vector, the DNA of the present invention is suitably and operably linked to a promoter, an enhancer, a terminator and / or a polyA signal sequence.

[0183] The combination of the above-mentioned functional elements of the recombinant expression vector of the present invention can promote the transcription and translation of DNA and enhance the stability of mRNA.

[0184] The basic framework of the recombinant expression vector can be any known expression vector, including plasmids or viruses, and viral vectors include, but are not limited to, for example, retroviral vectors (the virus prototype is Moloney murine leukemia virus (MMLV)) and lentiviral vectors (the virus prototype is human immunodeficiency virus type I (HIV)). The recombinant vector expressing the TCR of the present invention can be obtained by conventional recombinant DNA techniques in the art.

[0185] In one embodiment, the expression of the α chain and β chain genes on the recombinant expression vector can be driven by two different promoters, including various known types, such as strong expression, weak expression, continuous expression, inducible, tissue-specific, and differentiation-specific promoters. The promoter can be viral or non-viral (e.g., eukaryotic cell promoter), such as CMV promoter, promoter on LTR of MSCV, EF1-α promoter, and PGK-1 promoter, SV40 promoter, Ubc promoter, CAG promoter, TRE promoter, CaMKIIa promoter, human β-actin promoter. The driving direction of the two promoters can be the same direction or the opposite direction.

[0186] In another embodiment, the expression of the α chain and β chain genes on the recombinant expression vector can be driven by the same promoter. For example, in the case of encoding a single-chain chimeric T cell receptor, the nucleotide sequence of the α chain and the nucleotide sequence of the β chain are connected by the Furin-F2A polypeptide coding sequence.

[0187] In other embodiments, the recombinant expression vector may contain coding sequences of other functional molecules in addition to the α chain and β chain genes. One embodiment includes expressing an autofluorescent protein (such as GFP or other fluorescent proteins) for in vivo tracking imaging. Another embodiment includes expressing an inducible suicide gene system, such as inducing the expression of herpes simplex virus-thymidine kinase (HSV-TK) protein, or inducing the expression of Caspase 9 (iCasp9) protein. The expression of these "safety-switches" can increase the safety of the TCR gene-modified cells of the present invention for use in vivo (see the document "Front. Pharmacol., 2014; 5: 1-8). Another embodiment includes expressing human chemokine receptor genes, such as CCR2, which can bind to the corresponding chemokine ligands highly expressed in tumor tissues, thereby increasing the homing of the TCR gene-modified cells of the present invention in tumor tissues.

[0188] The present invention uses a T cell receptor modified immune cell, the surface of which is modified by the T cell receptor of the present invention, wherein the cell includes a primitive T cell or a precursor cell thereof, a NKT cell, or a T cell strain.

[0189] The "modification" in the "T cell receptor modification" refers to the expression of the T cell receptor of the present invention in cells through gene transfection, that is, the T cell receptor is anchored on the cell membrane of the modified cell through the transmembrane region and has the function of recognizing the antigen polypeptide / MHC complex.

[0190] The present invention also relates to a method for preparing an immune cell modified with a T cell receptor according to the present invention, comprising the following steps:

[0191] 1) Providing cells;

[0192] 2) providing a nucleic acid encoding a T cell receptor of the present invention;

[0193] 3) Transfecting the nucleic acid into the cells.

[0194] The cells in step 1) can be derived from mammals, including humans, dogs, mice, rats and transgenic animals thereof. The cells can be autologous or allogeneic. Allogeneic cells include cells from identical twins, allogeneic stem cells, and genetically modified allogeneic T cells.

[0195] The cells described in step 1) include primitive T cells or their precursor cells, NKT cells, or T cell strains. The term "naive T cells" refers to mature T cells in peripheral blood that have not yet been activated by the corresponding antigen. These cells can be isolated by methods known in the art. For example, T cells can be obtained from different tissues and organs, including peripheral blood, bone marrow, lymphoid tissue, spleen, umbilical cord blood, and tumor tissue. In one embodiment, T cells can be derived from hematopoietic stem cells (HSCs), including from bone marrow, peripheral blood or umbilical cord blood, and separated and obtained by stem cell marker molecules such as CD34. In one embodiment, T cells can be derived from induced pluripotent stem cells (iPS cells), including introducing specific genes or specific gene products into somatic cells, converting the somatic cells into stem cells, and then inducing differentiation into T cells or their precursor cells in vitro. T cells can be obtained by commonly used methods such as density gradient centrifugation, and examples of density gradient centrifugation include Ficoll or Percoll density centrifugation. One embodiment is to obtain a product of enriched T cells from peripheral blood using apheresis or leukapheresis. One embodiment is to label a specific cell population with an antibody and then separate it by magnetic beads (e.g. system (Miltenyi Biotec)), or flow cytometry separation to obtain enriched CD8 + or CD4 + T cells.

[0196] Preferably, the T cell precursor cells are hematopoietic stem cells. The coding gene of the TCR of the present invention can be directly introduced into hematopoietic stem cells, and then transferred into the body to further differentiate into mature T cells; or the coding gene can be introduced into T cells differentiated from hematopoietic stem cells under specific conditions in vitro.

[0197] The cells can be resuspended in a freezing solution and stored in liquid nitrogen. Common freezing solutions include, but are not limited to, PBS solutions containing 20% ​​DMSO and 80% human serum albumin. The cells are frozen at -80°C with a temperature drop of 1°C per minute and then stored in the gas phase of a liquid nitrogen tank. Other freezing methods are to directly freeze the cells in the freezing solution at -80°C or in liquid nitrogen.

[0198] The nucleic acid described in step 2) is the nucleic acid described in the present invention, including the DNA and RNA.

[0199] The transfection includes physical, biological and chemical methods. The physical method is to introduce the TCR gene into the cell in the form of DNA or RNA through calcium phosphate precipitation, liposomes, microinjection, electroporation, gene guns and other approaches. Currently, there are commercial instruments, including electrotransfer instruments, such as Amaxa Nucleofector-II (Amaxa Biosystems, Germany), ECM830 (BTX) (Harvard Instruments, USA), Gene Pulser II (BioRad, USA), and Multiporator (Eppendort, Germany). The biological method is to introduce the TCR gene into the cell through a DNA or RNA vector. Retroviral vectors (such as γ retroviral vectors) are commonly used tools for transfection and insertion of exogenous gene fragments into animal cells (including human cells). Other viral vectors are derived from lentivirus, poxvirus, herpes simplex virus, adenovirus and adenovirus-associated virus. The chemical method is to introduce polynucleotides into cells, including colloidal dispersion systems, such as macromolecular complexes, nanocapsules, microspheres, microbeads, micelles and liposomes. Regardless of how the TCR gene is introduced into the cell, various detection methods are used to analyze whether the target gene is introduced into the target cell. The detection methods include common molecular biological methods (such as Southern blotting and Northern blotting, RT-PCR and PCR, etc.), or common biochemical methods (such as ELISA and Western blotting), as well as the methods mentioned in the present invention.

[0200] Preferably, the transfection is performed by a retroviral vector or a lentiviral vector.

[0201] The culture of the cells after transfection can be carried out according to their respective conventional methods and conditions according to practical applications. For example, T cells can be amplified in vitro after being activated by TCR / CD3 complexes on the surface and auxiliary stimulatory molecules (such as CD28). Stimulants (such as anti-TCR, CD3 or CD28 antibodies) that activate TCR, CD3 and CD28 can be adsorbed on the surface of the culture container, or on the surface of the co-culture (such as magnetic beads), or can be directly added to the cell culture fluid for co-culture. Another embodiment is to co-culture T cells with trophoblasts, which express auxiliary stimulatory molecules or corresponding ligands, including but not limited to HLA-A2, β2-microglobulin, CD40, CD83, CD86, CD127, 4-1BB.

[0202] According to the usual mammalian cell in vitro culture method, T cells are cultured and expanded under appropriate culture conditions. For example, cells can be passaged when they reach a confluence of more than 70%, and fresh culture medium is generally replaced every 2 to 3 days. When the cells reach a certain number, they can be used directly, or frozen as described above. The in vitro culture time can be within 24 hours or up to 14 days or longer. After the frozen cells are thawed, they can be used in the next step.

[0203] In one embodiment, the cells can be cultured in vitro for a few hours to 14 days, or any number of hours in between. T cell culture conditions include the use of basal culture fluids, including but not limited to RPMI 1640, AIM-V, DMEM, MEM, a-MEM, F-12, X-Vivo 15, and X-Vivo. Other conditions required for cell survival and proliferation include but are not limited to the use of serum (human or fetal bovine serum), interleukin-2 (IL-2), insulin, IFN-γ, IL-4, IL-7, GM-CSF, IL-10, IL-12, IL-15, IL-21, TGF-β and TNF-a, other culture additives (including amino acids, sodium pyruvate, vitamin C, 2-mercaptoethanol, growth hormone, growth factors). The cells can be placed in appropriate culture conditions, for example, the temperature can be at 37°C, 32°C, 30°C or room temperature, and the air conditions can be (for example) containing 5% CO 2 of air.

[0204] Chimeric antigen receptor-modified immune cells

[0205] The chimeric antigen receptor modified immune cells include primitive T cells or their precursor cells, NKT cells, T cell strains or NK cells.

[0206] The chimeric antigen receptor comprises an operably connected, sequentially connected antigen binding domain, a spacer, a transmembrane region and an intracellular domain, wherein the antigen binding domain is capable of specifically recognizing and binding to the extracellular antigen determining region of the marker polypeptide, the spacer is used to separate the antigen binding domain and the transmembrane region, and the intracellular domain is used for signal transduction.

[0207] The definitions of the terms "antigen binding domain", "spacer region", "transmembrane region" and "intracellular domain" in the present invention can be found in "Introduction to Immunology, Yu Shanqian, Higher Education Press, 2008"; and "Immunobiology, 7th edition, Kenneth Murphy, Paul Travers, Mark Walport, etc."

[0208] The antigen binding domain is preferably a single chain antibody (ScFv) comprising a light chain and a heavy chain, and the light chain and the heavy chain can be connected to each other by a linker, such as Fig.52 shown.

[0209] The chimeric antigen receptor can modify immune cells through lentiviral infection and mRNA electroporation.

[0210] The oncolytic adenovirus is combined with the T cell receptor modified immune cell or the chimeric antigen receptor modified immune cell Therapeutic agents for cell-mediated

[0211] Preferably, in the therapeutic agent of the present invention, the first composition and the second composition are each independently present in the therapeutic agent without being mixed with each other.

[0212] In some embodiments, the first pharmaceutically acceptable carrier and the second pharmaceutically acceptable carrier are the same. In other embodiments, the first pharmaceutically acceptable carrier and the second pharmaceutically acceptable carrier are different.

[0213] In some cases, the therapeutic agent may also be understood as a combination of drugs.

[0214] Preferably, the first composition comprises a therapeutically effective amount of the recombinant oncolytic adenovirus (preferably, the first composition comprises 5×10 7 -5×10 12 vp / day dose of the recombinant oncolytic adenovirus, more preferably comprising 5×10 7 to 1.5×10 12 VP / day dose of the recombinant oncolytic adenovirus, more preferably comprising 5×10 8 Up to 1×10 12 VP / day dose of the recombinant oncolytic adenovirus, more preferably comprising 1×10 9 Up to 5×10 11 VP / day dose of the recombinant oncolytic adenovirus, more preferably comprises 3×1010 Up to 3×10 11 VP / day dose of the recombinant oncolytic adenovirus).

[0215] In some embodiments, the active ingredient of the first pharmaceutical composition is the recombinant oncolytic adenovirus.

[0216] The recombinant oncolytic adenovirus can be administered by a commonly used administration method in the art, for example, it can be formulated for administration by intratumoral injection, intraperitoneal administration, subarachnoid administration, or intravenous administration.

[0217] Preferably, the second composition comprises a therapeutically effective amount of the immune cells (T cell receptor modified immune cells or chimeric antigen receptor modified immune cells) of the present invention. Preferably, the second composition comprises a total dose range of 1×10 3 -1×10 9 The immune cells contain cells / Kg body weight.

[0218] The immune cells can be formulated for administration via an artery, vein, subcutaneous, intradermal, intratumoral, intralymphatic, intralymph node, subarachnoid space, intramedullary, intramuscular or intraperitoneal route.

[0219] Preferably, the therapeutic agent consists of the first composition and the second composition.

[0220] Those skilled in the art will appreciate that the therapeutic agents of the present invention may also contain suitable pharmaceutically acceptable excipients, including pharmaceutical or physiological carriers, excipients, diluents (including physiological saline, PBS solution), and various additives, including carbohydrates, lipids, polypeptides, amino acids, antioxidants, adjuvants, preservatives, and the like.

[0221] The present invention also provides use of the therapeutic agent in preparing a medicine for treating tumors and / or cancers.

[0222] The tumors and / or cancers include: breast cancer, head and neck tumors, synovial cancer, kidney cancer, connective tissue cancer, melanoma, lung cancer, esophageal cancer, colon cancer, rectal cancer, brain cancer, liver cancer, bone cancer, choriocarcinoma, gastrinoma, pheochromocytoma, prolactinoma, von Hippel-Lindau disease, Zollinger-Ellison syndrome, anal cancer, bile duct cancer, bladder cancer, ureter cancer, glioma, neuroblastoma, meningioma, spinal cord tumors, osteochondroma, chondrosarcoma, Ewing's sarcoma, carcinoma of unknown primary site, carcinoid, fibrosarcoma, Paget's disease, cervical cancer, gallbladder cancer, eye cancer, Kaposi's sarcoma, prostate cancer, testicular cancer, squamous cell carcinoma of the skin, mesothelioma, multiapical myeloma, ovarian cancer, pancreatic endocrine tumor, glucagonoma, pancreatic cancer, penile cancer, pituitary cancer, soft tissue sarcoma, retinoblastoma, small intestine cancer, stomach cancer, thymic cancer, trophoblastic carcinoma, hydatidiform mole, endometrial cancer, vaginal cancer, vulvar cancer, mycosis fungoides, insulinoma, heart cancer, meningeal cancer, blood cancer, peritoneal cancer, and pleural cancer.

[0223] The present invention also provides a medicine kit of a combined drug with synergistic effect for treating tumors and / or cancers, comprising:

[0224] A first container containing a first composition of a therapeutic agent according to the present invention;

[0225] a second container containing a second composition of a therapeutic agent according to the present invention, wherein the first container and the second container are separate; and

[0226] Instructions for use that specify when and how to administer the drug.

[0227] The present invention also provides use of the medicine kit in preparing medicines for treating or preventing tumors and / or cancers.

[0228] The tumors and / or cancers include: breast cancer, head and neck tumors, synovial cancer, kidney cancer, connective tissue cancer, melanoma, lung cancer, esophageal cancer, colon cancer, rectal cancer, brain cancer, liver cancer, bone cancer, choriocarcinoma, gastrinoma, pheochromocytoma, prolactinoma, von Hippel-Lindau disease, Zollinger-Ellison syndrome, anal cancer, bile duct cancer, bladder cancer, ureter cancer, glioma, neuroblastoma, meningioma, spinal cord tumors, osteochondroma, chondrosarcoma, Ewing's sarcoma, carcinoma of unknown primary site, carcinoid, fibrosarcoma, Paget's disease, cervical cancer, gallbladder cancer, eye cancer, Kaposi's sarcoma, prostate cancer, testicular cancer, squamous cell carcinoma of the skin, mesothelioma, multiapical myeloma, ovarian cancer, pancreatic endocrine tumor, glucagonoma, pancreatic cancer, penile cancer, pituitary cancer, soft tissue sarcoma, retinoblastoma, small intestine cancer, stomach cancer, thymic cancer, trophoblastic carcinoma, hydatidiform mole, endometrial cancer, vaginal cancer, vulvar cancer, mycosis fungoides, insulinoma, heart cancer, meningeal cancer, blood cancer, peritoneal cancer, and pleural cancer.

[0229] The present invention also provides a method for treating tumors and / or cancers, comprising:

[0230] administering the first composition of the therapeutic agent according to the present invention to a tumor and / or cancer patient; and

[0231] The second composition of the therapeutic agent according to the present invention is administered to the tumor and / or cancer patient.

[0232] The first and second compositions of the therapeutic agent can be administered simultaneously (e.g., simultaneously injected intratumorally as a mixture), separately but simultaneously (e.g., administered by intratumoral and intravenous injections, respectively), or sequentially (e.g., first administering the first composition, then administering the second composition; or first administering the second composition, then administering the first composition).

[0233] Preferably, the method comprises the following steps performed in sequence:

[0234] 1) administering the first composition to the tumor and / or cancer patient; and

[0235] 2) After administering the first composition, administering the second composition of the therapeutic agent to the tumor and / or cancer patient.

[0236] Preferably, the second composition of the therapeutic agent is administered to the tumor and / or cancer patient 1-30 days after the first administration of the first composition.

[0237] The term "administering the second composition of the therapeutic agent to the tumor and / or cancer patient on day 1-30 after first administering the first composition" means that the time interval between the first administration of the second composition and the first administration of the first composition is 1-30 days (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 days), or the time interval between the first administration of the second composition and the most adjacent administration of the first composition is 1-30 days (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 days). Preferably, the time interval between the first administration of the second composition and the most recent previous administration of the first composition is 3-14 days (e.g., 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 days).

[0238] In a preferred embodiment of the present invention, the administration dose of the recombinant oncolytic adenovirus is 5×10 7 -5×10 12 vp / day, 1-2 times a day, for 1-7 consecutive days, or any value between the above ranges.

[0239] In a preferred embodiment of the present invention, the administration dose of the immune cells (T cell receptor modified immune cells or chimeric antigen receptor modified immune cells) is such that the total dose range for each course of treatment is 1×10 3 -1×10 9 Preferably, the drug is administered 1 to 3 times a day for 1 to 7 consecutive days.

[0240] In certain embodiments, the method for treating tumors and / or cancers further comprises administering to the patient other drugs for treating tumors and / or cancers, and / or drugs for regulating the patient's immune system, to enhance the number and function of the immune cells in the body. The other drugs for treating tumors and / or cancers include, but are not limited to: chemotherapy drugs, such as cyclophosphamide, fludarabine; radiotherapy drugs; immunosuppressants, such as cyclosporine, azathioprine, methotrexate, mycophenolate, FK50; antibodies, such as antibodies against CD3, IL-2, IL-6, IL-17, TNF.

[0241] In certain embodiments, the method for treating tumors and / or cancers further comprises administering to the patient other drugs for treating tumors and / or cancers, and / or drugs for regulating the patient's immune system, for removing the number and function of the immune cells modified by the T cell receptors carrying the suicide gene in vivo when the immune cells produce severe toxic side effects. The other drugs for treating tumors and / or cancers include, but are not limited to, chemically induced dimerization (CID) drugs, AP1903, phosphorylated ganciclovir, anti-Cd20 antibodies, anti-CMYC antibodies, and anti-EGFR antibodies.

[0242] The recombinant oncolytic adenovirus can be formulated for administration by intratumoral injection, intraperitoneal administration, subarachnoid administration, or intravenous administration.

[0243] The immune cells can be formulated for administration via artery, vein, subcutaneous, intradermal, intratumoral, intralymphatic, intralymph node, subarachnoid space, intramedullary, intramuscular or intraperitoneal routes.

[0244] The tumors and / or cancers include: breast cancer, head and neck tumors, synovial cancer, kidney cancer, connective tissue cancer, melanoma, lung cancer, esophageal cancer, colon cancer, rectal cancer, brain cancer, liver cancer, bone cancer, choriocarcinoma, gastrinoma, pheochromocytoma, prolactinoma, von Hippel-Lindau disease, Zollinger-Ellison syndrome, anal cancer, bile duct cancer, bladder cancer, ureter cancer, glioma, neuroblastoma, meningioma, spinal cord tumors, osteochondroma, chondrosarcoma, Ewing's sarcoma, carcinoma of unknown primary site, carcinoid, fibrosarcoma, Paget's disease, cervical cancer, gallbladder cancer, eye cancer, Kaposi's sarcoma, prostate cancer, testicular cancer, squamous cell carcinoma of the skin, mesothelioma, multiapical myeloma, ovarian cancer, pancreatic endocrine tumor, glucagonoma, pancreatic cancer, penile cancer, pituitary cancer, soft tissue sarcoma, retinoblastoma, small intestine cancer, stomach cancer, thymic cancer, trophoblastic carcinoma, hydatidiform mole, endometrial cancer, vaginal cancer, vulvar cancer, mycosis fungoides, insulinoma, heart cancer, meningeal cancer, blood cancer, peritoneal cancer, and pleural cancer.

[0245] The following further explains or illustrates the content of the present invention by way of examples, but these examples should not be construed as limiting the scope of protection of the present invention.

[0246] example

[0247] Unless otherwise stated, the experimental methods used in the following examples were performed using conventional experimental procedures, operations, materials, and conditions in the field of bioengineering.

[0248] Unless otherwise specified, the percentage concentration (%) of each reagent refers to the volume percentage concentration (% (v / v)) of the reagent.

[0249] Materials and methods

[0250] Cells AD293, MRC-5, Hela, A549, U251, HCT116, PANC1, HT29, H460, and MDA-MB-231 were purchased from ATCC; HUVEC was purchased from Auscell Biotechnology (Shanghai) Co., Ltd.

[0251] Oncolytic adenovirus H101 was purchased from Shanghai Sanwei Biotechnology Co., Ltd.

[0252] Mice were purchased from Beijing Weitonglihua Experimental Animal Technology Co., Ltd.

[0253] PBS formula: 8 mM Na 2 HPO 4 , 136 mM NaCl, 2 mM KH 2 PO 4 , 2.6 mM KCl, pH 7.2-7.4.

[0254] Cell line: The cell line used to prepare lentiviral particles is 293T cells (ATCC CRL-3216). The presenting cell line used to present antigenic peptides is T2 cells (174xCEM.T2, ATCC CRL-1992). The tumor cell lines used for functional testing are human colorectal cancer colo205 cells (ATCC CCL-222), HT-29 cells (HTB-38) and HCT116 cells (ATCC CCL-247), human breast cancer MDA-MB-231 cells (ATCC HTB-26) and MCF7 cells (ATCC HTB-22), human ovarian cancer SKOV3 cells (ATCC HTB-77), human pancreatic cancer PANC-1 cells (ATCC CRL-1469), human glioma U87MG cells (ATCC HTB-14), human hepatocellular carcinoma HepG2 cells (ATCC HB-8065), human non-small cell lung cancer NCI-H460 cells (ATCC HTB177) and small cell lung cancer NCI-H446 cells (ATCC HTB-171). The cell lines were maintained in RPMI-1640 complete medium (Lonza, cat#12-115F) supplemented with 10% fetal calf serum FBS (ATCC30-2020), 2 mmol / L L-glutamic acid, 100 μg / ml penicillin and 100 μg / ml streptomycin.

[0255] Peripheral blood: The human peripheral blood products used in the experiment were from healthy donors, wherein the human peripheral blood products used in Examples 8-11 were from the Pacific Blood Center in San Francisco (PBMC #1 and PBMC #2 were Trima residual cell fractions #R32334 and #R33941 from the Apheresis collection kit, respectively).

[0256] The cell counting method used in the following examples is as follows:

[0257] CCK8 method: add 10 μl CCK8 solution to each well of cells, incubate in a 37°C incubator for 1 to 4 hours, shake at low speed on a shaker for 5 minutes to fully dissolve and mix the crystals, and use an enzyme marker to detect the absorbance value (OD) at 450 nm. 450 ) Inhibition rate calculation formula: Cell proliferation inhibition percentage (IR%) = 1-(OD 450 Test product-OD 450 blank) / (OD 450 Negative control - OD 450 blank)×100%.

[0258] The MTT method used in Example 4 was as follows: 10 μl of MTT solution (5 mg / ml) was added to each well of cells, and the cells were cultured in a 37°C incubator for 4 hours. The culture medium was discarded, and 150 μl of DMSO was added to each well. The cells were shaken at a low speed on a shaker for 10 minutes to fully dissolve the crystals and mix them. The absorbance value (OD) at 490 nm was detected using an enzyme marker. 490 ) Inhibition rate calculation formula: Cell proliferation inhibition percentage (IR%) = 1-(OD 490 Test product-OD 490 blank) / (OD 490 Negative control - OD 490 blank)×100%.

[0259] Trypan blue staining method: Wash the cells with PBS, digest them with trypsin, suspend the cells in PBS, add trypan blue dye solution with a final concentration of 0.04% (w / v), count under a microscope, dead cells will be stained light blue, and live cells will not be stained. The number of live cells is taken as the final data.

[0260] Source of culture plates: The 6-well cell culture plates (the culture medium volume per well is 2 ml), 12-well cell culture plates (the culture volume per well is 1 ml), 24-well cell culture plates (the culture volume per well is 500 μl), and 96-well cell culture plates (the culture volume per well is 100 μl) used in each example were all obtained from Corning.

[0261] In vitro induction of Her2 / neu 369-377 specific killer T cells (CTL): Peripheral blood was centrifuged (×400g) for 30 minutes on Ficoll-Paque Premium (Sigma-Aldrich, cat#GE-17-5442-02) to obtain mononuclear cells (PBMC). First, the HLA-A2 phenotype of the cells was detected by staining with fluorescein FITC-labeled anti-HLA-A2 antibody (Biolegend, cat#343303). After flow cytometry analysis (the flow cytometer was MACSQuant Analyzer 10 (Miltenyi Biotec), and the results were analyzed using Flowjo software (Flowjo)), RNA of positive cells was extracted, reverse transcribed into cDNA and cloned into a vector, and then HLA gene sequencing analysis was performed to determine that the cell type was HLA-A*0201. HLA-A2-positive PBMC cells were cultured in the culture wells of a 24-well culture plate, and the culture medium was the above-mentioned RPMI-1640 complete medium. 2×10e6 / ml PBMC were added to each well, and Her2 / neu 369-377 peptide (Her2-E75, synthesized by Peptide2.0, 10 μg / ml dissolved in DMSO) was added to the final concentration of 1 μg / ml. 2 After culturing in an incubator at 37°C for 16-24 hours, the following cytokines were added at final concentrations: human IL-2 (Peprotech, cat#200-02) 100 IU / ml, human IL-7 (Peprotech, cat#200-07) 5 ng / ml, and human IL-15 (Peprotech, cat#200-15) 5 ng / ml. After 10 to 14 days of culture, the cultured T cells were restimulated with antigens: 10e6 of the cultured cells obtained above were added to each well of a 24-well plate, and 2×10e6 HLA-A2-positive PBMC cells treated with 25 μg / ml mitomycin C (Santa Cruz Biotechnology, cat# SC-3514) for 2 hours were added as trophoblasts, Her2 / neu 369-377 polypeptide was added to each well at a final concentration of 1 μg / ml, and IL-2 100 IU / ml, IL-7 5 ng / ml, and IL-15 5 ng / ml (final concentration) were added after overnight culture. After two rounds of the above antigen stimulation and restimulation, the amplified T cells were collected for phenotypic analysis and T cell cloning.

[0262] Flow cytometry analysis and single cell isolation: The phenotype of T cells expressing Her2 / neu 369-377-specific TCR was analyzed by flow cytometry. The cells to be tested were collected and placed in a 1.5 ml tube (the number of cells was about 10e5) and washed with 1 ml of DPBS solution (2.7 mM KCl, 1.5 mM KH 2 PO 4 , 136.9 mM NaCl, 8.9 mM Na 2 HPO 4 7H 2 O, pH 7.4), and then resuspended in 100 μl DPBS containing 1% calf serum, and 5 μl fluorescein APC-labeled anti-human CD8 antibody (Biolegend, cat#300912) and 10 μl fluorescein PE-labeled Her2-E75 / HLA-A2 tetramer (Her2-E75 tetramer, MBL International Co., cat#T01014) or Her2-E75 / HLA-A2 pentamer (Her2-E75 pentamer, Proimmune, cat#F214-2A-D) were added. After incubation on ice for 30 minutes, the cells were washed twice with DPBS solution and resuspended in 100 μl PBS solution (8 mM Na 2 HPO 4 , 136 mM NaCl, 2 mM KH 2 PO 4 , 2.6 mM KCl, pH 7.2-7.4) for flow cytometry analysis. The flow cytometer was MACSQuant Analyzer10 (Miltenyi Biotec), and the results were analyzed using Flowjo software (Flowjo). T cell clones were obtained by single cell separation and culture using a flow cytometer (FACS sorter). PBMCs stimulated with Her2 / neu369-377 polypeptide antigen were stained with APC-labeled anti-human CD8 antibody and PE-labeled Her2-E75 / HLA-A2 pentamer, and then separated by flow cytometry (model: Sony cell sorterSH800). Single CD8 + Her2-E75 / HLA-A2 pentamer +After the cells were sorted into a single well of a 96-well culture plate, HLA-A2-positive PBMC cells treated with 25 μg / ml mitomycin C for 2 hours were added, 10e5 cells per well, 1 μg / ml Her2 / neu 369-377 polypeptide was added and cultured overnight, and then RPMI-1640 complete culture medium containing IL-2 100 IU / ml, IL-7 5 ng / ml, and IL-15 5 ng / ml was added. Fresh culture medium containing the cytokines was replaced every 3-4 days, and the growth of T cell clones was observed under a microscope. The proliferated T cells were collected, and antigen restimulation was performed according to the above method to obtain a sufficient number of cells, phenotypic or functional detection was performed, and RNA was extracted for TCR gene cloning.

[0263] T cell function test: In order to detect the ability of T cells transfected with TCR genes to recognize antigen epitope peptides, 10e5 T cells transfected with TCR genes and 10e5 T2 cells were added to each well of a 96-well plate and mixed cultured in 100 μl / well RPMI-1640 complete medium. Each test group was a duplicate well. Then, Her2 / neu 369-377 peptides of different final concentrations (1 μg / ml, 0.5 μg / ml, 0.1 μg / ml, 0.05 μg / ml, 0.01 μg / ml, 0.005 μg / ml, 0.001 μg / ml and 0.0001 μg / ml) were added and placed in 5% CO 2 In order to determine the key amino acid sites of the epitope antigen recognized by the TCR, 10e5 T cells transfected with the TCR gene and 10e5 T2 cells were added to each well of the 96-well plate, and then the epitope peptide to be tested was added at a final concentration of 0.1 μg / ml and placed in a 5% CO 2 , and incubate overnight at 37°C. After 24 hours, the supernatant was collected and IFN-γ in the supernatant was detected using the human IFN-γ ELISA Read-set-Go kit (eBioscience, cat#88-7316) or the human IFN-γ DuoSet ELISA kit (R&D Systems, cat#DY285B) according to the manufacturer's instructions.

[0264] In order to detect the ability of T cells transfected with TCR genes to recognize tumor cell lines, a certain number of PBMC cells transfected with TCR genes and tumor cells were added as target cells in each well of a 96-well plate according to different effector-target ratios. After culturing for 24 hours, the supernatant was collected to detect the secreted interferon-γ in the supernatant. Each test group was a duplicate well or triplicate well. In the antibody function blocking test, anti-human CD8 antibody (Biolegend, cat#300912) at a final concentration of 10 μg / ml was added to the cell culture wells at the same time, and the cells were placed in 5% CO 2 , and incubate overnight at 37°C. Collect cell supernatants after 18-24 hours, and detect IFN-γ in the supernatant using human IFN-γ ELISA Read-set-Go kit (eBioscience, cat#88-7316) or human IFN-γ DuoSet ELISA kit (R&D Systems, cat#DY285B) according to the manufacturer's instructions.

[0265] In order to detect the ability of T cells transfected with TCR genes to kill tumor cells, 1×10e4 target cells were added to each well of a 24-well culture plate and cultured for 24 hours to allow the target cells to completely adhere to the wall. The suspended cells were removed and a certain number of T cells transfected with TCR genes were added according to the set effect-target ratio. After 24 hours of culture, the suspended cells were removed, and the adherent cells were collected by trypsin digestion and trypan blue staining to count the live cells. Killing rate (Cytotoxicity) % = (the number of live cells of the initial target cells-the number of live cells of the target cells at the end of the culture) / the number of live cells of the initial target cells × 100. Each experimental group was repeated or triplicate, and the significance of the difference was analyzed by Student's t-test. Alternatively, the killing activity was detected by the MTT method.

[0266] Description of the MTT method used in Example 11:

[0267] Trypsin digested the cells in the logarithmic growth phase, collected them by centrifugation after termination, and evenly dispersed them to prepare a single cell suspension; the cell concentration was adjusted to 0.1-10×10 4 / ml (the number of cells to be inoculated was adjusted according to the growth conditions of different cells), inoculated into a 96-well cell culture plate, the culture system was 100 μl / well, and placed at 37°C, 5% CO 2 Culture in an incubator overnight to allow cells to fully adhere to the wall, reaching 70-80% on the next day; count using a counting plate, and use a countstar counter to verify the correctness of the count. Take out the 96-well plate, add 100 μl of pre-prepared T cell and TCR-T cell suspension, vortex slightly before adding, and add 100 μl of serum-free medium for corresponding cell culture to the blank control well; place at 37°C, 5% CO 2Incubate for 24 hours in the incubator; take the cells after 24 hours, centrifuge at 400g, and after 10 minutes, take 180μl of culture medium and put it into a new 96-well plate, and keep the sample for the subsequent ELISA detection of supernatant IFN-γ level. The detection steps can refer to the detection instructions. Note: The supernatant can be frozen at -80℃ for subsequent detection. Add new 100μl complete culture medium to each well, add 10μl MTT solution (5mg / ml, i.e. 0.5% MTT) to each well, and continue to culture for 4-6 hours; set up the effector cell control group, 4 hours after adding MTT, centrifuge at 300g for 5 minutes, centrifuge the effector cells stained with MTT to the bottom of the plate, discard the supernatant, and then add DMSO for detection. Add 150μl DMSO to each well, shake at low speed on a shaker for 10 minutes to fully dissolve the crystals, and detect its absorbance at 490nm on an enzyme marker.

[0268] Obtaining monoclonal TCR genes: Total RNA was purified from T cell clones using the Zymo Quick-RNA Microprep kit (Zymo Research, cat#R1050), and cDNA was obtained using the Smarter RACE 5' / 3' kit (Takara Bio, USA, cat#634858) using this as a template. PCR was performed using the 5'-CDS primer and the TCRβ chain 3' primer 5'-GCCTCTGGAATCCTTTCTCTTG-3' (SEQ ID NO:24) and the α chain 3' primer 5'-TCAGCTGGACCACAGCCGCAG-3' (SEQ ID NO:25) to amplify the full sequence gene fragments of TCRα and β, and cloned into the pRACE vector (Takara Bio, USA, cat#634858) respectively. Transform the competent bacteria Stellar (Takara Bio, USA, cat#636763) and obtain the plasmid for sequencing.

[0269] Preparation of recombinant TCR lentiviral expression vector: The viral vector used to express TCR is a replication-deficient lentiviral vector, including: a lentiviral vector pCDH-EF1α-MCS-(PGK-GFP) expressing GFP, which can be purchased from System Biosciences (Cat#CD811A-1); and a vector pCDH-EF1α-MCS that does not express GFP, which is obtained by removing the PGK promoter and GFP gene on the pCDH-EF1α-MCS-(PGK-GFP) vector using conventional techniques in the art. According to the obtained TCR gene sequence, the full gene sequence of the TCRβ chain and α chain and the cleavable F2A sequence and Furin enzyme fragment between them are synthesized and linked to the multiple cloning site downstream of the EF-1α promoter of the vector. The transcription order of the inserted TCR is TCRβ chain (without stop codon), Furin enzyme fragment, F2A fragment, TCRα chain (for methods, see the document "Gene Ther. 2008Nov; 15(21): 1411-1423"). The vector expressing GFP is driven by the PGK promoter in reverse. The vector not expressing GFP has the PGK promoter and GFP fragment removed.

[0270] Preparation of recombinant TCR lentiviral particles: TCR lentiviral particles were obtained by transfecting 293T / 293FT cells with Lipofectaine 2000 transfection reagent (invitrogen, #11668019). 293T / 293FT cells and transfection procedures were prepared according to the manufacturer's instructions. Transfection was performed in a 6-well culture plate. First, Opti-MEM 1 culture medium (Thermo Fisher, cat#51985091) was used to prepare a liposome mixed solution of the transfection plasmid. According to the manufacturer's instructions, 6 μl of lipofectaine 2000 reagent, 0.8 μg of TCR lentiviral vector plasmid and 1.8 μg of viral packaging plasmid of the pCDH system (SBI, cat#LV500A-1) were added to 250 μl of culture medium. After mixing and incubating for 25 minutes, the mixture was added to the 293T / 293FT cell culture wells. 5% CO 2 The cells were cultured at 37°C for 16 hours, and then replaced with DMEM medium without FBS (Thermo Fisher, cat#11965092). The cell supernatants were collected after 24 and 48 hours of culture, respectively, and the supernatants were centrifuged at 2000 g for 10 min. The viral supernatants obtained after filtration with a 0.4 μm filter membrane were concentrated using a lentivirus concentrate (GeneCopoeiaTM#LPR-LCS-01) according to the manufacturer's instructions and then used to infect cells.

[0271] Recombinant TCR lentiviral transfection of human T cells: After thawing, the frozen primary PBMC cells were cultured in RPMI-1640 complete culture medium for 24 hours, and the dead cells were removed by Ficoll-Paque Premium density gradient centrifugation (×400g) for 30 minutes. The cells were placed in 24-well culture wells treated with 2μg / ml anti-human CD3 antibody (Biolegend, OKT3 clone cat#317303) and 2μg / ml anti-human CD28 antibody (Biolegend, cat#302914) for 24 hours (100μl of DPBS solution containing the above CD3 antibody and CD28 antibody was added to each well) at a cell concentration of 2×10e6 / ml. Dynabead human T-CD3 / CD8 magnetic beads (Thermo Fisher, cat#11131D) can also be used to stimulate and activate the PBMC cells according to the manufacturer's instructions. After 24 hours of culture, the cells were collected and 100 μl of concentrated TCR lentiviral particles (3×10e8Tu / ml) were added to the wells of a 24-well plate. The cells were cultured with RPMI-1640 complete culture medium or X-VIVO15 (Lonza#04-418Q) containing IL-2100IU / ml, IL-7 5ng / ml, and IL-15 5ng / ml. The culture medium containing the above cytokines was replaced with fresh culture medium every 3 days. RestroNectin pre-treated culture plates (Takara, cat#T110A) can also be used to infect activated PBMC cells with viruses according to the manufacturer's instructions. Phenotypic and functional tests can generally be performed after 72 hours. Transfection of T cell lines is also carried out according to the above steps. If the viral vector is marked with GFP, GFP-positive cells can generally be observed under a fluorescence microscope 48 hours after transfection.

[0272] Preparation Example 1: Construction of E1A gene expression vector

[0273] Two PCR primers (P1: GGA) were designed based on the human adenovirus type 5 (AD5) genomic DNA sequence (ACCESSION: AC_000008) in Genbank of NCBI (i.e., National Center for Biotechnology Information, website: https: / / www.ncbi.nlm.nih.gov) AGATCTGGACTGAAAATGAG (SEQ ID No. 30), P2: TGAGGTCAGATGTAACCAAGATTA (SEQ ID No. 31); Note: The 5' end of primer P1 added a BglII restriction site, which is underlined); the oncolytic virus (H101) genomic DNA produced by Shanghai Sanwei Biotechnology Co., Ltd. was extracted as a template, and a high-fidelity PCR was performed to amplify the 1164 bp sequence between 551-1714 on the AD5 genomic DNA. The actual size was 1173 bp (see Figure 1 ), which includes the coding region of the E1A gene (excluding the E1A promoter sequence) and part of the 3'UTR region. The PCR product obtained was digested with BglII and cloned into the vector pShuttle-CMV (purchased from Agilent) between the BglII and EcoRV sites in the multi-cloning site region (MCS) to obtain the intermediate vector pShuttle-E1A. The obtained pShuttle-E1A positive clones were screened and confirmed by PCR using P1 and P2. The results are shown in Figure 2 , the construction process see Figure 3 The positive clones were sequenced, and the sequencing results were completely consistent with the corresponding sequences on the AD5 genomic DNA.

[0274] PCR primers P3 and P4 were redesigned (P3: CGC GTCGAC TACTGTAATAGTAATCAATTACGG (SEQ IDNo.32) and P4: GAC GTCGAC TAAGATACATTGATGAGTTTGGAC (SEQ ID No. 33); Note: SalI restriction site was added to the 5' end of both primers, underlined), and the obtained pShuttle-E1A positive clone was used as a template for high-fidelity PCR amplification. The PCR product contained the E1A expression frame including the CMV promoter, E1A gene fragment and SV40 polyA. The size of the PCR product was 2017 bp ( Figure 4 ).

[0275] The PCR product of the E1A expression cassette was digested with SalI and cloned into the SalI site in the MCS region of the pShuttle vector (purchased from Agilent). The positive clones with the E1A expression cassette inserted were screened by PCR using primers P3 and P4 ( Figure 5 ) and confirmed by digestion with BglII. The clones with E1A expression cassette inserted in the forward direction will produce two fragments of 7200 bp and 1400 bp after BglII digestion, and the clones with E1A expression cassette inserted in the reverse direction will produce two fragments of 7970 bp and 630 bp after BglII digestion ( Figure 6 ),choose Figure 6 The intermediate vector pShuttle-MCS-E1A was finally obtained. The construction process is shown in Figure 7 The obtained pShuttle-MCS-E1A positive clones were sequenced, and the results were completely consistent with the expected sequence.

[0276] Preparation Example 2: Construction of shRNA expression vector

[0277] According to the human PDL1 variant 1 sequence in Genbank on the NCBI website (ACCESSION: NM_014143), three shRNA sequences targeting the 168-190, 430-452 and 589-611 regions of its coding region mRNA were designed (shPDL1-1 (or shPDL1-#1), shPDL1-2 (or shPDL1-#2) and shPDL1-3 (or shPDL1-#3), SEQ ID NO.45, SEQ ID NO.48, SEQ ID NO.51 respectively). In addition, a negative control sequence shPDL1-NC that is not related to human PDL1 mRNA was also designed. The sequence is as follows:

[0278] (1) shPDL1-1

[0279] Synthetic sense sequence (SEQ ID No.43):

[0280]

[0281] Synthetic antisense sequence (SEQ ID No.44):

[0282]

[0283] shRNA DNA (SEQ ID No.45):

[0284]

[0285] (2)shPDL1-2

[0286] Synthetic sense sequence (SEQ ID No.46):

[0287]

[0288] Synthetic antisense sequence (SEQ ID No.47):

[0289]

[0290] shRNA DNA (SEQ ID No.48):

[0291]

[0292] Synthetic sense sequence (SEQ ID No.49):

[0293]

[0294] Synthetic antisense sequence (SEQ ID No.50):

[0295]

[0296] shRNA DNA (SEQ ID No.51):

[0297]

[0298] Synthetic NC sense sequence (SEQ ID No.52):

[0299]

[0300] Synthetic NC antisense sequence (SEQ ID No.53):

[0301]

[0302] shNC DNA (SEQ ID No.54):

[0303]

[0304] The four sequences were ligated to the BbsI and HindIII sites on the pSGU6 / GFP / Neo vector (purchased from Shanghai Sangon Biotechnology Co., Ltd.) using the sticky ends reserved at both ends of the shRNA sequence that are complementary to BbsI and HindIII to obtain four vectors that can express shPDL1 (pSGU6 / GFP / Neo-shPDL1-NC, pSGU6 / GFP / Neo-shPDL1-1, pSGU6 / GFP / Neo-shPDL1-2 and pSGU6 / GFP / Neo-shPDL1-3).

[0305] Experimental Example 1: Detection of the inhibitory effect of shPDL1

[0306] Detection of the effect of shPDL1 on hPDL1 mRNA (human PDL1) in U251 and H460 cells

[0307] First, 2 × 10 5U251 and H460 cells were seeded 12 hours in advance, and each well was inoculated with 4 μl lipofectamin 2000:1.6 μg shRNA.

[0308] U251 and H460 were transfected with expression vector DNA in a proportional relationship. Two cell samples were collected at 24 hours and 48 hours respectively. Total RNA was extracted and reverse transcribed. Real-time PCR was used to detect the expression level of human PDL1 mRNA in cells with the mRNA level of GAPDH gene as the control. The results showed that compared with the control, shPDL1-#1, 2, and 3 all produced inhibitory effects on hPDL1 mRNA within a certain period of time, among which shPDL1-#1 had the most significant inhibitory effect on hPDL1 mRNA ( Figure 8 ).

[0309] In addition, the inhibitory effects of the three shPDL1s were also tested at the protein level. The four plasmids pSGU6 / GFP / Neo-shPDL1-NC, pSGU6 / GFP / Neo-shPDL1-1, pSGU6 / GFP / Neo-shPDL1-2 and pSGU6 / GFP / Neo-shPDL1-3 were transiently transfected into 293T cells with pcDNA3.3-hPDL1-3×FLAG at an equal molar ratio (1:1). The plasmid pcDNA3.3-hPDL1-3×FLAG can express human PDL1 protein fused with a 3×FLAG tag. After 48 hours, the cell samples were collected and lysed for Western blot analysis. The results (see Fig. 9 ) proved that shPDL1-#1 could significantly reduce the overexpression of hPDL1.

[0310] The construction process of the pcDNA3.3-hPDL1-3×FLAG plasmid is as follows: First, two primers were designed based on the mRNA sequence of the human PDL1 gene in NCBI (P11:

[0311] CGCGTCGACATGAGGATATTTGCTGTCTTTAT (SEQ ID No.40), P12: CCGCTCGAGCGTCTCCTCCAAATGTGTATCAC (SEQ ID No.41)), total RNA of U251 cells was extracted by Trizol, and hPDL1 cDNA was obtained by RT-PCR using the RNA as a template and cloned into the pShuttle-IRES-hrGFP-1 vector (purchased from Agilent), hPDL1 was fused with the downstream FLAG tag to obtain the intermediate vector pShuttle-HPDL1-IRES-hrGFP-1. A primer (P15: CGCCTATTACACCCACTCGTGCAG (SEQ ID No. 42)) was designed again and used in combination with P11 to amplify a sequence of hPDL1cDNA-FLAG-IRES-hrGFP on pShuttle-hPDL1-IRES-hrGFP-1, and the fragment was cloned into the pcDNA3.3-TOPO vector (purchased from Invitrogen), and finally the pcDNA3.3-hPDL1-FLAG vector was obtained. The inserted fragment was sequenced to confirm that the sequence was completely correct.

[0312] Preparation Example 3: Preparation of genomic DNA of oncolytic adenovirus (OAd-shPDL1)

[0313] 1. After confirming the inhibitory effect of shPDL1, the coding frame including the U6 promoter and the entire shPDL1 sequence was cloned into pShuttle-MCS-E1A. First, the pSGU6 / GFP / Neo-shPDL1 vector was digested with SacI, and then the sticky ends formed by SacI digestion were cut flat with T4 DNA polymerase and recovered by ethanol / ammonium acetate precipitation. Finally, the coding frame sequence including the U6 promoter and shPDL1 sequence was recovered after digestion with KpnI; at the same time, the pShuttle-MCS-E1A vector was double-digested with KpnI and EcoRV and recovered. Finally, the three shPDL1 coding frames were connected to the pShuttle-MCS-E1A vector to obtain the final vector pShuttle-U6-shPDL1-CMV-E1A. The process is shown in Fig.10 Select several colonies to extract plasmids and perform KpnI / HindIII restriction enzyme digestion for identification. Correct cloning will produce a band of 370 bp (see Fig.11 ). The pShuttle-U6-shPDL1-CMV-E1A plasmid with the correct enzyme digestion was selected for sequencing, and the sequencing results were completely correct.

[0314] 2. The obtained four plasmids, pShuttle-MCS-E1A (control plasmid), pShuttle-U6-shPDL1-1-CMV-E1A, pShuttle-U6-shPDL1-2-CMV-E1A and pShuttle-U6-shPDL1-3-CMV-E1A, were linearized by PmeI and transferred into BJ5183 bacteria, and homologous recombination was performed with the pAdEasy-1 plasmid (purchased from Agilent) containing AD5 adenovirus genomic DNA (E1 and E3 regions deleted), thereby integrating the CMV-E1A-SV40pA expression frame and / or the U6-shPDL1 coding frame into the genomic DNA of the AD5 adenovirus, thereby obtaining the genomic DNA of the oncolytic adenovirus (OAd-shPDL1) that can express the target gene and replicate ( Fig.12 ).

[0315] The specific experimental process is as follows:

[0316] (1) Preparation of BJ5183 competent cells.

[0317] BJ5183 (with pAdEasy-1 plasmid) stored at -80°C in our laboratory was inoculated into LB / Amp medium and activated by overnight culture at 37°C and 200RPM. BJ5183 competent bacteria were prepared using the Super Competent Cell Preparation Kit (B529303-0040) of Sangon Biotech Co., Ltd., and 100 μl was dispensed into each tube and stored at -80°C for later use.

[0318] (2) Homologous recombination between pShuttle-related plasmids and pAdEasy-1 plasmid.

[0319] Take 1 μg of pShuttle-MCS-E1A, pShuttle-U6-shPDL1-1-CMV-E1A, pShuttle-U6-shPDL1-2-CMV-E1A and pShuttle-U6-shPDL1-3-CMV-E1A plasmid DNA respectively, use 1 μl PmeI to digest them, react at 37℃ for 1.5 hours, and then add 1 μl alkaline phosphatase to dephosphorylate the linearized DNA fragments. Then add the digestion products directly to 100 μl BJ5183 competent bacteria for conventional transformation experiments, and finally spread the transformed bacterial solution on Kana-resistant LB plates and culture at 37℃ overnight. The next day, pick the colonies that appear on the plate and inoculate them in LB / Kana for overnight culture. After extracting the plasmid DNA and performing conventional PacI digestion, the digestion products are analyzed by electrophoresis. Depending on the location where homologous recombination may occur, three different types of homologous recombination may occur ( Fig.13), the plasmids that can produce 4.5Kb or 3Kb fragments after PacI digestion are all plasmids that have undergone correct homologous recombination. The electrophoresis results of the digestion products ( Fig.14 ) proved that correct homologous recombination occurred between pShuttle-MCS-E1A, pShuttle-U6-shPDL1-1-CMV-E1A, pShuttle-U6-shPDL1-2-CMV-E1A and pShuttle-U6-shPDL1-3-CMV-E1A and pAdEasy-1 plasmid, and the genomic DNA of the packaged oncolytic adenovirus (collectively referred to as OAd-shPDL1) and its control virus (pAdEasy-U6-shPDL1#1-CMV-E1A, pAdEasy-U6-shPDL1#2-CMV-E1A, pAdEasy-U6-shPDL1#3-CMV-E1A and pAdEasy-CMV-E1A) were successfully obtained. The inserted shPDL1 coding frame and E1A expression frame in the obtained positive clones were sequenced, and the sequence was completely correct.

[0320] Preparation Example 4: Packaging and amplification of oncolytic adenovirus (OAd-shPDL1)

[0321] (1) Preparation of genomic DNA for packaging oncolytic adenovirus (OAd-shPDL1)

[0322] Take 2 μg of the obtained pAdEasy-CMV-E1A, pAdEasy-U6-shPDL1#1-CMV-E1A, pAdEasy-U6-shPDL1#2-CMV-E1A and pAdEasy-U6-shPDL1#3-CMV-E1A plasmid DNA respectively, add 2 μl PacI enzyme to each, react at 37°C for 2 hours, precipitate the DNA with ethanol ammonium acetate, rinse with 70% ethanol, and dissolve the DNA precipitate in 10 μl clean ddHO 2 O, and then transfected into AD293 for virus packaging.

[0323] (2) Packaging of oncolytic adenovirus (OAd-shPDL1)

[0324] AD293 cells with good growth status were inoculated into 6-well plates one day in advance. The number of cells inoculated should be such that the cell coverage rate was 60-70% when the transfection experiment was performed the next day. About 2 μg of the prepared linearized DNA was mixed with 6 μl of Attractene transfection reagent from QIAGEN and added to the AD293 cells. After cross mixing, the cells were placed in a cell culture incubator (37°C, 5% CO 2) for about 10-14 days, and observe the cell pathological changes every 2-3 days. When small pieces of cells appear and become "beaded", the range gradually expands until a large number of cells fall off, the cells can be gently blown to recover the cells and culture supernatant, and stored in a -80℃ refrigerator or directly further amplified. The process is shown in Fig.15 .

[0325] (3) Amplification of oncolytic adenovirus (OAd-shPDL1)

[0326] Similarly, the AD293 cells with good growth status were inoculated in a 6cm cell culture dish one day in advance. The number of cells inoculated was preferably 70-80% when the cell coverage rate was 70% for the transfection experiment on the second day. 800-1000μl of the virus supernatant collected previously was added to each 6cm cell culture dish, and the same cross-mixing was returned to the cell culture medium for continued culture. Usually, after 48 hours, a large number of cells can be seen to become round and fall off. At this time, the cells and culture supernatant can be collected. Next, continue to amplify the virus in a 10cm cell culture dish. When inoculating the virus, the cell density is also about 70%. Each 10cm cell culture dish is added with 1200-1500μl of the virus supernatant collected previously. After 48 hours, a large number of cell lesions can be seen to fall off, and the cells and supernatant are recovered. Finally, the virus was amplified in a 15cm culture dish. When the cell density was about 70%, 2ml of the virus culture supernatant collected in the 10cm culture dish was added. After mixing, the cells and culture supernatant were collected for 48 hours. Later, the virus can be cyclically amplified in a 15cm culture dish to the required amount of virus.

[0327] (4) Determination of oncolytic adenovirus (OAd-shPDL1) titer

[0328] At present, the methods for determining adenovirus titer include VP method, GTU / BFU method, plaque method, TCID50 method and Hexon staining counting (kit) method. The more accurate methods with high reproducibility are TCID50 method and Hexon staining counting method. In this example, the Hexon staining counting method was used to determine the number of active virus particles (unit: PFU / ml) in the obtained virus supernatant. The results are shown below. The three pShuttle-U6-shPDL1-CMV-E1A plasmids and one control plasmid pShuttle-MCS-E1A described in the present invention were homologously recombined with the pAdEasy-1 plasmid to produce 6 pAdEasy-U6-shPDL1-CMV-E1A plasmids and 2 pAdEasy-CMV-E1A (see Fig.13Each plasmid can produce two correct forms of homologous recombination, and two correct plasmids are obtained, which can produce 4.5K or 3K bands respectively after PacI digestion). The 8 homologous recombination plasmids obtained were used to package viruses in AD293, and a total of 8 oncolytic viruses were obtained: OAd-C-4.5K, OAd-C-3K, OAd-shPDL1#1-4.5K, OAd-shPDL1#1-3K, OAd-shPDL2#1-4.5K, OAd-shPDL1#2-3K, OAd-shPDL1#3-4.5K and OAd-shPDL1#3-3K. The 8 viruses are abbreviated as: C-4.5K, C-3K, 1-4.5K, 1-3K, 2-4.5K, 2-3K, 3-4.5K and 3-3K, respectively. Among them, C-4.5K and C-3K are the same virus with the same sequence, 1-4.5K and 1-3K are the same virus with the same sequence, 2-4.5K and 2-3K are the same virus with the same sequence, and 3-4.5K and 3-3K are the same virus with the same sequence.

[0329] The titer of the virus obtained is:

[0330] Control oncolytic virus: OAd-C-4.5K 2.91*10 8 PFU / ml

[0331] OAd-C-3K 2.3*10 8 PFU / ml

[0332] Oncolytic virus (Oad-shPDL1): OAd-shPDL1#1-4.5K 1.58*10 8 PFU / ml

[0333] OAd-shPDL1#1-3K 2.06*10 8 PFU / ml

[0334] OAd-shPDL1#2-4.5K 2.06*10 8 PFU / ml

[0335] OAd-shPDL1#2-3K 1.94*10 8 PFU / ml

[0336] OAd-shPDL1#3-4.5K 1.58*10 8 PFU / ml

[0337] OAd-shPDL1#3-3K 1.94*10 8 PFU / ml

[0338] Example 1: Replication ability of oncolytic adenovirus (OAd-shPDL1) in cells (tumor cells and normal cells)

[0339] Cells (HUVEC, MRC-5, Hela, A549 and U251) were seeded in 12-well plates at a seeding rate of 1.5 × 10 cells per well. 5 Each cell was cultured in 1 ml of medium (HUVEC cells were cultured in Allcells special medium, both cells and medium were purchased from Allcells Biotechnology (Shanghai) Co., Ltd.; MRC-5 cells were cultured in MEM+10% FBS medium; Hela cells were cultured in RPMI1640+10% FBS medium; A549 cells were cultured in DMEM / F12+10% FBS medium; U251 cells were cultured in MEM+10% FBS, all medium were purchased from Gibco). After 12 hours, the medium was removed and the cells were rinsed once with PBS and then Fig.16 500 μl of virus suspension (the virus was prepared in Preparation Example 4) was added in the manner shown, and the virus infection multiplicity (MOI) was 10. After the virus and cells were incubated for 90 minutes, the virus suspension was removed by aspiration, and the cells were rinsed twice with PBS, with this time as 0 hr, and one cell sample was collected by trypsin digestion, and the second cell sample was collected 48 hr later. The genomic DNA of the cell samples collected at 0 hr and 48 hr were extracted, and Q-PCR was performed using specific primers for adenovirus type 5 E1A (P5: TCCGGTTTCTATGCCAAACCT (SEQ ID No. 34) and P6: TCCTCCGGTGATAATGACAAGA (SEQ ID No. 35)), Hexon gene (P7: CCATTACCTTTGACTCTTGTGT (SEQ ID No. 36) and P8: GGTAGTCCTTGTATTTAGTATC (SEQ ID No. 37)), and human GAPDH (P9: CATGCCTTCTTGCCTCTTGTCTCTTAGAT (SEQ ID No. 38) and P10: CCATGGGTGGAATCATATTGGAACATGTAA (SEQ ID No. 39)) genes. The replication of the virus in the cells 48 hr after infection was analyzed based on the Q-PCR results. Comparison of the replication ability of oncolytic adenovirus (OAd-shPDL1) in different cells is shown in Fig.17 .

[0340] like Fig.17The results show that the four types of oncolytic adenoviruses constructed in the present invention (control virus C-4.5K, OAd-shPDL1 virus 1-4.5K, 2-4.5K and 3-4.5K) have different replication abilities in the detected cells. The oncolytic virus of the present invention has a very strong replication ability in the detected tumor cells, including in the immortalized human embryonic lung fibroblast cell line. It also shows a strong replication ability, but the replication ability in the human primary cell HUVEC is very low, and the replication ability in normal human cells is about 42-444 times lower than that in the tumor cell line or the cell line with a tendency to tumorigenesis (for example: immortalized human embryonic lung fibroblast cell line MRC5). Therefore, it can be considered that the oncolytic adenovirus of the present invention has a strong tumor cell bias in selective replication, has higher safety in the future application of clinical oncolytic viruses, and has greater room for the use of viruses.

[0341] Example 2: Killing ability of oncolytic adenovirus (OAd-shPDL1) on tumor cells

[0342] In this example, the killing ability of the oncolytic adenovirus (OAd-shPDL1) of the present invention was detected by CCK8 experiment. Cells (U251, Hela and A549) were inoculated in a 96-well plate, and the inoculation number was 1.5×10 3 cells, and the volume of each well culture medium (U251 cell culture uses MEM + 10% FBS; Hela cell culture uses RPMI1640 + 10% FBS medium; A549 cell culture uses DMEM / F12 + 10% FBS medium; all culture media are purchased from Gibco) is 100 μl. After 12 hours, 50 μl of culture medium is aspirated, and 50 μl of virus (control virus C-4.5K, OAd-shPDL1 virus 1-4.5K, 2-4.5K and 3-4.5K prepared in Preparation Example 4) and a mixture of simple culture medium are added (the time point is recorded as 0 hr), and the multiplicity of infection (MOI) is 1, 3, 10, 30, 100 and 300 respectively. Three duplicate wells are set for each multiplicity of infection. 10μl CCK8 (purchased from Dongren Chemical Technology Co., Ltd.) was added at 48hr and 72hr respectively, and the culture was incubated for 1hr and then the light absorbance at 450nm was detected. The killing ability of different viruses on cells was judged based on the obtained light absorbance values. The commercial oncolytic adenovirus H101 was used as a control. The same MOI of virus was used to treat the same cells in the experiment, and the light absorbance values ​​were detected at the same time at the same time point. In addition, 1μM paclitaxel solution was used as a system positive control. The dose-killing effect of oncolytic adenovirus (OAd-shPDL1) on three tumor cells and the half-killing dose (IC 50 ) The result is as follows Figure 18-21 shown.

[0343] The results showed that the oncolytic adenovirus of the present invention (control virus C-4.5K, OAd-shPDL1 virus 1-4.5K, 2-4.5K and 3-4.5K) had a significant dose-dependent relationship in killing U251, A549 and Hela. Compared with the commercial oncolytic adenovirus H101, the virus of the present invention had a similar killing effect, and the killing of U251 cells was even better than H101. The statistical analysis of the killing effect showed significant differences. In addition, the oncolytic virus of the present invention had a half-killing dose (IC 50 ) were compared and found that the IC of this type of virus against human brain glioma cell U251 50 The lowest, suggesting that it may have more important clinical value in the treatment of human brain glioma.

[0344] Example 3: Efficacy of shPDL1 expressed by oncolytic adenovirus (OAd-shPDL1)

[0345] In order to facilitate the detection of the efficacy of shPDL1 expressed by the oncolytic adenovirus (OAd-shPDL1) of the present invention, this example specifically constructs two cell lines that can stably express hPDL1 with a FLAG tag: A549 / hPDL1-FLAG and Hela / hPDL1-FLAG. The construction process is briefly described as follows: the pcDNA3.3-hPDL1-FLAG vector (also known as pcDNA3.3-hPDL1-FLAG-IRES-hrGFP vector) obtained according to the method shown in Preparation Example 2 is transfected into A549 and Hela cells using lipofectamin 2000, because the vector carries the Neomycin gene, and then G418 is added for three rounds of screening, and finally A549 / hPDL1-FLAG and Hela / hPDL1-FLAG cell lines that can stably express hPDL1 and GFP proteins with a FLAG tag are obtained.

[0346] The above two cell lines were treated with H101 and the four oncolytic adenoviruses described in the present invention (the control virus C-4.5K, OAd-shPDL1 virus 1-4.5K, 2-4.5K and 3-4.5K prepared in Example 4), and the virus infection multiplicity (MOI) was 10. Cell samples were collected 48 hours after virus infection, lysed, and Western blot analysis was performed. Anti-FLAG antibody was used to detect changes in the expression level of hPDL1 with FLAG tag. The results are shown in Fig. 22 and 23The results of Western blot showed that after A549 and Hela cells were treated with oncolytic adenovirus, the expression levels of hPDL1 increased to varying degrees. However, after the same cells were treated with three types of OAd-shPDL1 oncolytic viruses, the originally elevated expression of hPDL1 was inhibited to varying degrees, especially OAd-shPDL1-1 (1-4.5K), which had the most obvious inhibitory ability, which was consistent with the previous Q-PCR results and Western blot results after co-transfection.

[0347] Preparation Example 5: Ultracentrifugation Purification Procedure for Oncolytic Adenovirus

[0348] 1) Preparation of oncolytic adenovirus solution before ultracentrifugation.

[0349] The adenovirus culture supernatant obtained in Preparation Example 4 was used to infect 293 cells in a 15CM culture dish according to the volume ratio of virus supernatant to cell culture medium (AD:DMEM=2:20) and incubated at 37°C and 5% CO 2Continue to culture in the incubator for about 36 hours. After about 50% of the cells have cytopathic effect (CPE) under the microscope and the cells are suspended, the cells and culture fluid in the culture dish are collected by blowing or cell scraping, and can be stored at 4°C for a short time, and need to be stored at -20°C or -80°C for a long time; usually, the amount of virus purified by one ultracentrifugation is about the amount of virus produced by 60-80 15CM culture dishes (including culture medium supernatant and infected 293 cells). The collected 293 cells and culture medium supernatant containing oncolytic virus were centrifuged at 4°C, 3000RPM for 30 minutes, and the subsequent experiments were divided into supernatant and precipitation. A) The supernatant after centrifugation is transferred to another new bottle and can be temporarily stored at 4°C for the subsequent infection of cells to amplify the virus. At the end of the virus amplification, all the supernatants can be mixed with PEG8000 solution (aqueous solution of 2.5M NaCl containing 20% ​​PEG 8000) in a ratio of 2:1 and precipitated on ice for 1 hour or overnight. Then centrifuge at 12000RPM for 20 minutes, discard the supernatant and retain the virus precipitate. Finally, use an appropriate amount of 10mMTris·Cl (pH8.0) solution to resuspend the virus precipitate until it is completely dispersed. Centrifuge at 7000RPM for 5 minutes and retain the virus-containing supernatant. Load the virus-containing supernatant directly into a gradient cesium chloride centrifuge tube for ultracentrifugation. B) After centrifugation, wash the cell precipitate gently with a small amount of 10mMTris·Cl (pH8.0) solution (do not blow), wash the culture medium on the cell surface, and discard it. Resuspend the cell precipitate of each 10-12 15CM culture dishes with 3mlTris·Cl, divide the cell suspension into aliquots, and store at -20℃. The storage time before centralized purification shall not exceed 2 months. After the samples are collected, place the cell suspension in a 37℃ water bath to melt, shake vigorously for 30 seconds, put the sample back into the -80℃ refrigerator or place it in a dry ice / pure ethanol mixture to quickly freeze the cell suspension. Repeat the freeze-thaw process 3-5 times to completely destroy the cell membrane, release the virus from the cell, and obtain the virus solution. If it is not purified immediately, it can be stored at -20°C. Before ultracentrifugation purification, the virus solution obtained in this step is thawed in a 37°C water bath and centrifuged at room temperature for 10 minutes at a speed of 16000RPM. Collect the supernatant containing the virus, and the supernatant can be temporarily stored on ice at low temperature.

[0350] 2) Purification of AD virus by cesium chloride density gradient centrifugation

[0351] Cesium chloride density gradient centrifugation is still the most commonly used method for separating and purifying various viruses. It is mainly based on the different buoyancy densities of different types of viruses, which are separated from other components in the cell lysate in the CsCl solution. After collecting the target virus-specific bands, the cesium chloride is removed using a PD-10 desalting column to finally obtain the purified virus. This method can be used to obtain extremely high-purity viruses. The specific purification procedure is as follows:

[0352] 1. Prepare the cesium chloride density gradient for the first ultracentrifugation: first add 1.6 ml of light CsCl (1.2 g / ml) to the Beckman ultracentrifuge tube, and then slowly add 1.05 ml of heavy CsCl (1.45 g / ml) to the bottom; you can also change the volume of light and heavy CsCl added according to the volume of the ultracentrifuge tube, adding 2.5 ml of light CsCl and 2.5 ml of heavy CsCl respectively (Note: do not mix the light and heavy CsCl in this step to keep a clear dividing line between them).

[0353] 2. Gently add 3-7 ml of virus-containing supernatant to the light CsCl liquid surface, then place the ultracentrifuge tube into the centrifuge sleeve, weigh and balance the two opposite centrifuge tubes, and hang them on the corresponding two hooks on the centrifuge rotor. (Note: The whole process must be done gently.)

[0354] 3. After the centrifuge tube is completely hung, centrifuge at 20°C and 40,000 RPM for 1 hour and 15 minutes.

[0355] 4. After centrifugation, secure the centrifuge tube to the universal clamp on the iron stand in the biosafety cabinet. Carefully use a 5 ml syringe equipped with an 18G needle to pierce the centrifuge tube from below the lowest complete virus particle band (~1 cm), and only aspirate the complete virus particle band, which can be stored on ice for a short time.

[0356] 5. Prepare the CsCl solution for the second ultracentrifugation: Add 6 ml of an equal volume of evenly mixed CsCl solution (3 ml each of light and heavy CsCl) to the ultracentrifuge tube, and carefully pour the virus solution collected in the previous step onto the prepared CsCl liquid surface. Also carefully place the poured centrifuge tube into the ultracentrifuge tube sleeve, and then weigh and balance the two corresponding centrifuge tubes to be placed on the centrifuge rotor. Carefully hang the balanced centrifuge tube on the centrifuge rotor (note: the entire process must be gentle).

[0357] 6. Set the centrifugation parameters: 20°C, 40,000 RPM, centrifugation for 18 hours.

[0358] 7. After centrifugation, carefully remove the centrifuge tube and firmly fix it on the universal clamp on the iron stand in the biosafety cabinet. Carefully use a 5ml syringe with an 18G needle to pierce the centrifuge tube from below the complete virus particle band, and aspirate the complete virus particle band, which can be stored on ice for a short time.

[0359] 8. In the biosafety cabinet, take out a PD-10 desalting column (column volume is 5 ml) and cut off the bottom end, fix it on the iron frame to allow the maintenance solution inside to flow out naturally under the action of gravity. Add 3-4 times the column volume (15-20 ml) of dialysate (containing 1 mM MgCl 2The desalting column was thoroughly washed with 10 mM Tris solution (pH 7.4) containing 10% glycerol and stored at 4°C after filtration sterilization to completely replace the maintenance solution.

[0360] 9. Prepare 10 1.5 ml numbered centrifuge tubes for collecting viruses.

[0361] 10. After the dialysate has completely flowed out, add the virus solution collected by the second ultracentrifugation into the empty PD-10 column. Use the prepared centrifuge tube to collect the filtered fluid in the column overnight (1.2-1.5 ml / tube) according to the volume difference.

[0362] 11. Continue to add dialysis fluid for filtration, adding 2.5 ml each time, and continue to collect into the prepared centrifuge tubes until all 10 centrifuge tubes have been collected.

[0363] 12. Prepare 11 1.5ml centrifuge tubes and add 90μl 0.1% (w / v) SDS to each tube. Take out 10μl of virus from each of the 10 virus collection tubes and add them to the centrifuge tubes that have been pre-added with SDS and number them accordingly. Take another 10μl of dialysate and add it to the centrifuge tube with SDS as a system control. After thoroughly mixing the virus and SDS solution, place them at room temperature for 15-30 minutes, shaking occasionally. Then measure the light absorbance at 260nm and 280nm, and calculate the value according to the formula (1OD 260 =1×10 12 VP) Calculate the virus optical particle number concentration in the virus solution. OD 260 The value reflects the viral DNA concentration in the collected fluid, OD 280 The value reflects the protein concentration in the collected fluid, OD 260 / OD 280 The ratio is about 1.2-1.3.

[0364] 13. After diluting the obtained virus accordingly, select 100 μl of two dilutions of appropriate dilutions and infect AD293 cells of appropriate concentration that have been inoculated in a 24-well plate. After 48 hours, use an adenovirus titration kit (Shanghai Aoxiang Biotechnology Co., Ltd.) to detect the precise titer of the virus.

[0365] The high-quality virus liquid purified by ultracentrifugation is dispensed into different clean centrifuge tubes in different volumes according to the concentration and experimental needs, marked with the date and virus name, and stored at -80°C for future use.

[0366] Example 4: Killing ability of oncolytic adenovirus (OAd-shPDL1) on tumor cells (HCT116, PANC1, HT29 and H460)

[0367] In this example, the killing ability of oncolytic adenovirus (OAd-shPDL1) was detected by MTT assay. Human tumor cells (HCT116, PANC1, HT29 and H460) were inoculated in 96-well plates, and the number of cells inoculated in each well was 3×10 3 Each well was cultured in 100 μl of medium (McCoy's 5A + 10% FBS medium was used for HCT116 cell culture; DMEM + 10% FBS medium was used for PANC-1 cell culture; DMEM / F12 + 10% FBS medium was used for HT29 cell culture; RPMI1640 + 10% FBS was used for H460 cell culture, and all culture media were purchased from Gibco). After 12 hours, 50 μl of the medium was removed and 50 μl of a mixture of virus (the viruses used were control virus C-4.5K, OAd-shPDL1 virus 1-4.5K, 2-4.5K and 3-4.5K prepared by the method described in Preparation Example 5) and serum-free medium was added (the time point was recorded as 0 hr), and the multiplicity of infection (MOI) was 1, 3, 10, 30, 100 and 300, respectively. Three replicate wells were set for each multiplicity of infection. At 48 hr and 72 hr, 10 μl of MTT solution (purchased from Solebow Biotechnology Co., Ltd.) (5 mg / ml, i.e. 0.5% MTT) was added to each well, and the culture was continued for 4 hr; then all the culture medium was carefully aspirated, and contact with and aspiration of the cells was avoided as much as possible. 150 μl of DMSO was added to each well, and the mixture was shaken at a low speed on a shaker for 10 minutes to fully dissolve the crystals, and the absorbance at 490 nm was detected on a microplate reader. In this experiment, the commercial oncolytic adenovirus H101 was used as a control. The same cell was treated with the same MOI virus, and the light absorption value was detected at the same time at the same time point. In addition, a 1 μM paclitaxel solution was used as a system positive control. GraphPad Prism 5.04 was used to analyze the data, draw dose-effect curves, and calculate IC 50 The inhibition rate calculation formula is: cell proliferation inhibition percentage (IR%) = 1-(OD test sample-OD blank) × 100%. The killing effect of oncolytic adenovirus (OAd-shPDL1) on four tumor cells and the half-killing dose (IC50) results are as follows Figure 25-29 shown.

[0368] The results showed that the oncolytic adenovirus prepared by the present invention (control virus C-4.5K, OAd-shPDL1 virus 1-4.5K, 2-4.5K and 3-4.5K) had a significant dose-dependent relationship in killing HCT116, PANC1, HT29 and H460, and all had strong killing ability. Compared with the commercial oncolytic adenovirus H101, the virus of the present invention has a similar killing effect. It can be expected that the oncolytic adenovirus of the present invention can be used for the treatment of the above-mentioned types of tumors in future clinical applications.

[0369] Example 5: Efficacy of shPDL1 expressed by oncolytic adenovirus OAd-shPDL1

[0370] This example includes in vitro functional assays performed in cells and in vivo functional assays performed in tumor-bearing mouse models. The oncolytic adenoviruses used in the experiment were control virus C-4.5K and OAd-shPDL1 virus 1-4.5K (the viruses used were prepared by the method described in Preparation Example 5).

[0371] 1. In vitro cell experiments to detect the function of shPDL1 expressed by oncolytic adenovirus OAd-shPDL1

[0372] (1) Cell experiments on human breast cancer cells MDA-MB-231

[0373] The cell line used in this part of the experiment is the human breast cancer cell MDA-MB-231 with a high expression level of human PDL1. MDA-MB-231 cells were seeded in 3 wells of a 6-well plate, with a seeding number of 1×10 6 After 12 hours, 1×10 7 A mixture of 100 μl of serum-free L15 medium (L15 medium purchased from Gibco) containing 100 PFU (MOI=10) of C-4.5K and 1-4.5K oncolytic adenovirus was added to the remaining well as a blank control. The 6-well plate was gently shaken in a "cross" shape to distribute the virus as evenly as possible in the culture wells. The culture medium was incubated at 37°C and 5% CO 2After culturing in the incubator for 24 hours, the cells were digested with trypsin and the cell samples were recovered. The recovered cell samples were rinsed twice with clean PBS, and the recovered cell pellets were suspended in RIPA buffer (50mM Tris-Cl (pH7.4), 150mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS and 1 / 20 Cocktail protease inhibitors) with protease inhibitors. The cells were placed on ice for 30 minutes to lyse the cells, and the cell samples were shaken occasionally to mix them. After centrifugation at 12000RPM for 5 minutes, the lysis supernatant and cell pellet were recovered and stored at -20°C. Conventional Western blotting was used to detect the protein level of hPDL1 in the three recovered MDA-MB-231 cell lysis supernatants, and the primary antibody was the rabbit PDL1 antibody from Novusbio (Cat. No.: NBP2-15791). Each group of experiments was repeated three times. Western results and grayscale scanning value analysis are shown in Fig.30 .

[0374] According to the above Western experimental results, it can be seen that after the OAd-shPDL1 oncolytic virus of the present invention was used to treat MDA-MB-231 cells, the expression level of hDPL1 in the cells changed significantly. The expression level of hPDL1 in the MDA-MB-231 cells of the OAd-shPDL1 treatment group (1-4.5K group) was reduced by about 72.4% compared with the control group, while the expression level of hPDL1 in the cells of the oncolytic virus control group (C-4.5K group) did not change significantly.

[0375] Next, MDA-MB-231 cells were seeded in 3 wells of a 12-well plate, with 1×10 4 After 12 hours, 1×10 5 PFU (MOI = 10) of C-4.5K and 1-4.5K oncolytic adenoviruses were mixed with serum-free medium, and an equal volume of serum-free medium was added to the remaining well as a blank control. The 12-well plate was gently shaken in a "cross" shape to distribute the virus as evenly as possible in the culture wells. The culture medium was kept at 37°C and 5% CO. 2 After culturing in the incubator for 24 hours, the cell samples were recovered and FACS was performed using a CD274 flow cytometry antibody (purchased from ebioscience) to detect the percentage of cells expressing hPDL1 in the cell samples. Each group of experiments was repeated three times. The flow cytometry results are shown in Fig.31 .

[0376] The experimental results show that after treating MDA-MB-231 cells with the OAd-shPDL1 oncolytic virus of the present invention, the percentage of cells in which hPDL1 was detected on the cell membrane decreased by about 5 percentage points compared with the blank control group without any treatment, while the percentage of cells in which hPDL1 could be detected in the oncolytic virus control group (C-4.5K group) increased by about 9 percentage points compared with the blank control group without any treatment, which is consistent with the relevant literature that oncolytic viruses can cause increased expression levels of hPDL1 on the tumor surface after stimulating tumor cells (see (for example) the following scientific literature: "Dmitriy Zamarin, et al. PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy. J Clin Invest. 2018; 128 (4): 1413-1428."; "Zuqiang Liu, et al. Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy. Nat Commun. 2017 Mar 27; 8: 14754-14765."; or "Praveen K. Bommareddy, et al. Integrating oncolytic viruses in combination cancer immunotherapy. Nat Rev Immunol. 2018 May 9. doi: 10.1038 / s41577-018-0014-6."). The results shown show that after OAd-shPDL1 oncolytic virus treatment of MDA-MB-231 cells, the percentage of cells that stimulate tumor cells with oncolytic virus and increase hPDL1 expression can be reduced to 95% of the percentage of cells before stimulation. This also fully proves that the shPDL1 expressed in the OAd-shPDL1 oncolytic virus does knock down the expression level of hPDL1 in MDA-MB-231 tumor cells and reduces the number of cells expressing hPDL1 on the surface of MDA-MB-231 tumor cells.

[0377] (2) Cell experiments on human colon cancer cells HCT116

[0378] Human colon cancer cell HCT116 cells were inoculated in 3 wells of a 12-well plate, with 1×10 4 After 12 hours, 1×105 PFU (MOI = 10) of C-4.5K and 1-4.5K oncolytic adenoviruses were mixed with serum-free medium, and an equal volume of serum-free medium McCoy's 5A was added to the remaining well as a blank control. The 12-well plate was gently shaken in a "cross" shape to distribute the virus as evenly as possible in the culture wells. The culture medium was kept at 37°C and 5% CO. 2 After 24 hours of incubation in the incubator, the cells were digested with trypsin and the cell samples were recovered. FACS was performed using CD274 flow cytometry antibodies to detect the percentage of cells expressing hPDL1 in the cell samples. Each group of experiments was repeated three times. The flow cytometry results are shown in Fig.32 .

[0379] The experimental results show that after HCT116 cells were treated with the OAd-shPDL1 oncolytic virus of the present invention, the percentage of cells in which hPDL1 was detected on the cell membrane decreased by about 19.1% compared with the blank control group without any treatment, while the percentage of cells in which hPDL1 could be detected in the oncolytic virus control group (C-4.5K group) increased by about 5.3% compared with the blank control group without any treatment, which is consistent with the fact that oncolytic viruses can cause an increase in the expression level of hPDL1 on the tumor surface after stimulating tumor cells in the relevant literature (see (for example) the following scientific literature: "Dmitriy Zamarin, et al. PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy. J Clin Invest. 2018; 128 (4): 1413-1428."; "Zuqiang Liu, et al. Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy. Nat Commun. 2017 Mar 27; 8: 14754-14765."; or "Praveen K. Bommareddy, et al. Integrating oncolytic viruses in combination cancer immunotherapy. Nat Rev Immunol. 2018 May 9. doi: 10.1038 / s41577-018-0014-6."). The results show that after HCT116 cells were treated with OAd-shPDL1 oncolytic virus, the percentage of cells that stimulated tumor cells with oncolytic virus and increased hPDL1 expression was reduced to 80.9% of the percentage of cells before stimulation. This also fully proves that the shPDL1 expressed in the OAd-shPDL1 oncolytic virus indeed knocked down the expression level of hPDL1 in HCT116 tumor cells and reduced the number of cells expressing hPDL1 on the surface of HCT116 tumor cells.

[0380] 2. In vivo tumor-bearing mouse model experiment to detect the function of shPDL1 expressed by oncolytic adenovirus OAd-shPDL1

[0381] In this part of the experiment, human colon cancer cells HCT116 were inoculated subcutaneously on the backs of 9 BALB / C nude mice. The number of cells inoculated per nude mouse was 5×10 6After the cells formed tumors in the subcutaneous part of nude mice for about 9 days, they were randomly divided into 3 groups. The first group was not treated as a blank control group, and the second group was injected with an oncolytic adenovirus control virus C-4.5K in the subcutaneous tumor by intratumoral injection. The virus injection volume for each nude mouse was 1×10 9 PFU, the injection volume was 100 μl, and the third group was also injected with oncolytic adenovirus 1-4.5K in the subcutaneous tumor by intratumoral injection. The virus injection volume per nude mouse was 1×10 9 PFU, the injection volume was 100 μl. According to this injection dose and method, the injection was performed once a day for 3 consecutive days. No treatment was performed on the 4th day. On the 5th day, the nude mice were killed to recover the tumor tissue. A portion of all tissue samples was selected and added with RIPA buffer containing protease inhibitors (the formula is the same as above) and then homogenized to extract tissue proteins. Western blotting experiments were performed to detect the protein expression level of hPDL1 in tumor tissues after different treatments. The results are shown in Fig.33 and Fig.34 .

[0382] Bundle Fig.33 The band scans of the Western results shown were converted to grayscale values ​​and normalized according to the grayscale values ​​of the respective housekeeping genes (β-actin). Fig.34 The scatter plot shows that according to their respective median values, after the HCT116 cells inoculated subcutaneously in BALB / C were treated with the oncolytic adenovirus control virus (C-4.5), the expression of hPDL1 in this group was upregulated by 20% compared with the expression of hPDL1 in the blank control group without any treatment, while the protein expression level of hPDL1 in a group of HCT116 cells inoculated subcutaneously in BALB / C treated with the oncolytic adenovirus OAd-shPDL1 was 25% lower than that in the control virus treatment group, and the expression level was also lower than the expression of hPDL1 in the blank control group without any treatment. Therefore, this result proves that the shPDL1 expressed in the oncolytic adenovirus OAd-shPDL1 (1-4.5) does reduce the expression of hPDL1 in human tumor cell transplants in vivo.

[0383] Example 6: In vivo growth inhibition experiment of oncolytic adenovirus OAd-shPDL1 on human tumor cells inoculated subcutaneously in immunodeficient mice

[0384] In this example, NOD-SCID immunodeficient mice were first inoculated subcutaneously (the number of cells inoculated subcutaneously in each mouse was 5×10 6A tumor-bearing mouse animal model was prepared by using human colon cancer cells HCT116 (cells) to detect the growth inhibitory effect of oncolytic adenovirus OAd-shPDL1 (1-4.5K) on HCT116, and the oncolytic control virus C-4.5K was used as a negative control virus. The control virus C-4.5K and OAd-shPDL1 virus 1-4.5K used in the experiment were prepared by the method described in Preparation Example 5. The tumor volume of subcutaneous inoculation was selected to meet the requirements (tumor volume of 90-120mm 3 ) were randomly divided into 4 groups according to the block randomization method, with 3 mice in each group. The first group was the control group (blank control), and each mouse was injected with 100 μl of adenovirus storage solution (i.e., containing 1 mM MgCl 2 The second group was a medium-dose oncolytic control virus group (C-4.5K (medium)), and each mouse was injected with 100 μl containing 1×10 8 The third group was the medium-dose oncolytic virus group (1-4.5K (medium)), and each mouse was injected with 100 μl containing 1×10 8 The fourth group was a high-dose oncolytic virus group (1-4.5K (high)), and each mouse was injected with 100 μl containing 1×10 9 PFU of 1-4.5K virus suspension. The drug was administered three times in total during the entire experiment, every other day, and the first administration started on the day of grouping (recorded as day 0). The tumor diameter and mouse weight were measured twice a week. After the 21st day, the mice were killed and the tumors were taken for photography. The experimental results are shown in Fig.38 , Fig.39 , Fig.40 and Fig.41 .

[0385] In summary, the oncolytic adenovirus OAd-shPDL1 (1-4.5K) can inhibit the growth of HCT116 tumor cells inoculated subcutaneously in NOD-SCID immunodeficient mice to a certain extent. The high-dose group (1-4.5K (high)) showed a stronger growth inhibitory effect than the medium-dose group (1-4.5K (medium)) and the control virus group (C-4.5K (medium)), showing a significant dose-dependent relationship (see Fig.38 ), but the relative tumor proliferation rate (T / C%) did not reach below 40% (see Fig.39The same dose of OAd-shPDL1 (1-4.5K) and backbone control virus C-4.5K did not show better tumor inhibition effect in inhibiting tumor growth because the shPDL1 expressed by the OAd-shPDL1 (1-4.5K) virus led to a decrease in the expression level of hPDL1 in tumor cells (see Fig.38 , 39 , 41). The body weight of mice in all groups did not change significantly, indicating that the oncolytic adenovirus OAd-shPDL1 (1-4.5K) and the control virus group (C-4.5K) did not show significant toxicity to NOD-SCID-deficient mice (see Fig.40 ).

[0386] Next, BALB / C nude mice were subcutaneously inoculated (5×10 6 The tumor-bearing mouse model was prepared by using human colon cancer cells HCT116 (1-4.5K) to verify the growth inhibition effect of oncolytic adenovirus OAd-shPDL1 (1-4.5K) on HCT116, and the oncolytic control virus C-4.5K was used as a negative control virus. The tumor volume of subcutaneous inoculation reached the requirement (tumor volume of 90-120mm 3 ) were randomly divided into 5 groups according to the block randomization method, with 5 mice in each group. The first group was the control group (blank control (Control)), and each mouse was injected with 100 μl of adenovirus storage solution each time; the second group was the medium-dose oncolytic control virus group (C-4.5K (medium)), and each mouse was injected with 100 μl of 1×10 8 The third group was a low-dose oncolytic virus group (1-4.5K (low)), and each mouse was injected with 100 μl containing 1×10 7 The fourth group was the medium-dose oncolytic virus group (1-4.5K (medium)), and each mouse was injected with 100 μl containing 1×10 8 The fifth group was a high-dose oncolytic virus group (1-4.5K (high)), and each mouse was injected with 100 μl containing 1×10 9 PFU of 1-4.5K virus suspension. The drug was administered five times in total during the entire experiment, every other day, and the first administration started on the day of grouping (recorded as day 0). The tumor diameter and mouse weight were measured twice a week, and the mice were killed after the 28th day and the tumors were taken for photography. The experimental results are shown in Fig.42 , Fig.43 , Fig.44 and Fig.45 .

[0387] In summary, in the experiment of treating HCT116 tumor cells inoculated subcutaneously in BALB / C nude mice with oncolytic adenovirus OAd-shPDL1 (1-4.5K), both the high-dose group and the medium-dose group showed very good tumor inhibition effects (see Fig.42 ), the relative tumor proliferation rate (T / C%) of the high-dose group reached below 40%, and the relative tumor proliferation rate (T / C%) of the medium-dose group also reached below 40% in the experiment (see Fig.43 ). More importantly, the tumors on the backs of the nude mice in the high-dose group showed an obvious "tumor lysis" phenomenon - the surface ulcerated, and the tumor tissue at the original inoculation site was basically cleared after the scabs formed and fell off at the ulcerated site. Judging from the physical condition and weight of the animals, except for one nude mouse in the high-dose group whose tumor cells attached to the muscles of the back spine, making the inhibitory effect of OAd-shPDL1 (1-4.5K) not very obvious, the growth of the tumor cells inoculated on the backs of the remaining four nude mice was effectively inhibited. The bodies of these four nude mice were rounder and stronger than those of the nude mice in other groups. The tumor cells inoculated on the backs of two of the nude mice were no longer visible to the naked eye after being treated with OAd-shPDL1 (1-4.5K) (see Fig.44 , 45 ). Compared with the oncolytic virus backbone control virus group (C-4.5K) and the OAd-shPDL1 (1-4.5K) medium-dose group, the growth of tumors inoculated subcutaneously in nude mice in the OAd-shPDL1 (1-4.5K) medium-dose group also showed a more significant inhibitory effect (see Fig.42 , 43 , 45), it can be considered that the reduction of HPDL1 expression level in tumor cells caused by shPDL1 expressed by the shPDL1 expression frame in the OAd-shPDL1 (1-4.5K) medium-dose group played a key role in inhibiting tumor growth. The nude mice in the virus preservation fluid group lost a lot of weight and showed a malignant wasting constitution related to tumor growth.

[0388] Example 7: Verification of the growth inhibition of human tumor cells HCT116 inoculated subcutaneously in BALB / C nude mice by oncolytic adenovirus OAd-shPDL1

[0389] In order to further confirm the effective dose of OAd-shPDL1 (1-4.5K) for inhibiting the growth of HCT116 cells inoculated subcutaneously in BALB / C nude mice, this example expanded the sample size of the animal model and verified the effective dose of OAd-shPDL1 (1-4.5K) again. First, human colon cancer cells HCT116 were inoculated subcutaneously in BALB / C nude mice to prepare a tumor-bearing mouse animal model. The cell inoculation amount for each nude mouse was 5×10 6cells. The oncolytic virus C-4.5K was also selected as a negative control virus. The tumor volume of subcutaneous inoculation reached the requirement (tumor volume was 80-130mm 3 ) were randomly divided into 5 groups according to the block randomization method, with 7 mice in each group. The first group was the control group (Control group), and each mouse was injected with 100 μl of adenovirus storage solution (i.e., containing 1 mM MgCl 2 and 10% glycerol in 10 mM Tris solution (pH 7.4); the second group was the oncolytic control virus medium dose group (C-4.5K (1×10 8 Each mouse was injected with 100 μl containing 1×10 8 PFU of C-4.5K virus suspension; the third group was the oncolytic control virus high-dose group (C-4.5K (1×10 9 Each mouse was injected with 100 μl containing 1×10 9 PFU of C-4.5K virus suspension; the fourth group was the oncolytic virus 1-4.5K medium dose group (1-4.5K (1×10 8 Each mouse was injected with 100 μl containing 1×10 8 PFU 1-4.5K virus suspension; the fifth group is the high-dose oncolytic virus group (1-4.5K (1×10 9 Each mouse was injected with 100 μl containing 1×10 9 PFU of 1-4.5K virus suspension. During the entire experiment, the drug was administered five times, every other day, and the first dose started on the day of grouping (recorded as day 0). The tumor diameter was measured and the mouse body weight was weighed twice a week. On the 25th day, because the nude mice bearing tumors in the control group and the oncolytic control virus group had ruptured and reached the end of the experiment, all 35 mice were killed and the tumors were weighed and photographed. The blood and spleen of the same mouse were used to prepare a cell suspension, and flow cytometry antibodies for detecting BALB / C nude mouse NK cells and T cells (anti-mouse CD49b antibody and anti-mouse CD3 antibody, both purchased from ebioscience) were added for staining and FACS was performed to analyze the changes in the NK and T cell ratios of tumor cells in the tumor, blood and spleen. The experimental results are shown in Figure 2. Fig.46 , Fig.47 , Fig.48 , Fig.49 , Fig.50 and Fig.51 .

[0390] Preparation of blood cell suspension: After removing the mouse eyeball, blood was collected and added to the anticoagulant tube for shaking and mixing, and then placed on ice. After centrifugation at 500×g for 5 minutes, the supernatant was discarded and red blood cell lysis solution (purchased from Tiangen Biochemical Technology (Beijing) Co., Ltd., catalog number: #122-02) was added to fully mix the precipitated cells and react at room temperature for 10-15 minutes. After centrifugation at 500×g for 5 minutes, the supernatant was discarded and the cell pellet was retained. The cells were resuspended in PBS solution containing 1% BSA and centrifuged at 500×g for 5 minutes, and the supernatant was discarded and the cell pellet was retained. The cell pellet was divided into two parts, one of which was not treated as a control, and the other part was added with anti-BALB / C mouse CD3 and CD49b flow antibodies. After mixing, react at room temperature in the dark for 30 minutes and then perform FACS on the machine.

[0391] Preparation of spleen cell suspension: After dissecting mice and taking out the mouse spleen, place it in a 1.5ml centrifuge tube and temporarily store it on ice. Add 5ml of PBS solution containing 1% BSA to a clean 6cm culture dish, wrap the spleen with a nylon mesh, squeeze and grind the spleen in the culture dish to fully release spleen cells. Centrifuge the cell suspension at 500×g for 5 minutes and discard the supernatant. Add red blood cell lysis buffer to fully mix the precipitated cells and react at room temperature for 10-15 minutes, centrifuge again at 500×g for 5 minutes, discard the supernatant and retain the cell pellet, resuspend the cells with PBS solution containing 1% BSA and centrifuge at 500×g for 5 minutes, discard the supernatant and retain the cell pellet, divide the cell pellet into two parts, one part is not treated as a control, and the other part is added with anti-BALB / C mouse CD3 and CD49b flow antibodies, mix well, react at room temperature in the dark for 30 minutes, and then perform FACS on the machine.

[0392] Preparation of tumor tissue cell suspension: After dissecting mice and taking subcutaneous tumors, place them in 1.5ml centrifuge tubes and temporarily store them on ice. Cut a small piece of each tumor tissue into another set of centrifuge tubes and add 500μl collagenase. Use ophthalmic scissors to cut the tumor into small pieces and react at 37℃ for 30 minutes. Centrifuge the cell suspension at 500×g for 5 minutes, discard the supernatant, add red blood cell lysis buffer to mix the precipitated cells thoroughly and react at room temperature for 10-15 minutes. Centrifuge again at 500×g for 5 minutes, discard the supernatant and retain the cell pellet. Resuspend the cells again with PBS solution containing 1% BSA and centrifuge at 500×g for 5 minutes, discard the supernatant and retain the cell pellet. Divide the cell pellet into two parts, one of which is not treated as a control, and the other is added with anti-BALB / C mouse CD3 and CD49b flow cytometry antibodies. Mix well and react at room temperature in the dark for 30 minutes before loading on the machine for FACS.

[0393] In summary, in the experiment of treating HCT116 tumor cells inoculated subcutaneously in BALB / C nude mice with oncolytic adenovirus OAd-shPDL1 (1-4.5K), both the high-dose group and the medium-dose group showed very good tumor inhibition effects (see Fig.46 ), the relative tumor proliferation rate (T / C%) of the medium-dose group reached 40%, and that of the high-dose group was less than 40% (see Fig.47 ). Compare with the control virus C-4.5K (1×10 8 ) group and target oncolytic virus 1-4.5K (1×10 8 ) group showed a strong inhibitory effect on the growth of HCT116. The oncolytic virus 1-4.5K showed a strong inhibitory effect on the growth of HCT116. The statistical analysis of the tumor volume of the two groups showed a very significant difference between the two groups. 9 ) group and target oncolytic virus 1-4.5K (1×10 9 ) group on the growth inhibition of HCT116. In the early stage of administration, both viruses showed very strong growth inhibition on subcutaneously inoculated HCT116, but on the 10th day of the experiment, C-4.5K could not continue to inhibit tumor growth like 1-4.5K. C-4.5K (1×10 9 ) group began to grow subcutaneous tumors in nude mice, while 1-4.5K (1×10 9 ) group, the subcutaneous tumors of nude mice continued to be suppressed until the 17th day of the experiment, and there was also a very significant difference in the tumor volume between the two groups. Comprehensive analysis of the above results shows that the C-4.5K and 1-4.5K oncolytic viruses fully demonstrate the characteristics of oncolytic viruses. In addition, because 1-4.5K can express shPDL1, it shows a longer persistence of growth inhibition on HCT116 cells than C-4.5K. This example fully reflects that the shPDL1 expressed in the oncolytic virus 1-4.5K may weaken or relieve the immunosuppressive effect around the tumor and activate the surrounding immune cells due to changing the expression level of hPDL1 in human tumor cells, thereby achieving a combined killing effect on the tumor. There was no significant change in the body weight of all five groups of mice, indicating that no obvious toxicity was found in the two oncolytic adenoviruses on BALB / C nude mice (see Fig.48 The tumors of mice in each group were photographed and weighed (see Fig.49), and found that there was a significant difference in tumor weight between the 1-4.5K experimental group and the C-4.5K experimental group. After FACS analysis of NK and T cells in tumors, blood and spleen, it was found that the NK cells in the tumor tissue and blood of mice treated with 1-4.5K oncolytic virus were greatly improved compared with the control group (Control group) and the C-4.5K control oncolytic virus group. Among them, the NK cells in the blood of the 1-4.5K oncolytic virus group were twice that of the NK cells in the blood of the control group, and the NK cells in the tumor tissue increased by 5 times compared with the control group. There was no significant change in the NK cells in the spleen of each group of animals (see Fig.50 The analysis of T cells showed that the proportion of T cells in the blood of the animals in each group did not change significantly, 1-4.5K (1×10 8 ) T cells in spleen and tumor tissues of the experimental group were higher than those of C-4.5K (1×10 8 ) Similarly, there was a significant increase in T cells in the tissue (see Fig.51 ).

[0394] Comprehensive analysis of the above experimental results (see Examples 6 and 7), using the same oncolytic adenovirus OAd-shPDL1 (1-4.5K) to treat human colon cancer cells HCT116 subcutaneously inoculated in two different genetic backgrounds of immunodeficient mice, obtained very different tumor inhibition effects. OAd-shPDL1 (1-4.5K) showed very good tumor growth inhibition and tumor clearance effects on HCT116 subcutaneously inoculated in BALB / C nude mice, while the same dose (1×10 9 ) had no significant inhibitory effect on the same type of cells inoculated subcutaneously in NOD-SCID immunodeficient mice. Another virus with the same concentration (1×10 9) The backbone control virus (C-4.5K) showed a similar tumor inhibition effect to the OAd-shPDL1 (1-4.5K) oncolytic virus on HCT116 inoculated subcutaneously in BALB / C nude mice only at the initial stage of administration, but it could not continue to inhibit tumor growth like OAd-shPDL1 (1-4.5K) after the administration was stopped. Normally, in order to escape the killing and clearance of the body's immune system, tumor cells will highly express ligands such as PDL1 or PDL2 on their own surface. The binding of the above ligands to PD-1 will lead to tyrosine phosphorylation of the intracellular domain of PD-1 and recruit tyrosine phosphatase SHP-2, thereby reducing the phosphorylation of the TCR signaling pathway, reducing the activation signals downstream of the TCR pathway, as well as the activation of T cells and the production of cytokines, thereby forming an immunosuppressive microenvironment around the tumor, and the immune cells in this environment are in an inactive state. In addition, from the analysis of immunodeficient mouse strains, NOD-SCID immunodeficient mice have a higher degree of immunodeficiency, lacking T cells in the body, B cells exist but lack function, and NK cell function is extremely low; while BALB / C nude mice have a lower degree of immunodeficiency, also lacking T cells in the body, B cells exist but lack function, but retain fully functional NK cells, macrophages and antigen presenting cells mainly composed of dendritic cells. There are literature reports that NK, macrophages or dendritic cells in mice may play an important role in the joint killing process of inhibiting tumor growth (see (for example) the following scientific literature: "Kevin C. Barry, et al. A natural killer-dendritic cell axis defines checkpoint therapy-responsive tumor microenvironments. Nat Med. 2018 Jun 25. doi: 10.1038 / s41591-018-0085-8."). The difference between the oncolytic adenovirus OAd-shPDL1 (1-4.5K) and its backbone control virus C-4.5K is that the former contains an expression frame that can express shPDL1, which can express shPDL1 inside the invading tumor cells. shPDL1 reduces the level of hPDL1 in human tumor cells, thereby weakening or relieving the immunosuppressive state in the peritumoral environment, and ultimately maintaining a longer inhibitory state on tumor growth.In addition, there are also literature reports that PD1 on the surface of mouse immune cells and PDL1 on the surface of human cells can bind to each other and transmit immunosuppressive signals; conversely, the expression of shPDL1 in human tumor cells reduces the expression level of hPDL1 (see (for example) the following scientific literature: "David Yin-weiLin, et al. The PD-1 / PD-L1 complex resembles the antigen-binding Fv domains ofantibodies and T cell receptors. Proc Natl Acad Sci USA. 2008Feb 26; 105(8): 3011-6."; "Clement Viricel, et al. Human PD-1 binds differently to its human ligands: A comprehensive modeling study. J Mol Graph Model. 2015Apr; 57: 131-42."; or "Aaron T.Mayer, et al. Practical ImmunoPET radiotracer design considerations for human immune checkpoint imaging. J Nucl Med. 2017Apr; 58(4): 538-546."). It is believed that the decrease in the expression level of hPDL1 in tumor cells caused by the oncolytic adenovirus OAd-shPDL1 (1-4.5K) expressing shPDL1 in human tumor cells HCT116 weakened and relieved the inhibitory effect of the tumor surrounding immune cells (NK, macrophages or dendritic cells) in BALB / C nude mice, thereby showing a sustained inhibitory ability on the growth of HCT116.

[0395] The results of this part are also consistent with the synergistic effect shown by the oncolytic virus OAd-shPDL1 (1-4.5K) and human T cells expressing Her2TCR-6A5-mC in the combined killing of tumor cells in vitro.

[0396] Example 8: Induction of Her2 / neu 369-377 polypeptide (Her2-E75 epitope polypeptide)-specific killer T cells from peripheral blood of HLA-A2-positive normal donors

[0397] In this example, a low concentration of 1 μg / ml Her2 / neu 369-377 peptide was used to induce peptide-specific killer T cells from HLA-A2 positive normal PBMC (#2) through two rounds of in vitro stimulation, and flow cytometry analysis and single cell isolation were performed. The specific method is as described above. The results are as follows:

[0398] Fig.35 A right figure shows that 0.024% of lymphocytes are CD8 positive killer T cells that can bind to Her2 / neu369-377 / HLA-A2 pentamer (i.e. Her2-E75 pentamer). In the left figure, the control cells that were not stimulated with Her2 polypeptide did not show CD8 positive pentamer positive cells. The results show that in the natural T cell pool, the number of specific T cells that recognize Her2 / neu 369-377 antigen polypeptide is very small. Despite the small number, this group of T cells that can recognize Her2 / neu 369-377 polypeptide can still be clearly distinguished. In addition, according to the fluorescence intensity of binding to Her2-E75 pentamer, the positive cells include high affinity T cells and low affinity T cells. 300 CD8-positive pentamer-positive cells were separated by flow cytometry and then cultured as monoclonal cells. After two rounds of antigen peptide restimulation and cytokine amplification, a proliferating T cell clone Her2 CTL clone 6A5 (referred to as Her2 CTL 6A5) was obtained from these 300 separated single T cells. Fig.35 B right figure shows 97.9% CD8 + CTL cells can bind to Her2 / neu 369-377 / HLA-A2 tetramers (i.e. Her2-E75 tetramers), indicating that this purified T cell clone is not mixed with other irrelevant cells. The left picture shows control T cells that cannot bind to Her2-E75 tetramers.

[0399] Example 9: Obtaining the complete sequence of Her2 / neu 369-377 polypeptide-specific TCR

[0400] In this example, total RNA was directly purified from a certain number of Her2 CTL 6A5 cells obtained in Example 8, and paired TCR α chain and β chain gene sequences (i.e., the two chains can together form a functional TCR that recognizes antigenic polypeptides) were obtained by 5'-RACE RT-PCR, and the encoded TCR was called "Her2 TCR-6A5". The amino acid sequence of the α chain of the TCR is shown in SEQ ID NO:4, the coding sequence is shown in SEQ ID NO:12, and the amino acid sequence of the β chain of the TCR is shown in SEQ ID NO:7, and the coding sequence is shown in SEQ ID NO:15. This TCR exists in the peripheral T cell pool of HLA-A2 positive normal people, and will not cross-react with normal cells that express Her2 / neu protein in trace amounts and cause autoimmune reactions. In order to detect the antigen specificity and function of the obtained TCR, the TCR α chain and β chain sequences were cloned into a replication-deficient lentiviral expression vector. Fig.35 C shows a schematic diagram of the constructed TCR lentiviral vector structure fragment. The constant regions of the TCR α chain and β chain are replaced by mouse sequences from human sequences and connected by a cleavable connecting polypeptide. The expression of the 6A5 TCR α chain and β chain is driven by the EF-1α promoter. This promoter is a high-expression promoter in eukaryotic cells and will not be affected by factors such as methylation and cause loss of function. It is suitable for long-term expression of exogenous genes in vivo. The TCR α chain and β chain are connected by the F2A polypeptide sequence. The TCR α chain and β chain genes can be transcribed at the same time and translated by ribosome skipping, so that the TCR α chain and β chain polypeptides are separated from each other. This ensures the consistency of the expression of the TCR α chain and β chain, thereby forming the TCR dimer more efficiently. There is also a furin restriction site between the TCR α chain and the β chain to remove the redundant peptide segment at the carboxyl end of the β chain.

[0401] The nucleotide sequence of the TCR β chain and α chain (SEQ ID NO: 20) linked by a cleavable linking polypeptide and with the constant region replaced by the human sequence with the mouse sequence (the corresponding TCR is Her2 TCR-6A5-mC, and the amino acid sequence is shown in SEQ ID NO: 23) is connected to the above-mentioned vector to obtain a Her2 TCR-6A5-mC recombinant lentiviral vector. The Her2TCR-6A5-mC gene fragment was amplified by PCR and cloned into the downstream of the EF1-promoter of the above-mentioned lentiviral vector (i.e., pCDH-EF1α-MCS): the β fragment of Her2TCR-6A5-mC carrying the mouse constant region sequence was amplified by the 5' primer 5'-AGAGCTAGCGAATTCAACATGGGCTGCAGGCTGCTC-3' (SEQ ID NO: 26) and the 3' primer 5'-GGATCGCTTGGCACGTGAATTCTTTCTTTTGACCATAGCCAT-3' (SEQ ID NO: 27); the α gene of Her2TCR-6A5-mC carrying the mouse constant region sequence was amplified by the 5' primer 5'-TCCAACCCTGGGCCCATGCTCCTGTTGCTCATACCAGTG-3'

[0402] (SEQ ID NO: 28) and 3' primer 5'-GTTGATTGTCGACGCCCTCAACTGGACCACAGCCT-3' (SEQID NO: 29). PCR was performed using the Q5 High Fidelity PCR Kit (NEB, cat#M0543S) under the following reaction conditions: 98°C for 30 seconds, followed by 25 cycles of 98°C for 10 seconds, 65°C for 10 seconds, and 72°C for 3 minutes. The obtained TCR fragment was cloned into the MCS region downstream of the EF1α promoter of the pCDH-EF1α-MCS vector.

[0403] The constructed recombinant TCR lentiviral expression vector was prepared according to the above method to obtain the respective recombinant TCR lentiviral particles.

[0404] Example 10: Normal peripheral blood T cells were transfected with Her2 TCR-6A5-mC recombinant lentivirus to express a specific TCR that can recognize the Her2 / neu 369-377 polypeptide.

[0405] In order to further verify whether the TCR obtained by the present invention can be expressed in primary T cells and has the function of recognizing Her2 / neu antigen polypeptide, peripheral blood T cells from two different normal donors activated by CD3 / CD28 antibodies were transfected with recombinant lentiviral particles carrying the Her2 TCR-6A5-mC gene (Her2 TCR-6A5-mC recombinant lentiviral vector), and the cells were collected 14 days later for Her2-E75 tetramer staining. The specific method is as described above. The results are as follows:

[0406] Fig.36 A shows that lymphocytes in the peripheral blood mononuclear cells of both donors (#1PBMC and #2PBMC) can bind to Her2-E75 tetramers, indicating that the Her2 TCR-6A5-mC expressed by these cells can specifically recognize the Her2 / neu antigen peptide presented by HLA-A2. The results also show that among the Her2-E75 tetramer-positive cells (i.e., cells expressing Her2TCR-6A5-mC), CD8 + Positive rate of T killer cells and CD8 - The positive rates of lymphocytes are similar. - The lymphocytes are likely to be CD4 + T helper cells, if lentivirus-infected CD8 + and CD4 + The transfection efficiency of T cells is the same, indicating that CD4 + The exogenous Her2 / neu 369-377 specific TCR on the cell can effectively bind to the Her2-E75 tetramer. This further shows that the transfected Her2 TCR-6A5-mC can effectively bind to the Her2 / HLA-A2 complex without the auxiliary function of the CD8 molecule, that is, the recognition of the Her2 / neu 369-377 epitope peptide presented by HLA-A2 by Her2TCR-6A5-mC is CD8-independent. CD4 cells expressing Her2TCR-6A5-mC TCR secrete cytokines after recognizing the Her2 antigen, which can not only assist the function of killing T cells and the survival time in the body, but also induce specific T cells against endogenous tumor antigens by regulating the tumor microenvironment, thereby enhancing anti-tumor immunity.

[0407] 10e5 TCR-transfected PBMC cells were added to each well of a 96-well plate, and after mixed culture with different concentrations of Her2 / neu 369-377 antigen polypeptide presented by T2 cells (1×10e5 per well) (Her2 / neu 369-377 antigen polypeptide was diluted 10 times starting from 0.1 μg / ml, thereby obtaining different groups with final concentrations of 0.1 μg / ml, 0.01 μg / ml, 0.001 μg / ml and 0.0001 μg / ml), IFN-γ secreted by T cells in the supernatant was detected to determine the function of the TCR-expressing PBMC cells to specifically recognize the Her2 / neu 369-377 polypeptide. Fig.36 B shows that PBMC expressing Her2 TCR-6A5-mC can be activated by Her2 / neu 369-377 antigen peptide presented by T2 cells to secrete IFN-γ, indicating that primary T cells expressing exogenous Her2 TCR-6A5-mC can specifically recognize Her2 / neu 369-377 peptide presented by HLA-A2 molecules. The ability to recognize antigen peptides is related to the expression level of exogenous TCR on T cells. The half-maximum reaction (EC50) peptide concentrations of two different donors' PBMCs transfected with Her2 TCR-6A5-mC for recognizing antigen peptides were estimated by curve fitting to be approximately 1.6 ng / ml and 2.9 ng / ml, respectively (IC50 Tool program, http: / / www.ic50.tk / ). Although this reaction sensitivity is lower than the EC50 of high-affinity TCRs that recognize exogenous antigens such as viral antigens (EC50 is approximately 10e-10M) (see the literature "CANCERRESEARCH 1998; 58.4902-4908" and "HUMAN GENE THERAPY 2014; 25:730-739"), it is still within the medium and high TCR affinity range that can recognize common tumor-associated antigens (as described in the literature "Eur J Immunol (2012) 42:3174-9").

[0408] Fig.36 C shows that when T cells were co-cultured with antigenic polypeptides presented by T2 cells (T2+Her2-E75, i.e., Her2 / neu 369-377 polypeptide), the function of T cells to secrete IFN-γ was not significantly inhibited after adding anti-human CD8 antibodies. This indicates that the function of exogenous TCR to recognize Her2 / neu369-377 antigenic polypeptides does not require the auxiliary effect of CD8 molecules, and also shows that the recognition function of the Her2 TCR-6A5-mC TCR described in the present invention is non-CD8 function-dependent.

[0409] Example 11: Her2 / neu 369-377 polypeptide-specific TCR expressed by normal peripheral blood T cells after transfection with Her2 TCR-6A5-mC recombinant lentivirus can recognize HLA-A2 + Her2 / neu + Tumor cells

[0410] First, the expression of HLA-A2 and Her2 / neu in the selected tumor cell lines was detected. The tumor cell lines included colorectal cancer Colo205 and HCT116, breast cancer MDA-MB-231 and MCF-7, pancreatic cancer PANC-1, glioma U87MG, and small cell lung cancer NCI-H446. Tumor cells were stained with anti-HLA-A2 antibody (BD Bioscences, cat#561341) and anti-human CD340 (erbB2) antibody (Biolegend, cat#324406) and then analyzed by flow cytometry. Fig.37 A The results showed that Colo205, MDA-MB-231, MCF-7, HCT116, and PANC-1 were all HLA-A2 + Her / neu + ; U87MG is HLA-A2 + , Her2 / neu - ; NCI-H446 is negative for HLA-A2 and Her2 / neu. These tumor cell lines not only originate from different tissues, but also express different HLA-A2 and Her2 / neu. Among them, U87MG and NCI-H446 cells can be used as negative controls for Her2 TCR-6A5-mC T cell function detection.

[0411] After adding 1×10e4 tumor cells to each well of a 96-well plate, a certain number of PBMC cells transfected with Her2 TCR-6A5-mC TCR or PBMC cells not transfected with Her2 TCR-6A5-mCTCR were added to each well of the 96-well plate as a control group according to the effector-target ratio (5:1). The effector-target ratio was 5:1. T cells were mixed with different tumor cell lines, and then the secreted IFN-γ in the supernatant was detected. The specific method is as described above. The results are as follows:

[0412] Fig.37 B shows that T cells expressing Her2 TCR-6A5-mC can be identified by HLA-A2 + Her2 / neu + The tumor cell lines activated and secreted IFN-γ, including colon cancer Colo205 and HCT116, breast cancer MDA-MB-231 and MCF-7, and pancreatic cancer PANC-1.+ Her2 / neu - Glioma U87MG, and HLA-A2 - Her2 / neu - The lung cancer NCI-H446 was unable to activate T cells transfected with Her2 TCR-6A5-mC, indicating that the Her2 TCR-6A5-mC TCR can specifically recognize the Her2 / neu antigen presented by HLA-A2 on the surface of tumor cells. The control group T cells derived from the same donor PBMC, cultured in parallel but not transfected with Her2 TCR-6A5-mC, could not be activated by the listed tumor cell lines, indicating that the response to tumor cells is not non-specific. The results also showed that the ability of Her2 TCR-6A5-mC T cells to recognize the Her2 / neu antigen presented by HLA-A2 is not closely related to the expression of HLA-A2 and Her2 / neu molecules on the surface of tumor cells. Different tumor cells may have different inhibitory effects on T cells. On the other hand, the expression level on the cell surface does not necessarily reflect the total expression level of Her2 / neu. The Her2 / neu expressed by some tumor cells is mainly present in the cell cytoplasm, and these antigens are more easily presented by HLA-A2 (see the literature "J Immunol 2006; 177:5088-5097").

[0413] 1×10e4 target cells were added to each well of the culture plate, and a certain number of PBMC cells transfected with TCR genes were added according to the set effector-target ratio (1:1, 5:1, 10:1, 20:1, 40:1). After 24 hours, the cytotoxic activity of T cells against tumor cells was measured. Fig.37 CK showed that T cells expressing Her2 TCR-6A5-mC TCR could specifically recognize and kill HLA-A2 compared with control T cells without TCR transfection. + Her2 / neu + The killing ability of tumor cell lines MCF-7, HCT116, PANC-1 and HEPG-2 was in a dose-dependent relationship with the number of Her2TCR-6A5-mCT cells. + Her2 / neu - The glioma U87MG, HLA-A2-Her2 / neu+ SKOV3 and HT-29, and HLA-A2 - Her2 / neu - The lung cancer NCI-H446 could not be specifically killed by Her2 TCR-6A5-mC T cells. The results also showed that when Her2 TCR-6A5-mC T cells increased to a certain number, they could kill HLA-A2 + Her2 / neu+ The tumor cells showed significant specific recognition and killing function. When the effector-target ratio was lower than 10:1, the specific killing function was not obvious, which may be related to the number of Her2 / neu epitope peptides presented by HLA-A2 on the surface of tumor cells. In order to further enhance the recognition and killing sensitivity of Her2 TCR-6A5-mC T cells to tumor cells, one strategy is to increase the number of tumor target cells expressing HLA-A2 and Her2 / neu.

[0414] Example 12: Combined killing effect of oncolytic adenovirus OAd-shPDL1 and human T cells expressing Her2 TCR-6A5-mC on human colorectal cancer cells HCT116 inoculated subcutaneously in NCG severely immunodeficient mice

[0415] In this experiment, human colorectal cancer cells HCT116 were inoculated subcutaneously on the dorsal side of the right forelimb of NCG severely immunodeficient mice to prepare a tumor-bearing animal model simulating the human environment for detecting the combined killing effect of oncolytic adenovirus OAd-shPDL1 (prepared by the method described in Preparation Example 5) and human T cells expressing Her2TCR-6A5-mC (prepared by the method described in Example 10) on human colorectal cancer cells HCT116 inoculated subcutaneously in severely immunodeficient mice NCG. The cell inoculation amount for each animal was 5×10 6 After 9 days of cell inoculation, subcutaneous tumors were selected to reach the required volume (tumor volume 90-120mm 3 ) were randomly divided into 4 groups according to the block randomization method, with 3 mice in each group. The day of grouping was set as day 0. The first group was the blank control group. Each mouse in the group was injected with 100 μl Ad preservation solution (i.e., containing 1 mM MgCl) intratumorally on day 0 and day 4, respectively. 2 The first group was injected with 100 μl of normal saline solution (pH 7.4) containing 10% glycerol and 10 mM Tris solution on the 2nd and 6th day. The second group was the 1-4.5K group. Each mouse in the group was injected with 100 μl of oncolytic adenovirus OAd-shPDL1 (1-4.5K) on the 0th and 4th day. The virus injection volume for each animal was 5×10 8 PFU, and 200 μl of normal saline was injected into the tail vein on the 2nd and 6th day; the third group was the 1-4.5K+Mock-T group (where "Mock-T" refers to control T cells), and each mouse in the group was injected with 100 μl of oncolytic adenovirus OAd-shPDL1 (1-4.5K) on the 0th and 4th day, respectively. The virus injection volume for each animal was 5×10 8 PFU, 200 μl of unmodified ordinary T cell suspension (suspending medium is physiological saline) was injected into the tail vein on the 2nd and 6th day, and the number of cells was 2×10 7The fourth group was the 1-4.5K+E75-TCRT group (where "E75-TCRT" refers to human T cells expressing Her2 TCR-6A5-mC). Each mouse in this group was injected intratumorally with 100 μl of oncolytic adenovirus OAd-shPDL1 (1-4.5K) on day 0 and day 4, respectively. The virus injection volume for each animal was 5×10 8 PFU, 200 μl of human T cells expressing Her2TCR-6A5-mC were injected into the tail vein on days 2 and 6, with a cell number of 2 × 10 7 The human T cells expressing Her2 TCR-6A5-mC injected twice in this group were cells with a positive rate of 25% E75-TCR on the 9th day and 20% on the 13th day. Each group of animals was subcutaneously injected with 100,000 IUIL2 next to the tumor on the 2nd, 3rd, 6th and 7th day to stimulate T cell proliferation and activation, so that human T cells can survive longer in NCG mice. The detailed dosing regimen of this experiment is shown in Fig.53 .

[0416] The subcutaneous tumor volume and weight of each mouse were measured starting from the day of grouping (day 0), and the measurements and records were made twice a week. The average tumor volume changes of each group of animals in the experimental results are shown in Fig.54 The changes in subcutaneous tumor volume of each animal are shown in Fig.55 The relative tumor growth inhibition rate (T / C) between animal groups is shown in Fig.56 The average weight changes of animals in each group are shown in Fig.57 At the end of the experiment (day 21), the statistical results of subcutaneous tumors and tumor weights of each group of animals are shown in Fig.58 The results of flow cytometry analysis of the number of T cells in the tumors of each group of animals are shown in Fig.59 The results of flow cytometry analysis of the number of T cells in the blood of each group of animals are shown in Fig.60 The results of flow cytometry analysis of the number of T cells in the spleen of each group of animals are shown in Fig.61 , Her2 + / PDL1 + The results of flow cytometry analysis of the number of double-positive cells are shown in Fig.62 .

[0417] From the above results, it can be seen that the growth of subcutaneous tumors in animals in the 1-4.5K+E75-TCRT group was well inhibited (see Fig.54 ), there was a very significant difference in the average volume of subcutaneous tumors of animals in the blank control group (P<0.001), and there was a significant difference in the average volume of subcutaneous tumors of animals in the oncolytic virus group alone (1-4.5K group) and the 1-4.5K+Mock-T group (P<0.05); Fig.55It can be seen that the volume change curve of subcutaneous tumor growth in each group of animals is relatively concentrated, and no significant abnormal values ​​appear; Fig.56 It can be seen that the relative growth inhibition rate (T / C%) of subcutaneous tumors in the fourth group 1-4.5K+E75-TCRT group reached an inhibition rate of less than 40% on the 11th day, reaching the effective standard of clinical drugs; Fig.57 It can be seen from the figure that the average weight change of each group of animals remained within a reasonable range (less than 5%), proving that no obvious toxicity was found after different drug combinations; Fig.58 It can be seen that the growth of subcutaneous tumors in the fourth group 1-4.5K+E75-TCRT group was indeed significantly inhibited (P<0.01); Fig.59 , Fig.60 and Fig.61 It can be seen that at the end of the experiment (two weeks after the last administration of immune cells), there were still a large number of human T cells (CD3 + );from Fig.62 It can be seen that in the fourth group, 1-4.5K+E75-TCRT group, Her2 + / PDL1 + The number of double-positive cells was the least, which was significantly different from the tumor cells of the same genotype in the first control group (P<0.05).

[0418] In summary, the combined killing effect of oncolytic adenovirus OAd-shPDL1 (1-4.5K) and human T cells expressing Her2TCR-6A5-mC (Group 4) on HCT116 cells inoculated subcutaneously with NCG was much stronger than that of oncolytic adenovirus OAd-shPDL1 (1-4.5K) alone (Group 2) and oncolytic adenovirus OAd-shPDL1 (1-4.5K) combined with control T cells (Mock-T) (Group 3). Considering that ordinary T cells (i.e., Mock-T) usually do not have a significant killing effect on HCT116 cells, human T cells expressing Her2 TCR-6A5-mC have a significant killing effect on HCT116 (HLA-A2 + / Her2 +) cells, we believe that the reason why the growth of tumors inoculated subcutaneously in the fourth group of animals was significantly inhibited is that the PDL1 shRNA expressed in the oncolytic adenovirus OAd-shPDL1 (1-4.5K) reduces the expression level of PDL1 protein in cells, thereby reducing the level of PDL1 protein on the tumor cell membrane and in the blood circulation system, and then weakens or partially relieves the immunosuppressive effect of the PDL1 / PD1 interaction. In addition to the oncolytic ability of the oncolytic adenovirus itself on tumor cells, it also enhances the killing effect of human T cells expressing Her2 TCR-6A5-mC on HCT116 cells. From this, we can further infer that the oncolytic adenovirus OAd-shPDL1 (1-4.5K) may also enhance the killing effect of other immune killer T cells (TCR-T and CAR-T) affected by the PDL1 / PD1 immune checkpoint on tumors (especially solid tumors). This drug delivery mode of combining oncolytic viruses and immune killer cells to kill tumors has enriched the treatment modes and methods of tumor treatment, and is very likely to become one of the breakthroughs in tumor treatment (especially solid tumors). SEQUENCE LISTING <110> Hangzhou Kangwanda Pharmaceutical Technology Co., Ltd. Synimmune, Inc. <120> Therapeutic agent comprising isolated recombinant oncolytic adenovirus and immune cells and its application <130> FI-191715-59:52 / C <160> 54 <170> PatentIn version 3.5 <210> 1 <211> 132 <212> PRT <213> Homo sapiens <400> 1 Met Leu Leu Leu Leu Ile Pro Val Leu Gly Met Ile Phe Ala Leu Arg 1 5 10 15 Asp Ala Arg Ala Gln Ser Val Ser Gln His Asn His His Val Ile Leu 20 25 30 Ser Glu Ala Ala Ser Leu Glu Leu Gly Cys Asn Tyr Ser Tyr Gly Gly 35 40 45 Thr Val Asn Leu Phe Trp Tyr Val Gln Tyr Pro Gly Gln His Leu Gln 50 55 60 Leu Leu Leu Lys Tyr Phe Ser Gly Asp Pro Leu Val Lys Gly Ile Lys 65 70 75 80 Gly Phe Glu Ala Glu Phe Ile Lys Ser Lys Phe Ser Phe Asn Leu Arg 85 90 95 Lys Pro Ser Val Gln Trp Ser Asp Thr Ala Glu Tyr Phe Cys Ala Val 100 105 110 Asn Asp Asn Asp Tyr Lys Leu Ser Phe Gly Ala Gly Thr Thr Val Thr 115 120 125 Val Arg Ala Asn 130 <210> 2 <211> 133 <212> PRT <213> Homo sapiens <400> 2 Met Gly Cys Arg Leu Leu Cys Cys Ala Val Leu Cys Leu Leu Gly Ala 1 5 10 15 Val Pro Met Glu Thr Gly Val Thr Gln Thr Pro Arg His Leu Val Met 20 25 30 Gly Met Thr Asn Lys Lys Ser Leu Lys Cys Glu Gln His Leu Gly His 35 40 45 Asn Ala Met Tyr Trp Tyr Lys Gln Ser Ala Lys Lys Pro Leu Glu Leu 50 55 60 Met Phe Val Tyr Ser Leu Glu Glu Arg Val Glu Asn Asn Ser Val Pro 65 70 75 80 Ser Arg Phe Ser Pro Glu Cys Pro Asn Ser Ser His Leu Phe Leu His 85 90 95 Leu His Thr Leu Gln Pro Glu Asp Ser Ala Leu Tyr Leu Cys Ala Ser 100 105 110 Ser Gln Glu Ala Gly Ser Tyr Asn Glu Gln Phe Phe Gly Pro Gly Thr 115 120 125 Arg Leo Thr Val Leo 130 <210> 3 <211> 9 <212> PRT <213> Humans (Homo sapiens) <400> 3 Lys Ile Phe Gly Ser Leu Ala Phe Leu 1 5 <210> 4 <211> 272 <212> PRT <213> Humans (Homo sapiens) <400> 4 Met Leu Leu Leu Leu Ile Pro Val Leu Gly Met Ile Phe Ala Leu Arg 1 5 10 15 Asp Ala Arg Ala Gln Ser Val Ser Gln His Asn His His Val Ile Leu 20 25 30 Ser Glu Ala Ala Ser Leu Glu Leu Gly Cys Asn Tyr Ser Tyr Gly Gly 35 40 45 Thr Val Asn Leu Phe Trp Tyr Val Gln Tyr Pro Gly Gln His Leu Gln 50 55 60 Leu Leu Leu Lys Tyr Phe Ser Gly Asp Pro Leu Val Lys Gly Ile Lys 65 70 75 80 Gly Phe Glu Ala Glu Phe Ile Lys Ser Lys Phe Ser Phe Asn Leu Arg 85 90 95 Lys Pro Ser Val Gln Trp Ser Asp Thr Ala Glu Tyr Phe Cys Ala Val 100 105 110 Asn Asp Asn Asp Tyr Lys Leu Ser Phe Gly Ala Gly Thr Thr Val Thr 115 120 125 Val Arg Ala Asn Ile Gln Asn Pro Asp Pro Ala Val Tyr Gln Leu Arg 130 135 140 Asp Ser Lys Ser Ser Asp Lys Ser Val Cys Leu Phe Thr Asp Phe Asp 145 150 155 160 Ser Gln Thr Asn Val Ser Gln Ser Lys Asp Ser Asp Val Tyr Ile Thr 165 170 175 Asp Lys Thr Val Leu Asp Met Arg Ser Met Asp Phe Lys Ser Asn Ser 180 185 190 Ala Val Ala Trp Ser Asn Lys Ser Asp Phe Ala Cys Ala Asn Ala Phe 195 200 205 Asn Asn Ser Ile Ile Pro Glu Asp Thr Phe Phe Pro Ser Pro Glu Ser 210 215 220 Ser Cys Asp Val Lys Leu Val Glu Lys Ser Phe Glu Thr Asp Thr Asn 225 230 235 240 Leu Asn Phe Gln Asn Leu Ser Val Ile Gly Phe Arg Ile Leu Leu Leu 245 250 255 Lys Val Ala Gly Phe Asn Leu Leu Met Thr Leu Arg Leu Trp Ser Ser 260 265 270 <210> 5 <211> 272 <212> PRT <213> artificial sequence <400> 5 Met Leu Leu Leu Leu Ile Pro Val Leu Gly Met Ile Phe Ala Leu Arg 1 5 10 15 Asp Ala Arg Ala Gln Ser Val Ser Gln His Asn His His Val Ile Leu 20 25 30 Ser Glu Ala Ala Ser Leu Glu Leu Gly Cys Asn Tyr Ser Tyr Gly Gly 35 40 45 Thr Val Asn Leu Phe Trp Tyr Val Gln Tyr Pro Gly Gln His Leu Gln 50 55 60 Leu Leu Leu Lys Tyr Phe Ser Gly Asp Pro Leu Val Lys Gly Ile Lys 65 70 75 80 Gly Phe Glu Ala Glu Phe Ile Lys Ser Lys Phe Ser Phe Asn Leu Arg 85 90 95 Lys Pro Ser Val Gln Trp Ser Asp Thr Ala Glu Tyr Phe Cys Ala Val 100 105 110 Asn Asp Asn Asp Tyr Lys Leu Ser Phe Gly Ala Gly Thr Thr Val Thr 115 120 125 Val Arg Ala Asn Ile Gln Asn Pro Asp Pro Ala Val Tyr Gln Leu Arg 130 135 140 Asp Ser Lys Ser Ser Asp Lys Ser Val Cys Leu Phe Thr Asp Phe Asp 145 150 155 160 Ser Gln Thr Asn Val Ser Gln Ser Lys Asp Ser Asp Val Tyr Ile Thr 165 170 175 Asp Lys Cys Val Leu Asp Met Arg Ser Met Asp Phe Lys Ser Asn Ser 180 185 190 Ala Val Ala Trp Ser Asn Lys Ser Asp Phe Ala Cys Ala Asn Ala Phe 195 200 205 Asn Asn Ser Ile Ile Pro Glu Asp Thr Phe Phe Pro Ser Pro Glu Ser 210 215 220 Ser Cys Asp Val Lys Leu Val Glu Lys Ser Phe Glu Thr Asp Thr Asn 225 230 235 240 Leu Asn Phe Gln Asn Leu Ser Val Ile Gly Phe Arg Ile Leu Leu Leu 245 250 255 Lys Val Ala Gly Phe Asn Leu Leu Met Thr Leu Arg Leu Trp Ser Ser 260 265 270 <210> 6 <211> 268 <212> PRT <213> artificial sequence <400> 6 Met Leu Leu Leu Leu Ile Pro Val Leu Gly Met Ile Phe Ala Leu Arg 1 5 10 15 Asp Ala Arg Ala Gln Ser Val Ser Gln His Asn His His Val Ile Leu 20 25 30 Ser Glu Ala Ala Ser Leu Glu Leu Gly Cys Asn Tyr Ser Tyr Gly Gly 35 40 45 Thr Val Asn Leu Phe Trp Tyr Val Gln Tyr Pro Gly Gln His Leu Gln 50 55 60 Leu Leu Leu Lys Tyr Phe Ser Gly Asp Pro Leu Val Lys Gly Ile Lys 65 70 75 80 Gly Phe Glu Ala Glu Phe Ile Lys Ser Lys Phe Ser Phe Asn Leu Arg 85 90 95 Lys Pro Ser Val Gln Trp Ser Asp Thr Ala Glu Tyr Phe Cys Ala Val 100 105 110 Asn Asp Asn Asp Tyr Lys Leu Ser Phe Gly Ala Gly Thr Thr Val Thr 115 120 125 Val Arg Ala Asn Ile Gln Asn Pro Glu Pro Ala Val Tyr Gln Leu Lys 130 135 140 Asp Pro Arg Ser Gln Asp Ser Thr Leu Cys Leu Phe Thr Asp Phe Asp 145 150 155 160 Ser Gln Ile Asn Val Pro Lys Thr Met Glu Ser Gly Thr Phe Ile Thr 165 170 175 Asp Lys Thr Val Leu Asp Met Lys Ala Met Asp Ser Lys Ser Asn Gly 180 185 190 Ala Ile Ala Trp Ser Asn Gln Thr Ser Phe Thr Cys Gln Asp Ile Phe 195 200 205 Lys Glu Thr Asn Ala Thr Tyr Pro Ser Ser Asp Val Pro Cys Asp Ala 210 215 220 Thr Leu Thr Glu Lys Ser Phe Glu Thr Asp Met Asn Leu Asn Phe Gln 225 230 235 240 Asn Leu Ser Val Met Gly Leu Arg Ile Leu Leu Leu Lys Val Ala Gly 245 250 255 Phe Asn Leu Leu Met Thr Leu Arg Leu Trp Ser Ser 260 265 <210> 7 <211> 312 <212> PRT <213> Humans (Homo sapiens) <400> 7 Met Gly Cys Arg Leu Leu Cys Cys Ala Val Leu Cys Leu Leu Gly Ala 1 5 10 15 Val Pro Met Glu Thr Gly Val Thr Gln Thr Pro Arg His Leu Val Met 20 25 30 Gly Met Thr Asn Lys Lys Ser Leu Lys Cys Glu Gln His Leu Gly His 35 40 45 Asn Ala Met Tyr Trp Tyr Lys Gln Ser Ala Lys Lys Pro Leu Glu Leu 50 55 60 Met Phe Val Tyr Ser Leu Glu Glu Arg Val Glu Asn Asn Ser Val Pro 65 70 75 80 Ser Arg Phe Ser Pro Glu Cys Pro Asn Ser Ser His Leu Phe Leu His 85 90 95 Leu His Thr Leu Gln Pro Glu Asp Ser Ala Leu Tyr Leu Cys Ala Ser 100 105 110 Ser Gln Glu Ala Gly Ser Tyr Asn Glu Gln Phe Phe Gly Pro Gly Thr 115 120 125 Arg Leu Thr Val Leu Glu Asp Leu Lys Asn Val Phe Pro Pro Glu Val 130 135 140 Ala Val Phe Glu Pro Ser Glu Ala Glu Ile Ser His Thr Gln Lys Ala 145 150 155 160 Thr Leu Val Cys Leu Ala Thr Gly Phe Tyr Pro Asp His Val Glu Leu 165 170 175 Ser Trp Trp Val Asn Gly Lys Glu Val His Ser Gly Val Ser Thr Asp 180 185 190 Pro Gln Pro Leu Lys Glu Gln Pro Ala Leu Asn Asp Ser Arg Tyr Cys 195 200 205 Leu Ser Ser Arg Leu Arg Val Ser Ala Thr Phe Trp Gln Asn Pro Arg 210 215 220 Asn His Phe Arg Cys Gln Val Gln Phe Tyr Gly Leu Ser Glu Asn Asp 225 230 235 240 Glu Trp Thr Gln Asp Arg Ala Lys Pro Val Thr Gln Ile Val Ser Ala 245 250 255 Glu Ala Trp Gly Arg Ala Asp Cys Gly Phe Thr Ser Glu Ser Tyr Gln 260 265 270 Gln Gly Val Leu Ser Ala Thr Ile Leu Tyr Glu Ile Leu Leu Gly Lys 275 280 285 Ala Thr Leu Tyr Ala Val Leu Val Ser Ala Leu Val Leu Met Ala Met 290 295 300 Val Lys Arg Lys Asp Ser Arg Gly 305 310 <210> 8 <211> 312 <212> PRT <213> artificial sequence <400> 8 Met Gly Cys Arg Leu Leu Cys Cys Ala Val Leu Cys Leu Leu Gly Ala 1 5 10 15 Val Pro Met Glu Thr Gly Val Thr Gln Thr Pro Arg His Leu Val Met 20 25 30 Gly Met Thr Asn Lys Lys Ser Leu Lys Cys Glu Gln His Leu Gly His 35 40 45 Asn Ala Met Tyr Trp Tyr Lys Gln Ser Ala Lys Lys Pro Leu Glu Leu 50 55 60 Met Phe Val Tyr Ser Leu Glu Glu Arg Val Glu Asn Asn Ser Val Pro 65 70 75 80 Ser Arg Phe Ser Pro Glu Cys Pro Asn Ser Ser His Leu Phe Leu His 85 90 95 Leu His Thr Leu Gln Pro Glu Asp Ser Ala Leu Tyr Leu Cys Ala Ser 100 105 110 Ser Gln Glu Ala Gly Ser Tyr Asn Glu Gln Phe Phe Gly Pro Gly Thr 115 120 125 Arg Leu Thr Val Leu Glu Asp Leu Lys Asn Val Phe Pro Pro Glu Val 130 135 140 Ala Val Phe Glu Pro Ser Glu Ala Glu Ile Ser His Thr Gln Lys Ala 145 150 155 160 Thr Leu Val Cys Leu Ala Thr Gly Phe Tyr Pro Asp His Val Glu Leu 165 170 175 Ser Trp Trp Val Asn Gly Lys Glu Val His Ser Gly Val Cys Thr Asp 180 185 190 Pro Gln Pro Leu Lys Glu Gln Pro Ala Leu Asn Asp Ser Arg Tyr Cys 195 200 205 Leu Ser Ser Arg Leu Arg Val Ser Ala Thr Phe Trp Gln Asn Pro Arg 210 215 220 Asn His Phe Arg Cys Gln Val Gln Phe Tyr Gly Leu Ser Glu Asn Asp 225 230 235 240 Glu Trp Thr Gln Asp Arg Ala Lys Pro Val Thr Gln Ile Val Ser Ala 245 250 255 Glu Ala Trp Gly Arg Ala Asp Cys Gly Phe Thr Ser Glu Ser Tyr Gln 260 265 270 Gln Gly Val Leu Ser Ala Thr Ile Leu Tyr Glu Ile Leu Leu Gly Lys 275 280 285 Ala Thr Leu Tyr Ala Val Leu Val Ser Ala Leu Val Leu Met Ala Met 290 295 300 Val Lys Arg Lys Asp Ser Arg Gly 305 310 <210> 9 <211> 306 <212> PRT <213> artificial sequence <400> 9 Met Gly Cys Arg Leu Leu Cys Cys Ala Val Leu Cys Leu Leu Gly Ala 1 5 10 15 Val Pro Met Glu Thr Gly Val Thr Gln Thr Pro Arg His Leu Val Met 20 25 30 Gly Met Thr Asn Lys Lys Ser Leu Lys Cys Glu Gln His Leu Gly His 35 40 45 Asn Ala Met Tyr Trp Tyr Lys Gln Ser Ala Lys Lys Pro Leu Glu Leu 50 55 60 Met Phe Val Tyr Ser Leu Glu Glu Arg Val Glu Asn Asn Ser Val Pro 65 70 75 80 Ser Arg Phe Ser Pro Glu Cys Pro Asn Ser Ser His Leu Phe Leu His 85 90 95 Leu His Thr Leu Gln Pro Glu Asp Ser Ala Leu Tyr Leu Cys Ala Ser 100 105 110 Ser Gln Glu Ala Gly Ser Tyr Asn Glu Gln Phe Phe Gly Pro Gly Thr 115 120 125 Arg Leu Thr Val Leu Glu Asp Leu Arg Asn Val Thr Pro Pro Lys Val 130 135 140 Ser Leu Phe Glu Pro Ser Lys Ala Glu Ile Ala Asn Lys Gln Lys Ala 145 150 155 160 Thr Leu Val Cys Leu Ala Arg Gly Phe Phe Pro Asp His Val Glu Leu 165 170 175 Ser Trp Trp Val Asn Gly Lys Glu Val His Ser Gly Val Ser Thr Asp 180 185 190 Pro Gln Ala Tyr Lys Glu Ser Asn Tyr Ser Tyr Cys Leu Ser Ser Arg 195 200 205 Leu Arg Val Ser Ala Thr Phe Trp His Asn Pro Arg Asn His Phe Arg 210 215 220 Cys Gln Val Gln Phe His Gly Leu Ser Glu Glu Asp Lys Trp Pro Glu 225 230 235 240 Gly Ser Pro Lys Pro Val Thr Gln Asn Ile Ser Ala Glu Ala Trp Gly 245 250 255 Arg Ala Asp Cys Gly Ile Thr Ser Ala Ser Tyr Gln Gln Gly Val Leu 260 265 270 Ser Ala Thr Ile Leu Tyr Glu Ile Leu Leu Gly Lys Ala Thr Leu Tyr 275 280 285 Ala Val Leu Val Ser Thr Leu Val Val Met Ala Met Val Lys Arg Lys 290 295 300 Asn Ser 305 <210> 10 <211> 396 <212> DNA <213> Homo sapiens <400> 10 atgctcctgt tgctcatacc agtgctgggg atgatttttg ccctgagaga tgccagagcc 60 cagtctgtga gccagcataa ccaccacgta attctctctg aagcagcctc actggagttg 120 ggatgcaact attcctatgg tggaactgtt aatctcttct ggtatgtcca gtaccctggt 180 caacaccttc agcttctcct caagtacttt tcaggggatc cactggttaa aggcatcaag 240 ggctttgagg ctgaatttat aaagagtaaa ttctccttta atctgaggaa accctctgtg 300 cagtggagtg acacagctga gtacttctgt gccgtgaatg ataacgacta caagctcagc 360 tttggagccg gaaccacagt aactgtaaga gcaaac 396 <210> 11 <211> 399 <212> DNA <213> Human (Homo sapiens) <400> 11 atgggctgca ggctgctctg ctgtgcggtt ctctgtctcc tgggagcggt ccccatggaa 60 acgggagtta cgcagacacc aagacacctg gtcatgggaa tgacaaataa gaagtctttg 120 aaatgtgaac aacatctggg tcataacgct atgtattggt acaagcaaag tgctaagaag 180 ccactggagc tcatgtttgt ctacagtctt gaagaacggg ttgaaaacaa cagtgtgcca 240 agtcgcttct cacctgaatg ccccaacagc tctcacttat tccttcacct acacaccctg 300 cagccagaag actcggccct gtatctctgc gccagcagcc aagaagccgg ttcctacaat 360 gagcagttct tcgggccagg gacacggctc accgtgcta 399 <210> 12 <211> 819 <212> DNA <213> Human (Homo sapiens) <400> 12 atgctcctgt tgctcatacc agtgctgggg atgatttttg ccctgagaga tgccagagcc 60 cagtctgtga gccagcataa ccaccacgta attctctctg aagcagcctc actggagttg 120 ggatgcaact attcctatgg tggaactgtt aatctcttct ggtatgtcca gtaccctggt 180 caacaccttc agcttctcct caagtacttt tcaggggatc cactggttaa aggcatcaag 240 ggctttgagg ctgaatttat aaagagtaaa ttctccttta atctgaggaa accctctgtg 300 cagtggagtg acacagctga gtacttctgt gccgtgaatg ataacgacta caagctcagc 360 tttggagccg gaaccacagt aactgtaaga gcaaatatcc agaaccctga ccctgccgtg 420 taccagctga gagactctaa atccagtgac aagtctgtct gcctattcac cgattttgat 480 tctcaacaa atgtgtcaca aagtaaggat tctgatgtgt atatcacaga caaaaccgtg 540 ctagacatga ggtctatgga cttcaagagc aacagtgctg tggcctggag caacaaatct 600 gactttgcat gtgcaaacgc cttcaacaac agcattattc cagaagacac cttcttcccc 660 agcccagaaa gttcctgtga tgtcaagctg gtcgagaaaa gctttgaaac agatacgaac 720 ctaaactttc aaaacctgtc agtgattggg ttccgaatcc tcctcctgaa agtggccggg 780 tttaatctgc tcatgacgct gcggctgtgg tccagctga 819 <210> 13 <211> 819 <212> DNA <213> artificial sequence <400> 13 atgctcctgt tgctcatacc agtgctgggg atgatttttg ccctgagaga tgccagagcc 60 cagtctgtga gccagcataa ccaccacgta attctctctg aagcagcctc actggagttg 120 ggatgcaact attcctatgg tggaactgtt aatctcttct ggtatgtcca gtaccctggt 180 caacaccttc agcttctcct caagtacttt tcaggggatc cactggttaa aggcatcaag 240 ggctttgagg ctgaatttat aaagagtaaa ttctccttta atctgaggaa accctctgtg 300 cagtggagtg acacagctga gtacttctgt gccgtgaatg ataacgacta caagctcagc 360 tttggagccg gaaccacagt aactgtaaga gcaaatatcc agaaccctga ccctgccgtg 420 taccagctga gagactctaa atccagtgac aagtctgtct gcctattcac cgattttgat 480 tctcaaacaa atgtgtcaca aagtaaggat tctgatgtgt atatcacaga caaatgcgtg 540 ctagacatga ggtctatgga cttcaagagc aacagtgctg tggcctggag caacaaatct 600 gactttgcat gtgcaaacgc cttcaacaac agcattattc cagaagacac cttcttcccc 660 agcccagaaa gttcctgtga tgtcaagctg gtcgagaaaa gctttgaaac agatacgaac 720 ctaaactttc aaaacctgtc agtgattggg ttccgaatcc tcctcctgaa agtggccggg 780 tttaatctgc tcatgacgct gcggctgtgg tccagctga 819 <210> 14 <211> 807 <212> DNA <213> artificial sequence <400> 14 atgctcctgt tgctcatacc agtgctgggg atgatttttg ccctgagaga tgccagagcc 60 cagtctgtga gccagcataa ccaccacgta attctctctg aagcagcctc actggagttg 120 ggatgcaact attcctatgg tggaactgtt aatctcttct ggtatgtcca gtaccctggt 180 caacaccttc agcttctcct caagtacttt tcaggggatc cactggttaa aggcatcaag 240 ggctttgagg ctgaatttat aaagagtaaa ttctccttta atctgaggaa accctctgtg 300 cagtggagtg acacagctga gtacttctgt gccgtgaatg ataacgacta caagctcagc 360 tttggagccg gaaccacagt aactgtaaga gcaaacatcc agaacccaga acctgctgtg 420 taccagttaa aagatcctcg gtctcaggac agcaccctct gcctgttcac cgactttgac 480 tcccaaatca atgtgccgaa aaccatggaa tctggaacgt tcatcactga caaaactgtg 540 ctggacatga aagctatgga ttccaagagc aatggggcca ttgcctggag caaccagaca 600 agcttcacct gccaagatat cttcaaagag accaacgcca cctaccccag ttcagacgtt 660 ccctgtgatg ccacgttgac cgagaaaagc tttgaaacag atatgaacct aaactttcaa 720 aacctgtcag ttatgggact ccgaatcctc ctgctgaaag tagcgggatt taacctgctc 780 atgacgctga ggctgtggtc cagttga 807 <210> 15 <211> 939 <212> DNA <213> Homo sapiens <400> 15 atgggctgca ggctgctctg ctgtgcggtt ctctgtctcc tgggagcggt ccccatggaa 60 acgggagtta cgcagacacc aagacacctg gtcatgggaa tgacaaataa gaagtctttg 120 aaatgtgaac aacatctggg tcataacgct atgtattggt acagcaag tgctaagag 180 ccactggagc tcatgtttgt ctacagtctt gagaacggg ttgaaaaca cagtgtgcca 240 agtcgcttct cacctgaatg cccacagc tctcacttat tccttcacct accaccctg 300 cagccagaag actcggccct gtatctctgc gccagcagcc aagaagccgg ttcctacaat 360 gagcagttct tcggggccagg gandacggctc accgtgctag aggacctga aaacgtgttc 420 ccaccgagg tcgctgtgtt tgagccatca gaagcagaga tctcccac ccaaaaggcc 480 acactggtat gcctggccac aggcttac cccgaccacg tggagctg ctggtggttg 540 aatgggaagg aggtgcacag tggggtcagc acgacccgc agcccctca ggagcagccc 600 gccctcaatg actccagata ctgcctgagc agccgcctga gggtctcggc caccttctgg 660 cagaaccccc gcaccactt ccgctgtcaa gtccagttct acgggctctc ggagaatgac 720 gagtggaccc aggataggggc caacccgtc acccagatcg tcagcgccga ggcctggggt 780 agagcagact gtggctcac ctccgagtct taccagcaag gggtcctgtc tgccaccatc 840 ctctatgaga tcttgctagg gaaggccacc ttgtatgccg tgctggtcag tgccctcgtg 900 ctgatggcca tggtcaagag aaaggattcc agaggctaa 939 <210> 16 <211> 939 <212> DNA <213> artificial sequence <400> 16 atgggctgca ggctgctctg ctgtgcggtt ctctgtctcc tgggagcggt ccccatggaa 60 acgggagtta cgcagacacc aagacacctg gtcatgggaa tgacaaataa gaagtctttg 120 aaatgtgaac aacatctggg tcataacgct atgtattggt acaagcaaag tgctaagaag 180 ccactggagc tcatgtttgt ctacagtctt gaagaacggg ttgaaaacaa cagtgtgcca 240 agtcgcttct cacctgaatg ccccaacagc tctcacttat tccttcacct acacaccctg 300 cagccagaag actcggccct gtatctctgc gccagcagcc aagaagccgg ttcctacaat 360 gagcagttct tcgggccagg gacacggctc accgtgctag aggacctgaa aaacgtgttc 420 ccacccgagg tcgctgtgtt tgagccatca gaagcagaga tctcccacac ccaaaaggcc 480 acactggtat gcctggccac aggctctac cccgaccacg tggagctgag ctggtgggtg 540 aatgggaagg aggtgcacag tggggtctgc acagacccgc agcccctcaa ggagcagccc gccctcaatg actccagata ctgcctgagc agccgcctga gggtctcggc caccttctgg 660 cagaacccc gcaaccactt ccgctgtcaa gtccagttct acgggctctc ggagaatgac gagtggaccc aggatagggc caaacccgtc acccagatcg tcagcgccga ggcctggggt 780 840. agagcagact gtggcttcac ctccgagtct taccagcaag gggtcctgtc tgccaccatc ctctatgaga tcttgctagg gaaggccacc ttgtatgccg tgctggtcag tgccctcgtg ctgatggcca tggtcaagag aaaggattcc agaggctaa <210> 17 <211> 921 <212> DNA <213> Orientation(artificial sequence) <400> 17 atgggctgca ggctgctctg ctgtgcggtt ctctgtctcc tgggagcggt ccccatgga acgggagtta cgcagacacc aagacacctg gtcatggga tgacaata gaagtctttg 180. aaatgtgaac aacatctggg tcataacgct atgtattggt acaagcaaag tgctaagaag ccactggagc tcatgtttgt ctacagtctt gaagaacggg ttgaaaacaa cagtgtgcca 240 agtcgcttct cacctgaatg ccccaacagc tctcacttat tccttcacct acacaccctg 300 cagccagaag actcggccct gtatctctgc gccagcagcc aagaagccgg ttcctacaat 360 gagcagttct tcgggccagg gacacggctc accgtgctag aggatctgag aaatgtgact 420 ccacccaagg tctccttgtt tgagccatca aaagcagaga ttgcaaacaa acaaaaggct 480 accctcgtgt gcttggccag gggctttctc cctgaccacg tggagctgag ctggtgggtg 540 aatggcaagg aggtccacag tggggtcagc acggaccctc aggcctacaa ggagagcaat 600 tatagctact gcctgagcag ccgcctgagg gtctctgcta cttctggca caatcctcgc 660 aaccacttcc gctgccaagt gcagttccat gggctttcag aggaggacaa gtggccagag 720 ggctcaccca aacctgtcac acagaacatc agtgcagagg cctggggccg agcagactgt 780 gggattacct cagcatccta tcaacaaggg gtcttgtctg ccaccatcct ctatgagatc 840 ctgctaggga aagccaccct gtatgctgtg cttgtcagta cactggtggt gatggctatg 900 gtcaaaagaa agaattcata a 921 <210> 18 <211> 1851 <212> DNA <213> artificial sequence <400> 18 atgggctgca ggctgctctg ctgtgcggtt ctctgtctcc tgggagcggt ccccatggaa 60 acgggagtta cgcagacacc aagacacctg gtcatgggaa tgacaaataa gaagtctttg 120 aaatgtgaac aacatctggg tcataacgct atgtattggt acaagcaaag tgctaagaag 180 ccactggagc tcatgtttgt ctacagtctt gaagaacggg ttgaaaacaa cagtgtgcca 240 agtcgcttct cacctgaatg ccccaacagc tctcacttat tccttcacct acacaccctg 300 cagccagaag actcggccct gtatctctgc gccagcagcc aagaagccgg ttcctacaat 360 gagcagttct tcgggccagg gacacggctc accgtgctag aggacctgaa aaacgtgttc 420 ccacccgagg tcgctgtgtt tgagccatca gaagcagaga tctcccacac ccaaaaggcc 480 acactggtat gcctggccac aggctctac cccgaccacg tggagctgag ctggtgggtg 540 aatgggaagg aggtgcacag tggggtcagc acagacccgc agcccctcaa ggagcagccc 600 gccctcaatg actccagata ctgcctgagc agccgcctga gggtctcggc caccttctgg 660 cagaacccc gcaaccactt ccgctgtcaa gtccagttct acgggctctc ggagaatgac gagtggaccc aggatagggc caaacccgtc acccagatcg tcagcgccga ggcctggggt 780 840. agagcagact gtggcttcac ctccgagtct taccagcaag gggtcctgtc tgccaccatc ctctatgaga tcttgctagg gaaggccacc ttgtatgccg tgctggtcag tgccctcgtg ctgatggcca tggtcaagag aaaggattcc agaggccgtg ccaagcgatc cggaagcgga 960 gcccctgtaa agcagacttt gaatttgac cttctcaagt tggcggggaga cgtcgagtcc aaccctgggc ccatgctcct gttgctcata ccagtgctgg ggatgatttt tgccctgaga 1080 1140. gatgccagag cccagtctgt gagccagcat aaccaccacg taattctctc tgaagcagcc tcactggagt tgggatgcaa ctattcctat ggtggaactg ttaatctctt ctggtatgtc cagtaccctg gtcaacacct tcagcttctc ctcaagtact tttcagggga tccactggtt 1260 aaaggcatca agggctttga ggctgaatt aataagagta aattctcctt taatctgagg aaaccctctg tgcagtggag tgacacagct gagtacttct gtgccgtgaa tgataacgac 1380 tacaagctca gctttggagc cggaaccaca gtaactgtaa gagcaaatat ccagaaccct 1440 gaccctgccg tgtaccagct gagagactct aaatccagtg acaagtctgt ctgcctattc 1500 accgatttg attctcaaac aaatgtgtca caaagtaagg attctgatgt gtatatcaca 1560 gacaaaaccg tgctagacat gaggtctatg gacttcaaga gcaacagtgc tgtggcctgg 1620 agcaacaaat ctgactttgc atgtgcaaac gccttcaaca acagcattat tccagaagac 1680 accttcttcc ccagcccaga aagttcctgt gatgtcaagc tggtcgagaa aagctttgaa 1740 acagatacga acctaaactt tcaaaacctg tcagtgattg ggttccgaat cctcctcctg 1800 aaagtggccg ggtttaatct gctcatgacg ctgcggctgt ggtccagctg a 1851 <210> 19 <211> 1851 <212> DNA <213> artificial sequence <400> 19 atgggctgca ggctgctctg ctgtgcggtt ctctgtctcc tgggagcggt ccccatggaa 60 acgggagtta cgcagacacc aagacacctg gtcatgggaa tgacaataa gaagtctttg 120 aaatgtgaac aacatctggg tcataacgct atgtattggt acagcaag tgctaagag 180 ccactggagc tcatgtttgt ctacagtctt gagaacggg ttgaaaaca cagtgtgcca 240 agtcgcttct cacctgaatg cccacagc tctcacttat tccttcacct accaccctg 300 cagccagaag actcggccct gtatctctgc gccagcagcc aagaagccgg ttcctacaat 360 gagcagttct tcggggccagg gandacggctc accgtgctag aggacctga aaacgtgttc 420 ccaccgagg tcgctgtgtt tgagccatca gaagcagaga tctcccac ccaaaaggcc 480 acactggtat gcctggccac aggcttac cccgaccacg tggagctg ctggtggttg 540 aatgggaagg aggtgcacag tggggtctgc acgacccgc agcccctca ggagcagccc 600 gccctcaatg actccagata ctgcctgagc agccgcctga gggtctcggc caccttctgg 660 cagaaccccc gcaccactt ccgctgtcaa gtccagttct acgggctctc ggagaatgac 720 gagtggaccc aggataggggc caacccgtc acccagatcg tcagcgccga ggcctggggt 780 agagcagact gtggcttcac ctccgagtct taccagcaag gggtcctgtc tgccaccatc 840 ctctatgaga tcttgctagg gaaggccacc ttgtatgccg tgctggtcag tgccctcgtg 900 ctgatggcca tggtcaagag aaaggattcc agaggccgtg ccaagcgatc cggaagcgga 960 gcccctgtaa agcagacttt gaattttgac cttctcaagt tggcgggaga cgtcgagtcc 1020 aaccctgggc ccatgctcct gttgctcata ccagtgctgg ggatgatttt tgccctgaga 1080 gatgccagag cccagtctgt gagccagcat aaccaccacg taattctctc tgaagcagcc 1140 tcactggagt tgggatgcaa ctattcctat ggtggaactg ttaatctctt ctggtatgtc 1200 cagtaccctg gtcaacacct tcagcttctc ctcaagtact tttcagggga tccactggtt 1260 aaaggcatca agggctttga ggctgaattt ataaagagta aattctcctt taatctgagg 1320 aaaccctctg tgcagtggag tgacacagct gagtacttct gtgccgtgaa tgataacgac 1380 tacaagctca gctttggagc cggaaccaca gtaactgtaa gagcaaatat ccagaaccct 1440 gaccctgccg tgtaccagct gagagactct aaatccagtg acaagtctgt ctgcctattc 1500 accgatttg attctcaaac aaatgtgtca caaagtaagg attctgatgt gtatatcaca 1560 gacaaatgcg tgctagacat gaggtctatg gacttcaaga gcaacagtgc tgtggcctgg 1620 agcaacaaat ctgactttgc atgtgcaaac gccttcaaca acagcattat tccagaagac 1680 accttcttcc ccagcccaga aagttcctgt gatgtcaagc tggtcgagaa aagctttgaa 1740 acagatacga acctaaactt tcaaaacctg tcagtgattg ggttccgaat cctcctcctg 1800 aaagtggccg ggtttaatct gctcatgacg ctgcggctgt ggtccagctg a 1851 <210> 20 <211> 1821 <212> DNA <213> artificial sequence <400> 20 atgggctgca ggctgctctg ctgtgcggtt ctctgtctcc tgggagcggt ccccatggaa 60 acgggagtta cgcagacacc aagacacctg gtcatgggaa tgacaaataa gaagtctttg 120 aaatgtgaac aacatctggg tcataacgct atgtattggt acaagcaaag tgctaagaag 180 ccactggagc tcatgtttgt ctacagtctt gaagaacggg ttgaaaacaa cagtgtgcca 240 agtcgcttct cacctgaatg cccacagc tctcacttat tccttcacct accaccctg 300 cagccagaag actcggccct gtatctctgc gccagcagcc aagaagccgg ttcctacaat 360 gagcagttct tcggggccagg gandacggctc accgtgctag aggatctgag aaatgtgact 420 ccaccagg tctccttgtt tgagccatca aaagcagaga ttgcaacaa aaaaggct 480 accctcgtgt gcttggccag gggctcttc cctgaccacg tggactgag ctggtggtg 540 aatggcaagg aggtccacag tggggtcagc acggaccctc aggcctacaa ggagagcaat 600 tatagctact gcctgagcag ccgcctgagg gtctctgcta ccttctggca caatcctcgc 660 aaccactcc gctgccaagt gcagttccat gggctttcag aggaggacaa gtggccagag 720 ggctcaccca aacctgtcac acagaacatc agtgcagagg cctggggccg agcagactgt 780 gggattacct cagcatccta tcacaaggg gtcttgtctg ccaccatcct ctatgagatc 840 ctgctaggga aagccaccct gtatgctgtg cttgtcagta cactggtggt gatggctatg 900 gtcaaagaa agaattcacg tgccaagcga tccggaagcg gagcccctgt aaagcagact 960 ttgaattttg accttctcaa gttggcggga gacgtcgagt ccaaccctgg gcccatgctc 1020 ctgttgctca taccagtgct ggggatgatt tttgccctga gagatgccag agcccagtct 1080 gtgagccagc ataaccacca cgtaattctc tctgaagcag cctcactgga gttgggatgc 1140 aactattcct atggtggaac tgttaatctc ttctggtatg tccagtaccc tggtcaacac 1200 cttcagcttc tcctcaagta cttttcaggg gatccactgg ttaaaggcat caagggcttt 1260 gaggctgaat ttaaaagag taaattctcc tttaatctga ggaaaccctc tgtgcagtgg 1320 agtgacacag ctgagtactt ctgtgccgtg aatgataacg actacaagct cagcttttgga 1380 gccggaacca cagtaactgt aagagcaaac atccagaacc cagaacctgc tgtgtaccag 1440 ttaaaagatc ctcggtctca ggacagcacc ctctgcctgt tcaccgactt tgactcccaa 1500 atcaatgtgc cgaaaaccat ggaatctgga acgttcatca ctgacaaac tgtgctggac 1560 atgaaagcta tggattccaa gagcaatggg gccattgcct ggagcaacca gacaagcttc 1620 acctgccaag atatcttcaa agagaccaac gccacctacc ccagttcaga cgttccctgt 1680 gatgccacgt tgaccgagaa aagctttgaa acagatatga acctaaactt tcaaaacctg 1740 tcagttatgg gactccgaat cctcctgctg aaagtagcgg gatttaacct gctcatgacg 1800 ctgaggctgt ggtccagttg a 1821 <210> 21 <211> 1255 <212> PRT <213> Homo sapiens <400> 21 Met Glu Leu Ala Ala Leu Cys Arg Trp Gly Leu Leu Leu Ala Leu Leu 1 5 10 15 Pro Pro Gly Ala Ala Ser Thr Gln Val Cys Thr Gly Thr Asp Met Lys 20 25 30 Leu Arg Leu Pro Ala Ser Pro Glu Thr His Leu Asp Met Leu Arg His 35 40 45 Leu Tyr Gln Gly Cys Gln Val Val Gln Gly Asn Leu Glu Leu Thr Tyr 50 55 60 Leu Pro Thr Asn Ala Ser Leu Ser Phe Leu Gln Asp Ile Gln Glu Val 65 70 75 80 Gln Gly Tyr Val Leu Ile Ala His Asn Gln Val Arg Gln Val Pro Leu 85 90 95 Gln Arg Leu Arg Ile Val Arg Gly Thr Gln Leu Phe Glu Asp Asn Tyr 100 105 110 Ala Leu Ala Val Leu Asp Asn Gly Asp Pro Leu Asn Asn Thr Thr Pro 115 120 125 Val Thr Gly Ala Ser Pro Gly Gly Leu Arg Glu Leu Gln Leu Arg Ser 130 135 140 Leu Thr Glu Ile Leu Lys Gly Gly Val Leu Ile Gln Arg Asn Pro Gln 145 150 155 160 Leu Cys Tyr Gln Asp Thr Ile Leu Trp Lys Asp Ile Phe His Lys Asn 165 170 175 Asn Gln Leu Ala Leu Thr Leu Ile Asp Thr Asn Arg Ser Arg Ala Cys 180 185 190 His Pro Cys Ser Pro Met Cys Lys Gly Ser Arg Cys Trp Gly Glu Ser 195 200 205 Ser Glu Asp Cys Gln Ser Leu Thr Arg Thr Val Cys Ala Gly Gly Cys 210 215 220 Ala Arg Cys Lys Gly Pro Leu Pro Thr Asp Cys Cys His Glu Gln Cys 225 230 235 240 Ala Ala Gly Cys Thr Gly Pro Lys His Ser Asp Cys Leu Ala Cys Leu 245 250 255 His Phe Asn His Ser Gly Ile Cys Glu Leu His Cys Pro Ala Leu Val 260 265 270 Thr Tyr Asn Thr Asp Thr Phe Glu Ser Met Pro Asn Pro Glu Gly Arg 275 280 285 Tyr Thr Phe Gly Ala Ser Cys Val Thr Ala Cys Pro Tyr Asn Tyr Leu 290 295 300 Ser Thr Asp Val Gly Ser Cys Thr Leu Val Cys Pro Leu His Asn Gln 305 310 315 320 Glu Val Thr Ala Glu Asp Gly Thr Gln Arg Cys Glu Lys Cys Ser Lys 325 330 335 Pro Cys Ala Arg Val Cys Tyr Gly Leu Gly Met Glu His Leu Arg Glu 340 345 350 Val Arg Ala Val Thr Ser Ala Asn Ile Gln Glu Phe Ala Gly Cys Lys 355 360 365 Lys Ile Phe Gly Ser Leu Ala Phe Leu Pro Glu Ser Phe Asp Gly Asp 370 375 380 Pro Ala Ser Asn Thr Ala Pro Leu Gln Pro Glu Gln Leu Gln Val Phe 385 390 395 400 Glu Thr Leu Glu Glu Ile Thr Gly Tyr Leu Tyr Ile Ser Ala Trp Pro 405 410 415 Asp Ser Leu Pro Asp Leu Ser Val Phe Gln Asn Leu Gln Val Ile Arg 420 425 430 Gly Arg Ile Leu His Asn Gly Ala Tyr Ser Leu Thr Leu Gln Gly Leu 435 440 445 Gly Ile Ser Trp Leu Gly Leu Arg Ser Leu Arg Glu Leu Gly Ser Gly 450 455 460 Leu Ala Leu Ile His His Asn Thr His Leu Cys Phe Val His Thr Val 465 470 475 480 Pro Trp Asp Gln Leu Phe Arg Asn Pro His Gln Ala Leu Leu His Thr 485 490 495 Ala Asn Arg Pro Glu Asp Glu Cys Val Gly Glu Gly Leu Ala Cys His 500 505 510 Gln Leu Cys Ala Arg Gly His Cys Trp Gly Pro Gly Pro Thr Gln Cys 515 520 525 Val Asn Cys Ser Gln Phe Leu Arg Gly Gln Glu Cys Val Glu Glu Cys 530 535 540 Arg Val Leu Gln Gly Leu Pro Arg Glu Tyr Val Asn Ala Arg His Cys 545 550 555 560 Leu Pro Cys His Pro Glu Cys Gln Pro Gln Asn Gly Ser Val Thr Cys 565 570 575 Phe Gly Pro Glu Ala Asp Gln Cys Val Ala Cys Ala His Tyr Lys Asp 580 585 590 Pro Pro Phe Cys Val Ala Arg Cys Pro Ser Gly Val Lys Pro Asp Leu 595 600 605 Ser Tyr Met Pro Ile Trp Lys Phe Pro Asp Glu Glu Gly Ala Cys Gln 610 615 620 Pro Cys Pro Ile Asn Cys Thr His Ser Cys Val Asp Leu Asp Asp Lys 625 630 635 640 Gly Cys Pro Ala Glu Gln Arg Ala Ser Pro Leu Thr Ser Ile Ile Ser 645 650 655 Ala Val Val Gly Ile Leu Leu Val Val Val Leu Gly Val Val Phe Gly 660 665 670 Ile Leu Ile Lys Arg Arg Gln Gln Lys Ile Arg Lys Tyr Thr Met Arg 675 680 685 Arg Leu Leu Gln Glu Thr Glu Leu Val Glu Pro Leu Thr Pro Ser Gly 690 695 700 Ala Met Pro Asn Gln Ala Gln Met Arg Ile Leu Lys Glu Thr Glu Leu 705 710 715 720 Arg Lys Val Lys Val Leu Gly Ser Gly Ala Phe Gly Thr Val Tyr Lys 725 730 735 Gly Ile Trp Ile Pro Asp Gly Glu Asn Val Lys Ile Pro Val Ala Ile 740 745 750 Lys Val Leu Arg Glu Asn Thr Ser Pro Lys Ala Asn Lys Glu Ile Leu 755 760 765 Asp Glu Ala Tyr Val Met Ala Gly Val Gly Ser Pro Tyr Val Ser Arg 770 775 780 Leu Leu Gly Ile Cys Leu Thr Ser Thr Val Gln Leu Val Thr Gln Leu 785 790 795 800 Met Pro Tyr Gly Cys Leu Leu Asp His Val Arg Glu Asn Arg Gly Arg 805 810 815 Leu Gly Ser Gln Asp Leu Leu Asn Trp Cys Met Gln Ile Ala Lys Gly 820 825 830 Met Ser Tyr Leu Glu Asp Val Arg Leu Val His Arg Asp Leu Ala Ala 835 840 845 Arg Asn Val Leu Val Lys Ser Pro Asn His Val Lys Ile Thr Asp Phe 850 855 860 Gly Leu Ala Arg Leu Leu Asp Ile Asp Glu Thr Glu Tyr His Ala Asp 865 870 875 880 Gly Gly Lys Val Pro Ile Lys Trp Met Ala Leu Glu Ser Ile Leu Arg 885 890 895 Arg Arg Phe Thr His Gln Ser Asp Val Trp Ser Tyr Gly Val Thr Val 900 905 910 Trp Glu Leu Met Thr Phe Gly Ala Lys Pro Tyr Asp Gly Ile Pro Ala 915 920 925 Arg Glu Ile Pro Asp Leu Leu Glu Lys Gly Glu Arg Leu Pro Gln Pro 930 935 940 Pro Ile Cys Thr Ile Asp Val Tyr Met Ile Met Val Lys Cys Trp Met 945 950 955 960 Ile Asp Ser Glu Cys Arg Pro Arg Phe Arg Glu Leu Val Ser Glu Phe 965 970 975 Ser Arg Met Ala Arg Asp Pro Gln Arg Phe Val Val Ile Gln Asn Glu 980 985 990 Asp Leu Gly Pro Ala Ser Pro Leu Asp Ser Thr Phe Tyr Arg Ser Leu 995 1000 1005 Leu Glu Asp Asp Asp Met Gly Asp Leu Val Asp Ala Glu Glu Tyr 1010 1015 1020 Leu Val Pro Gln Gln Gly Phe Phe Cys Pro Asp Pro Ala Pro Gly 1025 1030 1035 Ala Gly Gly Met Val His His Arg His Arg Ser Ser Ser Thr Arg 1040 1045 1050 Ser Gly Gly Gly Asp Leu Thr Leu Gly Leu Glu Pro Ser Glu Glu 1055 1060 1065 Glu Ala Pro Arg Ser Pro Leu Ala Pro Ser Glu Gly Ala Gly Ser 1070 1075 1080 Asp Val Phe Asp Gly Asp Leu Gly Met Gly Ala Ala Lys Gly Leu 1085 1090 1095 Gln Ser Leu Pro Thr His Asp Pro Ser Pro Leu Gln Arg Tyr Ser 1100 1105 1110 Glu Asp Pro Thr Val Pro Leu Pro Ser Glu Thr Asp Gly Tyr Val 1115 1120 1125 Ala Pro Leu Thr Cys Ser Pro Gln Pro Glu Tyr Val Asn Gln Pro 1130 1135 1140 Asp Val Arg Pro Gln Pro Pro Ser Pro Arg Glu Gly Pro Leu Pro 1145 1150 1155 Ala Ala Arg Pro Ala Gly Ala Thr Leu Glu Arg Pro Lys Thr Leu 1160 1165 1170 Ser Pro Gly Lys Asn Gly Val Val Lys Asp Val Phe Ala Phe Gly 1175 1180 1185 Gly Ala Val Glu Asn Pro Glu Tyr Leu Thr Pro Gln Gly Gly Ala 1190 1195 1200 Ala Pro Gln Pro His Pro Pro Pro Ala Phe Ser Pro Ala Phe Asp 1205 1210 1215 Asn Leu Tyr Tyr Trp Asp Gln Asp Pro Pro Glu Arg Gly Ala Pro 1220 1225 1230 Pro Ser Thr Phe Lys Gly Thr Pro Thr Ala Glu Asn Pro Glu Tyr 1235 1240 1245 Leu Gly Leu Asp Val Pro Val 1250 1255 <210> 22 <211> 10 <212> PRT <213> Homo sapiens <400> 22 Ser Leu Ala Phe Leu Pro Glu Ser Phe Asp 1 5 10 <210> 23 <211> 606 <212> PRT <213> artificial sequence <400> 23 Met Gly Cys Arg Leu Leu Cys Cys Ala Val Leu Cys Leu Leu Gly Ala 1 5 10 15 Val Pro Met Glu Thr Gly Val Thr Gln Thr Pro Arg His Leu Val Met 20 25 30 Gly Met Thr Asn Lys Lys Ser Leu Lys Cys Glu Gln His Leu Gly His 35 40 45 Asn Ala Met Tyr Trp Tyr Lys Gln Ser Ala Lys Lys Pro Leu Glu Leu 50 55 60 Met Phe Val Tyr Ser Leu Glu Glu Arg Val Glu Asn Asn Ser Val Pro 65 70 75 80 Ser Arg Phe Ser Pro Glu Cys Pro Asn Ser Ser His Leu Phe Leu His 85 90 95 Leu His Thr Leu Gln Pro Glu Asp Ser Ala Leu Tyr Leu Cys Ala Ser 100 105 110 Ser Gln Glu Ala Gly Ser Tyr Asn Glu Gln Phe Phe Gly Pro Gly Thr 115 120 125 Arg Leu Thr Val Leu Glu Asp Leu Arg Asn Val Thr Pro Pro Lys Val 130 135 140 Ser Leu Phe Glu Pro Ser Lys Ala Glu Ile Ala Asn Lys Gln Lys Ala 145 150 155 160 Thr Leu Val Cys Leu Ala Arg Gly Phe Phe Pro Asp His Val Glu Leu 165 170 175 Ser Trp Trp Val Asn Gly Lys Glu Val His Ser Gly Val Ser Thr Asp 180 185 190 Pro Gln Ala Tyr Lys Glu Ser Asn Tyr Ser Tyr Cys Leu Ser Ser Arg 195 200 205 Leu Arg Val Ser Ala Thr Phe Trp His Asn Pro Arg Asn His Phe Arg 210 215 220 Cys Gln Val Gln Phe His Gly Leu Ser Glu Glu Asp Lys Trp Pro Glu 225 230 235 240 Gly Ser Pro Lys Pro Val Thr Gln Asn Ile Ser Ala Glu Ala Trp Gly 245 250 255 Arg Ala Asp Cys Gly Ile Thr Ser Ala Ser Tyr Gln Gln Gly Val Leu 260 265 270 Ser Ala Thr Ile Leu Tyr Glu Ile Leu Leu Gly Lys Ala Thr Leu Tyr 275 280 285 Ala Val Leu Val Ser Thr Leu Val Val Met Ala Met Val Lys Arg Lys 290 295 300 Asn Ser Arg Ala Lys Arg Ser Gly Ser Gly Ala Pro Val Lys Gln Thr 305 310 315 320 Leu Asn Phe Asp Leu Leu Lys Leu Ala Gly Asp Val Glu Ser Asn Pro 325 330 335 Gly Pro Met Leu Leu Leu Leu Ile Pro Val Leu Gly Met Ile Phe Ala 340 345 350 Leu Arg Asp Ala Arg Ala Gln Ser Val Ser Gln His Asn His His Val 355 360 365 Ile Leu Ser Glu Ala Ala Ser Leu Glu Leu Gly Cys Asn Tyr Ser Tyr 370 375 380 Gly Gly Thr Val Asn Leu Phe Trp Tyr Val Gln Tyr Pro Gly Gln His 385 390 395 400 Leu Gln Leu Leu Leu Lys Tyr Phe Ser Gly Asp Pro Leu Val Lys Gly 405 410 415 Ile Lys Gly Phe Glu Ala Glu Phe Ile Lys Ser Lys Phe Ser Phe Asn 420 425 430 Leu Arg Lys Pro Ser Val Gln Trp Ser Asp Thr Ala Glu Tyr Phe Cys 435 440 445 Ala Val Asn Asp Asn Asp Tyr Lys Leu Ser Phe Gly Ala Gly Thr Thr 450 455 460 Val Thr Val Arg Ala Asn Ile Gln Asn Pro Glu Pro Ala Val Tyr Gln 465 470 475 480 Leu Lys Asp Pro Arg Ser Gln Asp Ser Thr Leu Cys Leu Phe Thr Asp 485 490 495 Phe Asp Ser Gln Ile Asn Val Pro Lys Thr Met Glu Ser Gly Thr Phe 500 505 510 Ile Thr Asp Lys Thr Val Leu Asp Met Lys Ala Met Asp Ser Lys Ser 515 520 525 Asn Gly Ala Ile Ala Trp Ser Asn Gln Thr Ser Phe Thr Cys Gln Asp 530 535 540 Ile Phe Lys Glu Thr Asn Ala Thr Tyr Pro Ser Ser Asp Val Pro Cys 545 550 555 560 Asp Ala Thr Leu Thr Glu Lys Ser Phe Glu Thr Asp Met Asn Leu Asn 565 570 575 Phe Gln Asn Leu Ser Val Met Gly Leu Arg Ile Leu Leu Leu Lys Val 580 585 590 Ala Gly Phe Asn Leu Leu Met Thr Leu Arg Leu Trp Ser Ser 595 600 605 <210> 24 <211> 22 <212> DNA <213> Artificial sequence <400> 24 gcctctggaa tcctttctct tg 22 <210> 25 <211> 21 <212> DNA <213> Artificial sequence <400> 25 tcagctggac cacagccgca g 21 <210> 26 <211> 36 <212> DNA <213> Artificial sequence <400> 26 agagctagcg aattcaacat gggctgcagg ctgctc 36 <210> 27 <211> 42 <212> DNA <213> Artificial sequence <400> 27 ggatcgcttg gcacgtgaat tctttctttt gaccatagcc at 42 <210> 28 <211> 39 <212> DNA <213> Artificial sequence <400> 28 tccaaccctg ggcccatgct cctgttgctc ataccagtg 39 <210> 29 <211> 35 <212> DNA <213> Artificial sequence <400> 29 gttgattgtc gacgccctca actggacccac agcct 35 <210> 30 <211> twenty three <212> DNA <213> Artificial sequence <400> 30 ggaagatctg gactgaaaat gag 23 <210> 31 <211> twenty four <212> DNA <213> Artificial sequence <400> 31 tgaggtcaga tgtaaccaag atta 24 <210> 32 <211> 33 <212> DNA <213> Artificial sequence <400> 32 cgcgtcgact actgtaatag taatcaatta cgg 33 <210> 33 <211> 33 <212> DNA <213> Artificial sequence <400> 33 gacgtcgact aagatacatt gatgagtttg gac 33 <210> 34 <211> twenty one <212> DNA <213> Artificial sequence <400> 34 tccggtttct atgccaaacc t 21 <210> 35 <211> twenty two <212> DNA <213> Artificial sequence <400> 35 tcctccggtg ataatgacaa ga 22 <210> 36 <211> twenty two <212> DNA <213> Artificial sequence <400> 36 ccattacctt tgactcttgt gt 22 <210> 37 <211> twenty two <212> DNA <213> Artificial sequence <400> 37 ggtagtcctt gtatttagta tc 22 <210> 38 <211> 29 <212> DNA <213> Artificial sequence <400> 38 catgccttct tgcctcttgt ctcttagat 29 <210> 39 <211> 30 <212> DNA <213> Artificial sequence <400> 39 ccatgggtgg aatcatattg gaacatgtaa 30 <210> 40 <211> 32 <212> DNA <213> Artificial sequence <400> 40 cgcgtcgaca tgaggatatt tgctgtcttt at 32 <210> 41 <211> 32 <212> DNA <213> Artificial sequence <400> 41 ccgctcgagc gtctcctcca aatgtgtatc ac 32 <210> 42 <211> twenty four <212> DNA <213> Artificial sequence <400> 42 cgcctattac acccactcgt gcag 24 <210> 43 <211> 62 <212> DNA <213> Artificial sequence <400> 43 crack tggagga gagatgttct tatcctccat ttcccttttt tg 62 <210> 44 <211> 62 <212> DNA <213> Orientation(artificial sequence) <400> 44 agctcaaaaa agggaaatgg aggate catctcttga atgttcttat cctccatttc cc 62 <210> 45 <211> 53 <212> DNA <213> Orientation(artificial sequence) <400> 45 gggaaatgga ggataagaac attcaagaga tgttcttatc ctccatttcc ctt <210> 46 <211> 62 <212> DNA <213> Orientation(artificial sequence) <400> 46 caccggatcc agtcacctct gacattcaa gagatgttca gaggtgactg gatccttttt tg 62 <210> 47 <211> 62 <212> DNA <213> Orientation(artificial sequence) <400> 47 agctcaaaaa aggatccagt cacctctgaa catctcttga atgttcagag gtgactggat cc 62 <210> 48 <211> 53 <212> DNA <213> Artificial sequence <400> 48 ggatccagtc acctctgaac attcaagaga tgttcagagg tgactggatc ctt 53 <210> 49 <211> 62 <212> DNA <213> Artificial sequence <400> 49 caccgagaat caacacaaca actaattcaa gagattagtt gttgtgttga ttctcttttt 60 tg 62 <210> 50 <211> 62 <212> DNA <213> Artificial sequence <400> 50 agctcaaaaa agagaatcaa cacaacaact aatctcttga attagttgtt gtgttgattc 60 tc 62 <210> 51 <211> 53 <212> DNA <213> Artificial sequence <400> 51 gagaatcaac acaacaacta attcaagaga ttagttgttg tgttgattct ctt 53 <210> 52 <211> 59 <212> DNA <213> Artificial sequence <400> 52 caccgttctc cgaacgtgtc acgtcaagag attacgtgac acgttcggag aattttttg 59 <210> 53 <211> 59 <212> DNA <213> Artificial Sequence <400> 53 agctcaaaaa attctccgaa cgtgtcacgt aatctcttga cgtgacacgt tcggagaac 59 <210> 54 <211> 50 <212> DNA <213> Artificial Sequence <400> 54 gttctccgaa cgtgtcacgt caagagatta cgtgacacgt tcggagaatt 50

Claims

1. A therapeutic agent for treating tumors and / or cancers, comprising: (a) a first composition, wherein the first composition comprises a first active ingredient in a first pharmaceutically acceptable carrier, the first active ingredient comprising an isolated recombinant oncolytic adenovirus, wherein the recombinant oncolytic adenovirus is a selective replication-type oncolytic adenovirus, and the genome of the recombinant oncolytic adenovirus is integrated with a coding sequence of an exogenous shRNA capable of inhibiting PDL1 expression in tumor cells; and (b) a second composition, wherein the second composition comprises a second active ingredient in a second pharmaceutically acceptable carrier, the second active ingredient comprising a T cell receptor modified immune cell; The genome of the recombinant oncolytic adenovirus is deleted from the E1B19K gene, the E1B55K gene, and all E3 region genes; the genome of the recombinant oncolytic adenovirus comprises an E1A gene coding sequence, and the expression of the E1A gene coding sequence is under the control of a promoter; The immune cells are T cells, and the T cells include primitive T cells or NKT cells. 2 . The therapeutic agent according to claim 1 , wherein the coding sequence of the exogenous shRNA is shown in any one of SEQ ID NOs. 45, 48 and 51.

3. The therapeutic agent according to claim 1, wherein the E1A gene coding sequence is under the control of CMV promoter.

4. The therapeutic agent according to claim 1, wherein the recombinant oncolytic adenovirus is obtained by genetically modifying type 5 adenovirus.

5. The therapeutic agent according to claim 1, wherein the first composition and the second composition are each independently present in the therapeutic agent without mixing with each other.

6. The therapeutic agent according to claim 1, wherein the first composition comprises a therapeutically effective amount of the recombinant oncolytic adenovirus.

7. The therapeutic agent of claim 1, wherein the second composition comprises a therapeutically effective amount of the T cell receptor-modified immune cells.

8. The therapeutic agent of claim 1, wherein the recombinant oncolytic adenovirus is formulated for administration by intratumoral injection, intraperitoneal administration, subarachnoid administration, or intravenous administration.

9. The therapeutic agent of claim 1, wherein the immune cells are formulated for administration via an artery, vein, subcutaneous, intradermal, intratumoral, intralymphatic, intralymph node, subarachnoid space, intramedullary, intramuscular or intraperitoneal route.

10. The therapeutic agent according to claim 1, wherein the therapeutic agent consists of the first composition and the second composition.

11. Use of the therapeutic agent according to any one of claims 1 to 10 in the preparation of a medicament for treating tumors and / or cancer.

12. The use according to claim 11, wherein the tumor and / or cancer comprises: Breast cancer, head and neck cancer, synovial cancer, kidney cancer, connective tissue cancer, melanoma, lung cancer, esophageal cancer, colon cancer, rectal cancer, brain cancer, Liver cancer, bone cancer, gastrinoma, pheochromocytoma, prolactinoma, anal cancer, bile duct cancer, bladder cancer, ureter cancer, glioma, neuroblastoma, meningioma, spinal cord tumors, osteochondroma, chondrosarcoma, Ewing's sarcoma, cancer of unknown primary site, carcinoid, cervical cancer, gallbladder cancer, eye cancer, prostate cancer, testicular cancer, squamous cell carcinoma of the skin, mesothelioma, multiapical myeloma, ovarian cancer, pancreatic endocrine tumor, pancreatic cancer, penile cancer, soft tissue sarcoma, small intestine cancer, stomach cancer, thymic cancer, trophoblastic carcinoma, hydatidiform mole, endometrial cancer, vaginal cancer, vulvar cancer, mycosis fungoides, heart cancer, blood cancer, peritoneal cancer and pleural cancer.

13. The use according to claim 11, wherein the tumor and / or cancer comprises: Pituitary cancer, meningeal cancer, fibrosarcoma, Kaposi's sarcoma, Paget's disease, retinoblastoma, glucagonoma, insulinoma, and choriocarcinoma.

14. A kit of combined drugs for treating tumors and / or cancers, comprising: A first container containing a first composition of the therapeutic agent according to any one of claims 1 to 10; a second container containing a second composition in a therapeutic agent according to any one of claims 1 to 10, wherein the first container and the second container are separate; and Instructions for use that specify when and how to administer the drug.

15. Use of the medicine kit according to claim 14 in preparing a medicine for treating or preventing tumors and / or cancers.

16. The use according to claim 15, wherein the tumor and / or cancer comprises: Breast cancer, head and neck cancer, synovial cancer, kidney cancer, connective tissue cancer, melanoma, lung cancer, esophageal cancer, colon cancer, rectal cancer, brain cancer, Liver cancer, bone cancer, gastrinoma, pheochromocytoma, prolactinoma, anal cancer, bile duct cancer, bladder cancer, ureter cancer, glioma, neuroblastoma, meningioma, spinal cord tumors, osteochondroma, chondrosarcoma, Ewing's sarcoma, cancer of unknown primary site, carcinoid, cervical cancer, gallbladder cancer, eye cancer, prostate cancer, testicular cancer, squamous cell carcinoma of the skin, mesothelioma, multiapical myeloma, ovarian cancer, pancreatic endocrine tumor, pancreatic cancer, penile cancer, soft tissue sarcoma, small intestine cancer, stomach cancer, thymic cancer, trophoblastic carcinoma, hydatidiform mole, endometrial cancer, vaginal cancer, vulvar cancer, mycosis fungoides, heart cancer, blood cancer, peritoneal cancer and pleural cancer.

17. The use according to claim 15, wherein the tumor and / or cancer comprises: Pituitary cancer, meningeal cancer, fibrosarcoma, Kaposi's sarcoma, Paget's disease, retinoblastoma, glucagonoma, insulinoma, and choriocarcinoma.

Citation Information

Cited By

  • A genetically engineered recombinant oncolytic adenovirus combined with immune cells and a preparation method thereof

    CN122768283A